Conditions: Dermatitis, Atopic
Keywords: Eczema AD Vaccine Nemolizumab Pruritis Itchy
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 242
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess the effect of nemolizumab (CD14152) on humoral immune responses to tetanus and meningococcal vaccination in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD).

Detailed description:
This is a randomized, double-blind, placebo-controlled, multi-center, parallel-group study in adult and adolescent participants (≥ 12 to 54 years) with moderate-to-severe AD. Eligible participants must have a documented history of inadequate response to topical AD medication(s). Approximately 200 participants were randomized 1:1 to receive either 30 mg nemolizumab (with a 60 mg loading dose) or placebo, stratified by baseline disease severity Investigator Global Assessment (IGA) (IGA = 3, moderate; IGA = 4, severe). The study consisted of a 2- to 4-week screening period, a 16-week treatment period, and an 8-week follow-up period (12 weeks after the last study drug injection).

Arms:
arm 1: Participants received a loading dose of nemolizumab (60 milligram \[mg\]) via 2 subcutaneous (SC) injections at baseline. Nemolizumab (30 mg) was administered via a single subcutaneous injection every 4 weeks (Q4W) at Weeks 4, 8, and 12. arm 2: Participants received a placebo via 2 SC injections at baseline. Placebo was administered via a single subcutaneous injection Q4W at Weeks 4, 8, and 12.

Interventions: intervention 1: Nemolizumab intervention 2: Placebo
Intervention descriptions: intervention 1: Nemolizumab was administered by 2 SC injections as 60-mg loading dose at baseline and a single 30-mg dose at Weeks 4, 8, and 12. intervention 2: Placebo was administered by 2 SC injections at baseline and a single dose at Weeks 4, 8, and 12.

Protocol document:
Prot_000.pdf: 
Name
Reason for Signature
Date
Document electronically signed in eDMS Regulatory Global
Signature page1 of 1
Version: 
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
11-Jul-2022 00:00:00
1.0
PPD


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0
Page 1 of 133
1
CLINICAL STUDY PROTOCOL
Galderma S.A.
Galderma Research and Development, LLC
A Randomized, Double-Blind, Placebo-Controlled Study to Assess Immunization 
Responses in Adult and Adolescent Subjects with Moderate-to-Severe Atopic Dermatitis 
Treated with Nemolizumab
Protocol Number: RD.06.SPR.118380
IND Number:
117122
EudraCT Number:
Not applicable
Name of Investigational Product:
Nemolizumab (CD14152)
Phase of Development:
2
Indication:
Moderate-to-severe atopic dermatitis 
Sponsor:
Galderma S.A.
Zählerweg 10
6300 Zug
Switzerland 
Galderma Research and Development, LLC
14501 North Freeway
Fort Worth, Texas 76177
United States
Protocol Version: 
4.0
Protocol Date:
06JUL22
-CONFIDENTIAL-
This document and its contents are the property of and confidential to Galderma S.A./Galderma R&D, 
LLC.
Any unauthorized copying or use of this document is prohibited.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 2 of 133
PROTOCOL APPROVAL SIGNATURES
Protocol Title:
Protocol Title: A Randomized, Double-Blind, Placebo-Controlled 
Study to Assess Immunization Responses in Adult and 
Adolescent Subjects with Moderate-to-Severe Atopic Dermatitis 
Treated with Nemolizumab
Protocol Number:
RD.06.SPR.118380
This study will be conducted in compliance with the clinical study protocol (and 
amendments), International Council for Harmonisation (ICH) guidelines for current 
Good Clinical Practice (GCP) and applicable regulatory requirements.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
PPD


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 3 of 133
INVESTIGATOR SIGNATURE PAGE
Protocol Title:
Protocol Title: A Randomized, Double-Blind, Placebo-Controlled 
Study to Assess Immunization Responses in Adult and Adolescent 
Subjects with Moderate-to-Severe Atopic Dermatitis Treated with 
Nemolizumab
Protocol Number:
RD.06.SPR.118380
Confidentiality and Current Good Clinical Practice (GCP)/E6(R2) Compliance 
Statement

I, the undersigned, have reviewed this protocol, including appendices, and I will 
conduct the study as described in compliance with this protocol (and 
amendments), GCP, and relevant International Council for Harmonisation (ICH)
guidelines.

I am thoroughly familiar with the appropriate use of the study drug, as described 
in this protocol and any other information provided by Galderma S.A./Galderma 
R&D, LLC including, but not limited to, the current investigator’s brochure.

Once the protocol has been approved by the independent ethics committee 
(IEC)/institutional review board (IRB), I will not modify this protocol without 
obtaining prior approval of Galderma S.A./Galderma R&D, LLC and of the 
IEC/IRB. I will submit the protocol amendments and/or any informed consent 
form modifications to Galderma S.A./Galderma R&D, LLC and the IEC/IRB, and 
approval will be obtained before any amendments are implemented.

I ensure that all persons or party assisting me with the study are adequately
qualified and informed about the Galderma S.A./Galderma R&D, LLC study drug 
and of their delegated study-related duties and functions as described in the 
protocol.

I ensure that source documents and trial records that include all pertinent 
observations on each of the site’s trial subjects will be attributable, legible, 
contemporaneous, original, accurate, and complete. 
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 4 of 133

I understand that all information obtained during the conduct of the study with 
regard to the subjects’ state of health will be regarded as confidential. No 
subjects’ names will be disclosed. All subjects will be identified by assigned 
numbers on all case report forms, laboratory samples, or source documents 
forwarded to the sponsor. Clinical information may be reviewed by the sponsor or 
its agents or regulatory agencies. Agreement must be obtained from the subject
before disclosure of subject information to a third party.

Information developed in this clinical study may be disclosed by Galderma S.A./
Galderma R&D, LLC to other clinical investigators, regulatory agencies, or other 
health authority or government agencies as required.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
PPD


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 5 of 133
2
SYNOPSIS
Title of Study:
A Randomized, Double-Blind, Placebo-Controlled Study to Assess Immunization 
Responses in Adult and Adolescent Subjects with Moderate-to-Severe Atopic Dermatitis 
Treated with Nemolizumab
Protocol Number:
RD.06.SPR.118380
Investigators/Study 
Sites:
Approximately 60 study sites are planned in the United States
Phase of 
Development:
Phase 2
Objectives:
Primary objective: The primary objective is to assess the effect of nemolizumab 
(CD14152) on humoral immune responses to tetanus and meningococcal vaccination in 
adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD).
Secondary objective: The secondary objectives are to assess the safety and efficacy of 
nemolizumab (CD14152) after a 16-week treatment period in adult and adolescent 
subjects with moderate-to-severe AD.
Study Endpoints:
Primary endpoint: 
Proportion of subjects with a positive serum IgG response to tetanus toxoid at Week 16 
(4 weeks post-vaccination) defined as:
≥ 4-fold increase in anti-tetanus IgG concentrations from baseline in subjects with 
pre-vaccination anti-tetanus IgG concentrations ≥ 0.1 IU/mL
OR
≥ 0.2 IU/mL anti-tetanus IgG concentrations in subjects with pre-vaccination anti-
tetanus IgG concentrations < 0.1 IU/mL
Secondary endpoints:
Vaccine response endpoints:
Proportion of subjects with a positive serum IgG response to tetanus toxoid at Week 16 
defined as: 
o
≥ 2-fold increase in anti-tetanus IgG concentrations from baseline in subjects 
with pre-vaccination anti-tetanus IgG concentrations ≥ 0.1 IU/mL
OR
o
≥ 0.2 IU/mL anti-tetanus IgG concentrations in subjects with pre-vaccination 
anti-tetanus IgG concentrations < 0.1 IU/mL
Proportion of subjects with serum anti-tetanus IgG concentrations of ≥ 0.1 IU/mL at 
Week 16
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 6 of 133
Proportion of subjects with serum anti-tetanus IgG concentrations of ≥ 1.0 IU/mL at 
Week 16
Proportion of subjects with a positive serum bactericidal antibody response to 
meningococcal serogroup C polysaccharide at Week 16 (4 weeks post-vaccination) 
defined as ≥ 4-fold increase in serum bactericidal assay (SBA) reciprocal titer from 
baseline
Proportion of subjects with a positive serum bactericidal antibody response to 
meningococcal serogroup C polysaccharide at Week 16 defined as SBA reciprocal titer 
≥ 8 
Safety endpoints:
Incidence and severity of adverse events (AEs), including AEs of special interest 
(AESI), treatment-emergent AEs (TEAEs), and serious AEs (SAEs)
Study Design:
This is a randomized, double-blind, placebo-controlled, multi-center, parallel-group study 
in adult and adolescent subjects (≥ 12 to 54 years) with moderate-to-severe AD. Eligible 
subjects must have a documented history of inadequate response to topical AD 
medication(s). 
Approximately 245 subjects will be randomized 1:1 to receive either 30 mg nemolizumab 
(with a 60 mg loading dose) or placebo, stratified by baseline disease severity (
 
 
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI
CCI




Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 8 of 133
is safe. Following Independent Ethics Committees/Institutional Review Boards
approval, the sponsor will send a written communication to the site confirming 
that the study is open for enrollment of adolescents. Adolescents must not be 
enrolled in the study until such communication is received.
2.
Chronic AD for at least 2 years before the screening visit, and confirmed according 
to American Academy of Dermatology Consensus Criteria (Appendix 1)2 at the time 
of the screening visit. 
3.
EASI score ≥ 16 at both the screening and baseline visits.
4.
IGA score ≥ 3 (based on the IGA scale ranging from 0 to 4, in which 3 is moderate 
and 4 is severe) at both the screening and baseline visits.
5.
AD involvement ≥ 10% of BSA at both the screening and baseline visits.
6.
Peak (maximum) pruritus NRS score of at least 4.0 at the screening and baseline 
visit. 
Peak pruritus (PP) NRS score at screening will be determined by a single NRS 
assessment (score ranging from 0 to 10) for the 24-hour period immediately 
preceding the screening visit.
Baseline PP NRS score will be determined based on the average of daily NRS scores 
(score ranging from 0 to 10) during the 7 days immediately preceding baseline 
(rounding is not permitted). A minimum of 4 daily scores out of the 7 days 
immediately preceding baseline is required for this calculation.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 9 of 133
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 10 of 133
Exclusion Criteria: 
Individuals meeting any of the following criteria at screening or baseline are ineligible to 
participate in this study
1.
Body weight < 30 kg.
2.
History of hypersensitivity (including anaphylaxis) to an immunoglobulin product 
(plasma-derived or recombinant, eg, monoclonal antibody) or to any of the study 
drug excipients.
3.
History of severe allergic reaction to either vaccine or to vaccine components,
including alum, thimerosal, phenol.
4.
Subjects for whom administration of the meningococcal vaccine provided in this 
study is contraindicated or medically inadvisable, according to prescribing 
information of the commercially available vaccine.
5.
Subjects for whom administration of the tetanus, diphtheria, and pertussis vaccine 
provided in this study is contraindicated or medically inadvisable, according to 
prescribing information of the commercially available vaccine, especially a history 
of seizures or progressive encephalopathy after previous dosing.
6.
Receipt of any vaccine (except inactivated influenza vaccine) within 12 weeks prior 
to screening, any meningococcal vaccine within 1 year prior to screening, or any 
tetanus-, diphtheria-, or pertussis-containing vaccine within 5 years prior to 
screening. 
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 11 of 133
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 12 of 133
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 13 of 133
Planned Sample Size:
Approximately 245 subjects are planned to be randomized in this study.
Therapies:
Investigational Therapy
Nemolizumab (CD14152) 30 mg and placebo will be provided as lyophilized powder for 
solution for injection for subcutaneous use only after reconstitution in a single-use pre 
filled dual-chamber syringe [DCS]. Subjects will receive a loading dose of nemolizumab 
(eg, 60 mg) or placebo by 2 subcutaneous injections at baseline and a single 30-mg dose 
at Weeks 4, 8, and 12. 
Immunization
At the Week 12 visit, subjects will receive single doses of Tdap and MCV4 vaccines.
Moisturizer 
Subjects will apply a moisturizer at least once daily, and liberally as needed, to dry skin 
and AD lesions beginning at screening, and throughout the study. The subjects’ current 
moisturizer or a moisturizer recommended by the investigator may be used. Use should 
not occur within 8 hours before each clinic/office visit. Whenever possible, subjects 
should use the same moisturizer throughout the study.
Topical Background Therapy
At the screening visit (≥14 days prior to baseline), subjects who are using a stable 
regimen of medium- or low-potency TCS therapy, with or without TCI therapy, should 
continue their therapy regimen in the study. Background therapy use should be adjusted 
to the disease activity and tolerability of the subject, including tapering when signs and 
symptoms improve, discontinuation when lesions clear, and restarting if signs and 
symptoms recur, at the discretion of the investigator.
Subjects who are not using a stable regimen of topical therapy at the screening visit 
should not use topical background therapy during the study, unless required as rescue 
therapy.
Subjects with a history of intolerance to TCS or for whom TCS is not advisable (eg, 
hypersensitivity, significant skin atrophy) must not use TCS background therapy. 
Rescue Therapy
If deemed to be medically necessary by the investigator (eg, to control intolerable AD 
signs/symptoms), topical and/or phototherapy rescue treatments can be prescribed to the 
subjects at any time during the study except during the screening period. Subjects 
receiving any rescue therapy during the screening period are not eligible to participate in 
the study. Subjects receiving systemic rescue during the treatment period must 
discontinue study treatment.
As a general guideline and per individual investigator judgment, rescue therapy should 
not be prescribed within the first 2 weeks after baseline (ie, Week 2) to allow a minimum 
time for study drug exposure.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 14 of 133
Permitted rescue therapies during the treatment period include: 
•
TCS (higher potency than used at baseline for subjects using TCS background 
therapy; any potency for subjects not using TCS background therapy)
•
TCI (only for subjects not using TCI background therapy at baseline)
•
Phototherapy
Rescue treatments are only approved and/or standard of care treatments that directly treat 
AD. Antihistamines, sleep aids, topical and systemic antibiotics, and anti-itch creams are 
not considered to be rescue therapy because they do not directly treat AD.
Whenever possible, investigators should first use topical medications as rescue therapy 
before escalating to systemic. If subjects receive topical treatments or phototherapy as 
rescue therapy, study drug administration should be continued unless there is a safety 
concern according to the investigator’s judgment. If subjects receive systemic rescue 
therapy, they should permanently discontinue study treatment.
Reference Therapy:
Matching placebo
Treatment Duration:
The expected duration of each subject’s participation in the study is up to 28 weeks, 
including an up to 4-week screening period, a 16-week treatment period, and an 8-week 
follow-up period (12 weeks after the last study medication injection).
The 12-week follow-up visit is not required for subjects who will continue in the LTE 
study (Protocol 118163).
Immunogenicity:
The following vaccine response assessments are planned according to the schedule of 
assessments:
• Tetanus toxoid IgG antibody concentration
• Meningococcal serogroup C SBA reciprocal titer
Efficacy:
Safety:
The following safety assessments are planned according to the schedule of assessments:
• AEs, including TEAE, AESIs, and SAEs
• Clinical laboratory tests 
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 15 of 133
• Physical examination and vital signs
• Respiratory examination and assessments (ie, asthma control test [ACT], peak 
expiratory flow [PEF])
• Electrocardiogram
Statistical Methods 
and Planned 
Analyses:
The Intent-to-Treat population (ITT) will consist of all randomized subjects. The 
modified Intent-to-Treat population (mITT) will consist of all randomized subjects who 
received at least one dose of study drug and vaccine injection, have an evaluable vaccine 
response and did not receive any systemic rescue therapy prior to the post-vaccination 
vaccine response assessment. The Safety population (SAF) will include all randomized 
subjects who receive at least 1 dose of study drug. The mITT population will be the 
primary population for vaccine response analyses. The ITT populationwill be the primary 
population for all efficacy analyses, and all safety data will be summarized based on the 
SAF population.
Vaccine Response Endpoints:
For the primary vaccine response endpoint, the estimate of the corresponding proportion 
of subjects with a positive serum IgG response to tetanus toxoid at Week 16 will be
adjusted for the randomization stratum baseline 
 (Moderate vs Severe) using 
the Cochran-Mantel-Haenszel (CMH) estimate of the risk difference and corresponding 
2-sided 90% CI. This primary analysis will be conducted on the mITT population.
Subjects in receipt of systemic rescue medication will not be vaccinated. As the primary 
analysis will be conducted on the mITT, no imputation is required. As sensitivity 
analysis, the same analysis will be conducted on the ITT population, and any subjects 
without an evaluable vaccine response will be regarded as a Non-Responder. A further 
analysis will be performed on the ITT with data as observed (ie, no imputation of missing 
data at Week 16).
All secondary vaccine response endpoints will be analyzed on the mITT, analyzed using 
the same methods as for the primary vaccine response endpoint above.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI
CCI
CCI




Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 17 of 133
3
TABLE OF CONTENTS
1
CLINICAL STUDY PROTOCOL..............................................................................1
PROTOCOL APPROVAL SIGNATURES ........................................................................2
INVESTIGATOR SIGNATURE PAGE .............................................................................3
2
SYNOPSIS ..................................................................................................................5
3
TABLE OF CONTENTS ..........................................................................................17
3.1
List of In-text Tables ............................................................................................22
3.2
List of In-text Figures...........................................................................................22
4
LIST OF ABBREVIATIONS ...................................................................................23
5
INTRODUCTION.....................................................................................................26
5.1
Background on Moderate-to-Severe Atopic Dermatitis.......................................26
5.2
Background on Nemolizumab..............................................................................27
Nonclinical Studies ......................................................................................27
Pharmacokinetic Profile...............................................................................28
Clinical Studies ............................................................................................29
5.3
Clinical Risks/Benefits.........................................................................................32
Nemolizumab...............................................................................................32
Vaccines.......................................................................................................34
5.4
Study Rationale and Dose Selection.....................................................................34
6
STUDY OBJECTIVES AND ENDPOINTS ............................................................36
6.1
Study Objectives...................................................................................................36
Primary Objective ........................................................................................36
Secondary Objectives...................................................................................36
6.2
Study Endpoints....................................................................................................36
Primary Endpoint .........................................................................................36
Secondary Endpoints....................................................................................36
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 18 of 133
7
INVESTIGATIONAL PLAN ...................................................................................39
7.1
Description of Overall Study Design and Plan.....................................................39
7.2
Discussion of Study Design..................................................................................41
7.3
End of Study.........................................................................................................43
8
SELECTION OF STUDY POPULATION...............................................................44
8.1
Inclusion Criteria..................................................................................................44
8.2
Exclusion Criteria.................................................................................................47
8.3
Rescreening ..........................................................................................................51
8.4
Study Withdrawal, Removal, and Replacement of Subjects................................51
Pregnancy.....................................................................................................53
COVID-19 Infection ....................................................................................53
9
TREATMENTS.........................................................................................................55
9.1
Details of Study Drug and Vaccines ....................................................................55
Study Drug ...................................................................................................55
Vaccines.......................................................................................................57
9.2
Dosage Schedule ..................................................................................................58
9.3
Measures to Minimize Bias: Study Treatment Assignment and Blinding ...........58
Method of Study Treatment Assignment.....................................................58
Blinding........................................................................................................59
9.4
Dosage Modification ............................................................................................60
9.5
Accountability and Compliance ...........................................................................61
9.6
Prior and Concomitant Therapies.........................................................................62
Permitted Concomitant Therapy ..................................................................63
Prohibited Medication/Therapy ...................................................................65
Product Technical Complaints.....................................................................67
9.7
Duration of Subject Participation.........................................................................67
Early Termination Visit ...............................................................................68
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 19 of 133
Unscheduled Visit........................................................................................68
10
STUDY PROCEDURES...........................................................................................69
11
IMMUNOGENICITY ASSESSMENTS ..................................................................74
11.1
Vaccine Response.................................................................................................74
Tetanus Toxoid IgG Antibody Concentration .............................................74
Meningococcal Serogroup C SBA Reciprocal Titer....................................74
13
SAFETY ASSESSMENTS .......................................................................................78
13.1
Adverse Events.....................................................................................................78
Adverse Events of Special Interest ..............................................................82
Serious Adverse Events ...............................................................................83
Procedure for Reporting a Serious Adverse Event ......................................84
Procedure for Reporting an Adverse Event of Special Interest ...................86
Procedure for Reporting Pregnancies ..........................................................87
Unexpected Adverse Reactions ...................................................................88
13.2
Clinical Laboratory Assessments .........................................................................88
Hematology..................................................................................................90
Clinical Chemistry .......................................................................................90
Urinalysis .....................................................................................................90
Pregnancy Testing........................................................................................90
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 20 of 133
Virology .......................................................................................................91
Tuberculosis Testing....................................................................................91
13.3
Vital Signs ............................................................................................................92
13.4
Height and Weight................................................................................................92
13.5
Physical Examination...........................................................................................92
13.6
Respiratory Assessments......................................................................................93
Asthma Control Test ....................................................................................93
Respiratory Examination..............................................................................94
Peak Expiratory Flow...................................................................................94
Respiratory Referrals ...................................................................................95
13.7
Electrocardiogram ................................................................................................95
14
PHARMACOKINETICS ..........................................................................................96
14.1
Pharmacokinetic Sampling...................................................................................96
14.2
Nemolizumab (CD14152) Quantification in Biological Sampling......................96
15
OTHER ASSESSMENTS.........................................................................................97
15.1
Independent Data Monitoring Committee............................................................97
15.2
Independent Adjudication Committee..................................................................97
16
STATISTICAL ANALYSIS .....................................................................................98
16.1
Analysis Populations ............................................................................................99
16.2
Subject Disposition.............................................................................................100
16.3
Demographics and Other Baseline Characteristics ............................................100
16.4
Vaccine Response Analysis................................................................................100
Definition of Primary Vaccine Response Endpoint...................................100
Analysis of Primary Vaccine Response Endpoint .....................................101
Sensitivity Analyses of the Primary Vaccine Response Endpoint.............101
Secondary Vaccine Response Endpoints ...................................................101
16.5
Efficacy Analyses...............................................................................................102
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved






Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 23 of 133
4
LIST OF ABBREVIATIONS
ACT
Asthma Control Test
AD
atopic dermatitis
ADA
anti-drug antibody
AE
adverse event
AESI
adverse event of special interest
ALT
alanine aminotransferase
AP
Average pruritus
AST
aspartate aminotransferase
CI
confidence interval
COVID-19
coronavirus disease-19
CPK
creatine phosphokinase
CRO
contract research organization
CYP450
cytochrome P450
DCS
dual-chamber, single-use syringe
ECG
electrocardiogram
eCRF
electronic case report form
GCP
Good Clinical Practice
HBcAb
hepatitis B core antibody
HBsAg
hepatitis B surface antigen
HIPAA
Health Insurance Portability and Accountability Act 
HIV
human immunodeficiency virus
IAC
Independent Adjudication Committee
IB
Investigator’s Brochure
ICF
informed consent form
ICH
International Council for Harmonisation of Technical Requirements 
for Pharmaceuticals for Human Use
IDMC
independent data monitoring committee
IEC
Independent Ethics Committee
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 24 of 133
IgE/G/M
immunoglobulin E/G/M
IL
interleukin
IRB
Institutional Review Board
IRR
injection-related reaction
IRT
interactive response technology
ITT
intent-to-treat
KLH
keyhole limpet hemocyanin
LOCF
last observation carried forward
LTE
long-term extension
MCV4
quadrivalent meningococcal conjugate vaccine
MI
multiple imputation
mITT
modified intent-to-treat
NAb
neutralizing antibody
NCA
non-compartmental analysis
NRS
numeric rating scale
PEF
peak expiratory flow
PK
pharmacokinetics
PRN
pro re nata (when necessary or as needed)
PRO
patient-reported outcome
PT
preferred term
PTC
product technical complaint
Q4W
every 4 weeks
SAE
serious adverse event
SAF
safety analysis population
SAP
statistical analysis plan
SC
subcutaneous
SIN
subject identification number
SNRI
serotonin-norepinephrine reuptake inhibitor
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI
CCI
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 25 of 133
SSRI
selective serotonin reuptake inhibitor
SUSAR
suspected unexpected serious adverse reaction
TB
tuberculosis
TCI
topical calcineurin inhibitor
TCS
topical corticosteroid
TEAE
treatment-emergent adverse event
Th2
type 2 helper T [cell]
TMF
Trial Master File
ULN
upper limit of normal
UPT
urine pregnancy test
US
United States
WOCBP
women of childbearing potential
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 26 of 133
5
INTRODUCTION
5.1
Background on Moderate-to-Severe Atopic Dermatitis
Atopic dermatitis (AD) is a chronic inflammatory skin disease estimated to occur in 10% 
to 20% of the population1 and up to 25% of children.2 The disease is characterized by 
pruritus (itching), xerosis (skin dryness), and eczematous lesions whose features include 
erythema, infiltration/papulation, oozing with crusting, excoriations, and lichenification.
The cause of AD, although still not completely understood, is probably multifactorial and 
involves complex interrelation between susceptibility genes, immunological factors, 
infections, and environmental factors to produce a skin barrier disturbance as well as 
immunologic dysregulation and inflammation.3,4,5 There are abundant data indicating 
cross-talk between the immune and neural system in induction of pruritus through 
activation of cytokine receptors on peripheral nerves. 6
Upon stimulation with allergens, dendritic cells in the skin stimulate type 2 helper T cells 
(Th2) and cause the subsequent release of pro-inflammatory cytokines, including 
interleukin (IL)-4, IL-5 and IL-13. High levels of Th2 cytokines in AD skin increase 
serine protease, which leads to further skin barrier dysfunction, and IL-31, which leads to 
pruritus and further inflammation and barrier dysfunction.7,8 The AD pathogenesis also 
involves Th17 and Th22 cells and Th1 cells in the chronic phase of AD. 9
IL-31 is involved in both primary AD pathophysiology and perpetuation of the 
itch-scratch cycle. IL-31 is preferentially produced by Th2 cells, following induction by 
IL-4, and its expression is consistently increased in the skin lesions of AD patients.7,10,11
Furthermore, the IL-31 receptor A (IL-31 RA) was found to be expressed in several 
tissues including the dorsal root spinal ganglia, which contain sensory nerve cells,12 and 
keratinocytes.13 Through interaction with its receptor, IL-31 promotes pruritus, Th2-
driven inflammation, and interrupts keratinocyte proliferation and differentiation.7,8,14,15
Together, these findings suggest that IL-31 is involved in the pathogenesis of pruritus and 
in inflammation in AD.
The scratching behavior associated with pruritus is believed to exacerbate AD lesions by 
causing mechanical damage to the skin, allowing the penetration of foreign antigens, 
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 27 of 133
triggering inflammatory responses, and leading to further aggravation of dermatitis and 
itching. This vicious circle of scratching → exacerbation of dermatitis → aggravation of 
itching is known as the “itch-scratch cycle”.16
Topical agents are the mainstay of AD therapy. Despite the demonstrated efficacy of 
topical treatments, they are not always sufficient to control moderate-to-severe AD in 
some patients, who therefore require the addition of phototherapy or a systemic treatment
to achieve sufficient control of AD.17 Due to the above described predominant role of IL-
31 in mediation of inflammatory itch, targeting and blocking the IL-31 pathway is 
expected to have a therapeutic effect in patients with AD, as well as those with other 
inflammatory pruritic conditions such as prurigo nodularis (PN), which are not 
adequately controlled by existing therapies. 
5.2
Background on Nemolizumab
Nemolizumab (CD14152) is a humanized anti-human IL-31 receptor A (RA) monoclonal 
modified immunoglobulin G (IgG) 2 antibody comprising a structure of 2 H-chains 
(445 amino acid residues) and 2 L-chains (214 amino acid residues) connected by 
16 disulfide bonds. Nemolizumab inhibits the binding of IL-31 to IL-31RA and 
subsequent transduction of the IL-31 signal into the cell.
Nonclinical Studies
The Investigator’s Brochure (IB) contains detailed information on non-clinical studies. 
In in vitro pharmacology studies, the characteristics of nemolizumab as an anti-IL-31RA 
neutralizing antibody were investigated. It was shown that nemolizumab binds to human 
and monkey IL-31RA, inhibits binding of IL-31 to IL-31RA and inhibits signaling via 
IL-31A. Nemolizumab did not affect the behavior of IL-6 and oncostatin M that utilize 
gp130, a cytokine receptor that has homology to IL-31RA. FcγRs and complement C1q 
are important molecules for eliciting the constant region-mediated effector activity of an 
antibody. Based on its binding affinity to FcγRs and human complement C1q, the risk of 
constant region-mediated effector activity was considered to be lower for nemolizumab 
than for IgG1. Nemolizumab did not show any antibody-dependent cell-mediated 
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 28 of 133
cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct cell death-
inducing activities in IL-31RA overexpressing A549 cells. 
In non-clinical safety studies, nemolizumab was well tolerated and safe in cynomolgus 
monkeys at doses of up to 25 mg/kg once every 2 weeks in 3- and 6-month intermittent 
SC dose toxicity studies. There was no immunotoxic effect after repeat dosing in the 
monkey. In the 6-month toxicology study, nemolizumab did not affect immunoglobulin 
(Ig)M or IgG responses to the T-cell dependent antigen keyhole limpet hemocyanin
(KLH) compared to controls when KLH was administered after 23 weeks of 
nemolizumab treatment.18
Pharmacokinetic Profile
The pharmacokinetic (PK) profile of nemolizumab was extensively assessed in subjects 
with AD. PK assessments after subcutaneous (SC) injections of weight-based (0.1 to 
3 mg/kg) or flat (10 to 90 mg) doses showed a dose proportional increase of 
nemolizumab serum concentrations after a single (mg/kg) injection and a less-than-
proportional increase after repeated administrations of flat doses between 30 and 90 mg. 
The terminal elimination half-life of nemolizumab was approximately 2 weeks after 
single and repeated administrations. No significant systemic accumulation was observed,
and steady state concentrations were achieved from 16 weeks of treatment without a 
loading dose and from 4 weeks of treatment when a loading (flat 2×) dose was 
administered. The systemic exposure to nemolizumab appeared to be slightly lower in 
AD subjects compared to healthy volunteers.
The PK profile of nemolizumab was also assessed in the phase 2a study with PN subjects, 
where a nemolizumab dose of 0.5 mg/kg was administered. Similar nemolizumab PK 
profiles were observed in subjects with AD and in subjects with PN. The similarity in 
nemolizumab exposure between the 2 populations was also confirmed using population 
PK modeling. The IB contains additional detailed information on the nemolizumab PK 
profile.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 29 of 133
Clinical Studies
The IB contains detailed information on clinical studies.
Studies have been completed in healthy subjects and subjects with AD, PN and uremic 
pruritus. Results of Phase 2 studies in AD and PN subjects are summarized below. 
5.2.3.1
Phase 2b Dose-Ranging Study: Atopic Dermatitis
The phase 2b study was a randomized, placebo-controlled, double-blind, parallel-group,
dose-ranging study to evaluate the efficacy, safety, and pharmacokinetics of various 
doses of nemolizumab in moderate-to-severe AD subjects with severe 
 
A total of 226 adult subjects were randomized: 57 subjects were randomized to placebo 
and 169 subjects were randomized to nemolizumab arms (55 subjects to 10 mg, 
57 subjects to 30 mg, and 57 subjects to 90 mg). Overall, all demographic and baseline 
disease characteristics were similar in all treatment groups.
The primary efficacy endpoint was percent change from baseline in 
 
to Week 24. At the Week 24 visit, a greater percent change 
reduction in 
 was observed with the nemolizumab 30-mg dose (least squares mean
difference vs placebo = 16.7%) and the difference was statistically significant (95%
confidence interval [CI] = -30.2, -3.2; p = 0.016) compared to placebo. The nemolizumab
10-mg dose showed a marginally statistically significant difference vs placebo (least 
squares mean difference = 13.6%; 95% CI = -27.3, 0.0; p = 0.051). However, the 
difference between the nemolizumab 90-mg dose and placebo did not achieve statistical 
significance.
The 
 rate was statistically significant 
(p < 0.05) for all nemolizumab doses at all timepoints from Week 2. 
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI
CCI
CCI
CCI
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 30 of 133
All doses of nemolizumab were associated with a slightly higher incidence of treatment-
emergent adverse events (TEAEs) when compared to placebo. There was no increase in 
the incidence of skin infections in the nemolizumab compared to the placebo groups,
although there was a higher incidence of non-skin infections with nemolizumab (mainly
rhinopharyngitis and upper respiratory tract infections). There was a dose-dependent
increase of asthma flares (1 [1.8%], 2 [3.6%], 7 [12.3%], and 10 [17.5%] in placebo, 
10 mg, 30 mg, and 90 mg, respectively) in subjects with pre-existing asthma. Events were
mostly mild or moderate (1 severe event with the highest dose), manageable, and 
reversible under treatment with study drug. Local and systemic injection-related reactions 
(IRRs) occurred more frequently in the placebo group compared to the active treatment 
groups. Finally, there was a low incidence of peripheral edema, with no serious cases and 
no imbalance with the placebo arm. There was a comparable percentage of subjects 
discontinuing treatment due to TEAE in the placebo and active treatment arms.
There was 1 non-related AE with a fatal outcome (82-year-old subject treated with the
10-mg dose died due to non-study drug-related aspiration pneumonia and
cardiopulmonary arrest). Three suspected unexpected serious adverse reactions
(SUSARs) were recorded in the study: exacerbation of AD (10-mg dose, withdrawal
from study), septic shock (90-mg dose, sepsis, Staphylococcus aureus–positive blood
culture, recovered/resolved without sequelae), and phlegmon/cellulitis of the right cheek
(30-mg dose, recovered/resolved without sequelae). All doses of nemolizumab were
associated with a slightly higher incidence of serious TEAEs (1 [1.8%], 3 [5.5%], 2 
[3.5%], and 2 [3.5%] in placebo, 10 mg, 30 mg, and 90 mg, respectively) but not severe 
TEAEs (6 [10.7%], 3 [5.5%], 5 [8.8%], and 2 [3.5%] in placebo, 10 mg, 30 mg, and 
90 mg, respectively) when compared to placebo. 
The safety and efficacy data generated in the phase 2b dose-finding study supported the
selection of the 30-mg dose as the treatment dose for the phase 3 studies in AD.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 31 of 133
5.2.3.2
Phase 2a Safety and Efficacy Study: Prurigo Nodularis
The phase 2a study was a randomized, placebo-controlled, double-blind, parallel-group, 
multi-center study to evaluate the safety and efficacy of nemolizumab in subjects 
suffering from PN over a 12-week treatment period. 
A total of 70 subjects were randomized: 36 subjects were randomized to placebo and 34
subjects were randomized to nemolizumab 0.5 mg/kg. Sixty subjects (85.7%) completed 
the study. Demographic characteristics were similar in both treatment groups. Disease 
characteristics at baseline were similar in both treatment groups, with the exception of the 
Prurigo Activity Score (PAS) at baseline, which was slightly higher in the placebo 
compared with the nemolizumab group, and more subjects in the nemolizumab group had 
a severe 
 compared with the placebo group.
The primary efficacy endpoint was percent change from baseline in 
 to Week 4 
(weekly average of the peak). Nemolizumab was clinically and statistically significantly 
superior to placebo in reducing the 
 at Week 4 (difference between 
treatment groups -38.0%; 95% CI -51.0, -25.0; p<0.001). 
The proportion of subjects with 
, a secondary endpoint, was higher in the 
nemolizumab group compared with the placebo group at Week 12 and at a follow-up visit 
at Week 18, and the differences were statistically significant (Week 12: difference 17.2%; 
p=0.020; Week 18: difference 32.0%; p=0.001).
Secondary endpoints also included 
 at other time points, Average Pruritus 
 PP and AP Verbal Rating Scale, Dynamic Pruritus Scale, and PAS. 
Improvements were statistically significantly greater in the nemolizumab group than in
the placebo group at all time points for pruritus endpoints and at or before Week 12 for 
PAS endpoints.
The most frequently reported TEAE was nasopharyngitis, the incidence of which was 
similar in the nemolizumab group (5 subjects, 14.7%) and the placebo group (4 subjects, 
11.1%). The incidence of neurodermatitis was higher in the placebo group (5 subjects, 
13.9%) compared with the nemolizumab group (2 subjects, 5.9%). The incidence of AD
was higher in the nemolizumab group (3 subjects, 8.8%) compared with the placebo 
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI
CCI
CCI
CCI
CCI
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 32 of 133
group (0 subjects). The percentage of subjects with severe TEAEs was higher in the 
nemolizumab group (5 subjects, 14.7%) compared with the placebo group (1 subject, 
2.8%). The incidence of TEAEs leading to permanent discontinuation of the study drug 
was similar between the nemolizumab and placebo groups.
The incidence of treatment-emergent SAEs was similar between the nemolizumab group 
(4 subjects, 11.8%) and the placebo group (3 subjects, 8.3%). Neurodermatitis was the 
most frequently reported treatment-emergent SAE, for which all subjects were in the 
placebo group (3 subjects, 8.3%). One subject in the nemolizumab group had a treatment-
emergent SAE related to study drug (dermatitis psoriasiform). There were no deaths 
reported during the study.
5.3
Clinical Risks/Benefits 
Nemolizumab
Results of previous clinical studies in adults demonstrated that treatment with 
nemolizumab had a marked effect on AD, pruritus, and pruritus-related sleep loss. 
Overall, nemolizumab was well tolerated when used as monotherapy or concomitantly 
with a topical corticosteroid (TCS). 
Based on the currently available information on nemolizumab and the risks associated 
with biologic agents in general, the important potential risks of nemolizumab treatment
include local and systemic IRRs, newly diagnosed asthma or worsening of asthma, 
exacerbation of AD, and skin and non-skin infections.
The following specific risk-minimization and safety follow-up measures have been 
planned in this clinical study: 
a.
The protocol will exclude subjects with asthma exacerbation requiring hospitalization 
in the preceding 12 months before screening, subjects whose asthma has not been 
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 33 of 133
well-controlled (ie, symptoms > 2 days per week, nighttime awakenings 2 or more
times per week, or some interference with normal activities) during the last 3 months 
before the screening visit, Asthma Control Test (ACT) score ≤ 19, and subjects with 
peak expiratory flow (PEF) below 80% of the predicted value. At all visits, all 
subjects will be asked about respiratory changes and a respiratory examination will be 
performed. Peak expiratory flow measurements will be performed for all subjects at 
screening, baseline, and regular intervals throughout the study. For subjects with a 
history of asthma, PEF measurements and ACT will be administered at all visits. 
Subjects diagnosed with de novo asthma will perform PEF and ACT assessments at 
all visits starting with the visit in which the diagnosis was confirmed. Subjects with a 
medical history of asthma will be referred to the physician managing their asthma if 
ACT ≤19, PEF < 80% of the predicted value, and/or unexpected worsening of 
asthma is observed or reported. Subjects without a medical history of asthma will be 
referred to a respiratory specialist if respiratory changes suggestive of asthma are 
observed or reported. An independent adjudication committee (IAC) will review all 
asthma AEs reported during the course of the study.
b. The exclusion criteria of this clinical study (ie, restricting entry of subjects with 
recent/current infections or known/suspected immunosuppression or unusually 
frequent, recurrent, severe, or prolonged infections) will prevent non-eligible patients 
from receiving nemolizumab. As no data are available in pregnant or breastfeeding 
women, these patients are not eligible for this study. 
c.
A slight trend of dose-dependent increase of peripheral edema was reported in the 
nemolizumab phase 2a study CIM003JG. Most events were mild (11 of 21), no case 
was serious, and none resulted in premature treatment discontinuation; no case was 
associated with renal or cardiac AEs. There were a few subjects reporting peripheral 
edema in the phase 2b 114322 study (2 [3.6%], 2 [3.6%], 4 [7%], and 2 [3.5%] in
placebo, 10-mg, 30-mg, and 90-mg groups, respectively). Peripheral edema will be 
followed as an AE of special interest (AESI) in this study.
d. As nemolizumab has not been evaluated in pediatric populations, with studies in 
adolescents currently ongoing, safety will be evaluated closely throughout the study, 
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 34 of 133
including a follow-up visit 12 weeks after the last study drug administration for 
subjects who do not rollover into the nemolizumab long-term extension (LTE) study.
e.
An independent data monitoring committee (IDMC) will monitor the safety data 
regularly throughout the study, including the AESIs listed in Section 13.1.1, which 
were defined based on the currently available safety information on nemolizumab and 
the risks associated with biologic agents in general.
In conclusion, when taking into consideration the currently available data of 
nemolizumab and the risk-minimization approaches to be implemented, the benefit/risk 
ratio of nemolizumab is considered to be favorable in this study.
Vaccines
During the study, subjects will also receive single doses of tetanus toxoid, reduced 
diphtheria toxoid, and acellular pertussis (
 and 
meningococcal (Groups A, C, Y, and W-135) polysaccharide dipththeria toxoid 
conjugate 
 vaccines. Contraindications, risks, 
warnings, and precautions of vaccination are as outlined in the respective prescribing 
information (Appendix 2, Appendix 3).19,20
Based on known cellular and immunological responses of IL-31RA signaling, putative 
risks of immune interference by nemolizumab following vaccination have not been 
previously identified.
5.4
Study Rationale and Dose Selection
The aim of the study is to investigate whether nemolizumab has an effect on the 
immunological response to vaccination in AD subjects. Although nemolizumab is not 
expected to impact immunization responses, the mechanism of IL-31 signaling in 
immunity is not yet fully elucidated, and the effect of blocking Th2 cell signaling via 
IL-31 on vaccination response has not been tested.
Two different common vaccines (Tdap and MCV4) that result in activation of both T 
cells and B cells to elicit an effective immune response were selected for use in this study 
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
PPD
PPD


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 35 of 133
to evaluate a broad immunological impact of coadministration of vaccines and 
nemolizumab.
The nemolizumab dose was selected based on the outcome of the Phase 2b dose-ranging 
study in adults SPR.114322, where the 30-mg dose (with 60-mg loading dose), when 
administered every 4 weeks (Q4W), provided the best benefit/risk ratio of the 3 doses 
(10 mg, 30 mg, and 90 mg) evaluated. The 30-mg dose was therefore selected as the dose 
to be developed for the treatment of AD. Across the full range of subject body weights in 
the Phase 2b study, the 30-mg dose (with 60-mg loading dose) provided a comparable 
observed exposure with respect to the body weight-based dose of 0.5 mg/kg tested during 
the Phase 2a AD and PN studies.
Adolescent subjects will be enrolled after the sponsor confirms the safety of the 30-mg 
Q4W dose in adolescents in a separate clinical study (SPR.116912).
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 36 of 133
6
STUDY OBJECTIVES AND ENDPOINTS
6.1
Study Objectives
Primary Objective
The primary objective is to assess the effect of nemolizumab (CD14152) on humoral 
immune responses to tetanus and meningococcal vaccination in adult and adolescent 
subjects with moderate-to-severe AD.
Secondary Objectives
The secondary objectives are to assess the safety and efficacy of nemolizumab 
(CD14152) after a 16-week treatment period in adult and adolescent subjects with 
moderate-to-severe AD.
6.2
Study Endpoints
Primary Endpoint
The primary endpoint of this study is the proportion of subjects with a positive serum IgG 
response to tetanus toxoid at Week 16 (4 weeks post-vaccination) defined as:

≥ 4-fold increase in anti-tetanus IgG concentrations from baseline in subjects with 
pre-vaccination anti-tetanus IgG concentrations ≥ 0.1 IU/mL
OR

≥ 0.2 IU/mL anti-tetanus IgG concentrations in subjects with pre-vaccination anti-
tetanus IgG concentrations < 0.1 IU/mL
Secondary Endpoints
6.2.2.1
Vaccine Response Endpoints
The secondary vaccine response endpoints are as follows:

Proportion of subjects with a positive serum IgG response to tetanus toxoid at 
Week 16 defined as: 
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 37 of 133
o
≥ 2-fold increase in anti-tetanus IgG concentrations from baseline in 
subjects with pre-vaccination anti-tetanus IgG concentrations ≥ 0.1 IU/mL
OR
o
≥ 0.2 IU/mL anti-tetanus IgG concentrations in subjects with pre-
vaccination anti-tetanus IgG concentrations < 0.1 IU/mL

Proportion of subjects with serum anti-tetanus IgG concentrations of ≥ 0.1 IU/mL 
at Week 16

Proportion of subjects with serum anti-tetanus IgG concentrations of ≥ 1.0 IU/mL 
at Week 16

Proportion of subjects with a positive serum bactericidal antibody response to 
meningococcal serogroup C polysaccharide at Week 16 (4 weeks post-
vaccination) defined as ≥ 4-fold increase in serum bactericidal assay (SBA) 
reciprocal titer from baseline

Proportion of subjects with a positive serum bactericidal antibody response to 
meningococcal serogroup C polysaccharide at Week 16 defined as SBA 
reciprocal titer ≥ 8 
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 38 of 133
6.2.2.3
Safety Endpoint
The safety endpoint of this study is as follows:

Incidence and severity of adverse events (AEs), including AESI (see 
Section 13.1.1), treatment-emergent AEs, and serious AEs
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 39 of 133
7
INVESTIGATIONAL PLAN
7.1
Description of Overall Study Design and Plan
This is a randomized, double-blind, placebo-controlled, multi-center, parallel-group study 
in adult and adolescent subjects (≥ 12 to 54 years) with moderate-to-severe AD. Eligible 
subjects must have a documented history of inadequate response to topical AD 
medication(s). 
Approximately 245 subjects will be randomized 1:1 to receive either 30 mg nemolizumab 
(with a 60 mg loading dose) or placebo, stratified by baseline disease severity 
 
16.9). 
The study consists of 3 periods with up to 28 weeks total study duration: a 2- to 4-week 
screening period, a 16-week treatment period, and an 8-week follow-up period (12 weeks 
after the last study drug injection). 
Screening Period
The screening period will evaluate subject eligibility. Subjects will apply a moisturizer at 
least once daily, beginning at screening. Subjects using a stable regimen of low- or 
medium-potency TCS with or without topical calcineurin inhibitor (TCI) at the screening 
visit (ie, ≥ 14 days prior to the baseline visit) should continue their therapy regimen. 
Subjects not using a stable regimen of TCS with or without TCI at the screening visit 
should not use these topical therapies during the study unless required as rescue therapy.
Rescue therapies are not permitted during the screening period.
Treatment Period
At the baseline visit, subjects will receive a loading dose of nemolizumab (60 mg) or 
placebo via 2 subcutaneous injections. Nemolizumab (30 mg) or placebo will then be 
administered via a single subcutaneous injection Q4W at Week 4, 8, and 12. At the 
Week 12 visit, subjects will also receive single doses of 
 
vaccines. Clinical assessments will 
occur according to the schedule of assessments in Table 4.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
PPD
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 40 of 133
Subjects will continue to apply a moisturizer at least once daily. Subjects using 
background topical therapy (TCS with or without TCI) from the screening visit will 
continue use in the treatment period, which should be adjusted according to the disease 
activity and tolerability, based on investigator clinical judgment. (Subjects not using 
background topical therapy from the screening visit should not apply background topical 
therapy in the study.) If deemed to be medically necessary by the investigator (eg, to 
control intolerable AD signs/symptoms), topical and/or phototherapy rescue therapies can 
be prescribed to any subject at any time during the study, except during the screening 
period.
Subjects who complete the Week 16 treatment period may be eligible to enroll into an
LTE study (Protocol 118163). 
Follow-Up Period
The follow-up visit is not required for subjects who participate in the LTE study.
Subjects who decline or are not eligible to enter into the LTE study will complete a 
follow-up visit at Week 24 (12 weeks after their last study drug injection).
Subjects who discontinue the study prematurely should complete an early termination 
visit and a follow-up visit 12 weeks after their last study drug injection.
The follow-up visit will be conducted 8 weeks after completing the treatment period 
and/or 12 weeks after the last study drug injection. Twelve weeks corresponds to 
approximately 5 half-lives when nemolizumab 30 mg is dosed subcutaneously every 
4 weeks.
An IDMC will review and monitor subject safety throughout the study, and an IAC will 
review all asthma-related AEs. Details on the IDMC and IAC, including the plan of 
analysis for outputs, the composition of the committees, the procedures, roles, 
responsibilities and their communications are provided in the IDMC and IAC charters, 
respectively.
An overview of the study design is present in Figure 1.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 41 of 133
Figure 1:
Study Design
7.2
Discussion of Study Design
The study population is selected based on the need to understand the effect of 
nemolizumab on immune responses to vaccination in subjects with AD. Tetanus and 
meningococcal vaccines were selected for evaluation in subjects ≥ 12 years through 
54 years of age based on their standard use, heterogeneous preparation (toxoid and 
conjugate polysaccharide), and indicated population. A placebo arm is included in the 
study to ensure any effect on vaccination response by nemolizumab can be detected.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 42 of 133
To evaluate the effect of nemolizumab on humoral immune responses to vaccination, the 
PK profile of nemolizumab was considered. No accumulation in serum is observed after 
repeated administration of nemolizumab. Nemolizumab demonstrates a time linear PK 
profile with steady state concentrations achieved by Week 4 following administration of a 
loading dose. The PK profile of Nemolizumab is predictable with time and is not affected 
by the immunogenicity of Nemolizumab; therefore, a treatment duration > 4 weeks is 
acceptable to evaluate this response.
The 16-week treatment period is considered adequate to measure immune responses to 
tetanus and meningococcal vaccination administered at Week 12 (immune response 
measured 4 weeks post-vaccination) as well as to evaluate the safety and efficacy of 
nemolizumab, with final study dose scheduled for Week 12. 
Immunization response to Tdap will be measured as anti-tetanus antibody titers (absolute 
anti-tetanus IgG concentrations and fold-increase in anti-tetanus IgG concentrations from 
baseline), taking into account subjects’ pre-vaccination anti-tetanus IgG concentrations. 
Immunization response to MCV4 will be assessed as anti-meningococcal serogroup C 
functional humoral response (SBA reciprocal titer and fold-increase in SBA reciprocal 
titer from baseline). These endpoints were selected based on positive response criteria 
defined by each vaccine 19,20 and by regulatory guidance 21,22,23 to demonstrate antibody 
quantitative and qualitative effects, respectively.
As the anti-tetanus IgG titer of ≥0.1 IU/mL is generally recognized as seroprotective, the 
primary endpoint was defined for subjects with and without existing pre-vaccination
seroprotective titers. Response for subjects with existing anti-tetanus IgG (≥0.1 IU/mL)
at baseline was defined as a 4-fold increase in anti-tetanus IgG titer from baseline, 
indicative of a booster response. Response for subjects without existing IgG 
(< 0.1 IU/mL) was defined as 0.2 IU/mL, a concentration 2-fold higher than the 
recognized seroprotection level. As subjects with already high anti-tetanus IgG titers at 
baseline may not achieve a 4-fold increase in IgG following vaccination, a secondary 
endpoint identical to the primary endpoint but with response defined as a 2-fold increase 
in titer for subjects with pre-existing anti-tetanus IgG was also included. 
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 43 of 133
A follow-up visit is scheduled for subject safety and will occur at the Week 24 visit 
(12 weeks after the last dose of study medication). The duration of the follow-up period 
corresponds to approximately 5 half-lives of nemolizumab, which is considered adequate 
to ensure subject safety.
7.3
End of Study
A subject will have fulfilled the requirements for study completion if/when the subject
has completed all study periods, including the follow-up visit at Week 24 or the last 
scheduled visit as indicated in the schedule of assessments (Table 4).
The end of the study will be the last subject’s last visit or the last subject’s scheduled visit 
as indicated in the schedule of assessments (Table 4).
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 44 of 133
8
SELECTION OF STUDY POPULATION
Section 7.1 provides information regarding the number of subjects planned to be 
randomized.
8.1
Inclusion Criteria
Individuals must meet all of the following criteria to be included in the study:
1. Male or female subjects aged ≥ 12 years through 54 years at the screening visit.
Note: Enrollment of subjects aged 12 to 17 years will begin after an interim PK 
and safety analysis of data from the phase 2 study SPR.116912 are conducted by 
the sponsor and an IDMC to determine whether enrollment of this age group is 
safe. Following Independent Ethics Committees (IECs)/Institutional Review 
Boards (IRBs) approval, the sponsor will send a written communication to the 
site confirming that the study is open for enrollment of adolescents. Adolescents 
must not be enrolled in the study until such communication is received.
2. Chronic AD for at least 2 years before the screening visit, and confirmed according to 
American Academy of Dermatology Consensus Criteria (Appendix 1)2 at the time of 
the screening visit.
3. EASI score ≥ 16 at both the screening and baseline visits.
4. IGA score ≥ 3 (based on the IGA scale ranging from 0 to 4, in which 3 is moderate 
and 4 is severe) at both the screening and baseline visits.
5. AD involvement ≥ 10% of BSA at both the screening and baseline visits.
6. Peak (maximum) pruritus NRS score of at least 4.0 at the screening and baseline visit. 
Peak pruritus (PP) NRS score at screening will be determined by a single NRS 
assessment (score ranging from 0 to 10) for the 24-hour period immediately 
preceding the screening visit.
Baseline PP NRS score will be determined based on the average of daily NRS scores 
(score ranging from 0 to 10) during the 7 days immediately preceding baseline 
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 45 of 133
(rounding is not permitted). A minimum of 4 daily scores out of the 7 days 
immediately preceding baseline is required for this calculation.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 46 of 133
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 47 of 133
8.2
Exclusion Criteria
Individuals meeting any of the following criteria at screening or baseline are ineligible to 
participate in this study:
1. Body weight < 30 kg.
2. History of hypersensitivity (including anaphylaxis) to an immunoglobulin product 
(plasma-derived or recombinant, eg, monoclonal antibody) or to any of the study drug 
excipients.
3. History of severe allergic reaction to either vaccine or to vaccine components 
including alum, thimerosal, phenol.
4. Subjects for whom administration of the meningococcal vaccine provided in this 
study is contraindicated or medically inadvisable, according to prescribing 
information of the commercially available vaccine.
5. Subjects for whom administration of the tetanus, diphtheria, and pertussis vaccine 
provided in this study is contraindicated or medically inadvisable, according to 
prescribing information of the commercially available vaccine, especially a history of 
seizures or progressive encephalopathy after previous dosing.
6. Receipt of any vaccine (except inactivated influenza vaccine) within 12 weeks prior 
to screening, any meningococcal vaccine within 1 year prior to screening, or any 
tetanus-, diphtheria-, or pertussis-containing vaccine within 5 years prior to screening. 
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 48 of 133
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 49 of 133
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 50 of 133
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 51 of 133
8.3
Rescreening
Screen failures may be allowed to rescreen up to 1 time, unless the reason for screen 
failure is related to disease severity inclusion criteria (
). 
Subjects who screen fail due to disease severity are not allowed to rescreen. Subjects who 
are rescreened must sign a new informed consent form (ICF) and be assigned a new 
subject identification number (SIN).
8.4
Study Withdrawal, Removal, and Replacement of Subjects
Although the importance of completing the entire clinical study will be explained to the 
subjects, any subject is free to discontinue his/her participation in the study at any time 
and for whatever reason, specified or unspecified, and without any prejudice. No 
constraints are to be imposed on the subject, and when appropriate, a subject may be 
treated with other conventional therapy when clinically indicated. Investigators or the 
sponsor can also withdraw subjects from the clinical study if deemed to be necessary.
If a subject discontinues study treatment or is withdrawn from the study for any reason, 
the study site must immediately notify the medical monitor. The date and the reason for 
study drug discontinuation must be recorded on the electronic case report form (eCRF). 
Subjects who prematurely discontinue study drug will be encouraged to complete the 
scheduled study visits. Subjects who complete or discontinue early from the study will be 
asked to return to the study site to complete the follow-up assessments as indicated in the 
schedule of assessments (Table 4).
In the event that a subject discontinues prematurely from the study because of a TEAE or 
serious TEAE, he/she will be followed up until it resolves (returns to normal or baseline 
values) or stabilizes, or until it is judged by the investigator to no longer be clinically 
significant.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 52 of 133
Once a subject is withdrawn from the study, the subject may not reenter the study.
Reasons for discontinuing study drug include, but are not limited to, the following:

Subject request (ie, consent withdrawal)

Non-compliance with the study drug or study schedule

Lost to follow-up

Occurrence of AEs, including laboratory abnormalities, not compatible with the 
continuation of subject participation in the study, in the investigator’s opinion, or 
unacceptable to the subject to continue, including but not limited to the following:
o
Serious immediate-type allergic manifestations including anaphylactic 
reaction
o
Serious worsening of asthma considered related to study drug administration
o
Diagnosis of a malignancy (except curatively treated in situ cervical 
carcinoma, squamous cell carcinoma [Bowen’s disease] or basal cell 
carcinoma)
o
Opportunistic infections such as but not limited to active TB and other 
infections whose nature or course suggest an immune-compromised or 
immune-suppressed status
o
Any serious infection or any severe infection requiring treatment with 
parenteral antibiotics or oral antibiotics/antivirals/antifungals for > 2 weeks
considered related to study drug administration
o
Confirmed or suspected COVID-19 infection (temporary discontinuation may 
be acceptable; for instructions on resuming study drug administration, see 
Section 8.4.2)

Pregnancy as indicated in Section 8.4.1

Use of non-permitted concurrent therapy (unless discussed and agreed upon with 
the investigator and medical monitor)

Use of systemic rescue therapy, as specified in Section 9.6.1.3 and Table 3 of 
Section 9.6.2

Treatment failure
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 53 of 133

Investigator request

Sponsor request, including any of the above criteria
Additionally, the sponsor may stop the study at any time for safety, regulatory, legal, or 
other reasons aligned with Good Clinical Practice (GCP) guidelines. This study may be 
terminated at the discretion of the sponsor or any regulatory agency. An investigator may 
elect to discontinue or stop the study at his or her study site for any reason, including 
safety or low enrollment.
Pregnancy
Subjects will be instructed that a known or suspected pregnancy occurring during the 
study should be confirmed and reported to the investigator (see Section 13.1.5). If a 
subject becomes pregnant, the investigator must withdraw the subject from the 
study without delay. The subject must not receive any further injection(s) of the 
study drug or vaccinations.
COVID-19 Infection
Study drug administration will be discontinued in a subject in whom a COVID-19 
infection is confirmed or suspected. COVID-19 must be specified as the reason for study 
drug discontinuation.
Study drug administration may resume in subjects with confirmed or suspected COVID-
19 infection based on investigator judgement after discussion with the medical monitor or 
Sponsor and only if the following minimum conditions are met:

For symptomatic subjects: At least 14 days have passed since recovery, defined as 
resolution of fever without the use of fever-reducing medications and 
improvement in respiratory symptoms (e.g. cough, shortness of breath)

For asymptomatic subjects: At least 21 days have passed since the positive 
polymerase chain reaction test and no symptoms.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 54 of 133
Note: The above should be considered minimum criteria. Where the local 
guidelines are more stringent for infection resolution criteria, those must 
be applied.
See Appendix 4 for additional guidance for management of subjects and study conduct 
during the COVID-19 pandemic.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 55 of 133
9
TREATMENTS
9.1
Details of Study Drug and Vaccines
Study Drug
“Study drug” or “study medication” refers to nemolizumab or placebo drug product for 
purposes of this double-blind study. The list of excipients are detailed in the IB.
Nemolizumab 30 mg and placebo will be provided as lyophilized powder for solution for 
injection for subcutaneous use only after reconstitution in a pre-filled, single-use, dual-
chamber syringe (DCS). 
The lyophilized nemolizumab (CD14152) powder (39 mg) and solution for reconstitution 
(0.595 mL) are stored in separate syringe chambers, with each DCS designed to deliver a 
30-mg dose of nemolizumab (CD14152) after reconstitution. 
Subjects will receive a loading dose of nemolizumab (eg, 60 mg) or placebo by 2 SC
injections at baseline and a single 30-mg dose at Weeks 4, 8, and 12.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 56 of 133
9.1.1.2
Study Drug Injection
All study drug injections will be performed by the study center staff at the study centers, 
following instructions provided in the current version of the pharmacy manual and the 
instructions for use. After confirming that the study drug is fully reconstituted, the 
pharmacist (or other qualified personnel) will deliver the DCS to the investigator or other 
qualified personnel, for subcutaneous injection in the subject’s abdomen, front upper 
thigh, or outer upper arm. Good hygiene practices and clean techniques must apply at all 
times. A different injection site should be selected for each injection. Refer to the current 
version of the pharmacy manual and the instructions for use for further details. The site of 
injection should be recorded in the subject’s treatment record as well as the eCRF at each 
time point.
After study drug administration or vaccine administration, subjects will be monitored 
closely for any signs or symptoms of hypersensitivity reaction before being discharged. 
For the first 2 visits where study drug is administered and after vaccines are administered, 
subjects should remain at the study center for at least 30 minutes following the 
injection(s).
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 57 of 133
9.1.2.1
Preparation of Vaccines
A pharmacist (or other qualified personnel) will prepare the vaccines for injection 
according to the instructions in the respective prescribing information. 
9.1.2.2
Injection of Vaccines
Vaccine administration will occur at the study centers by study center/clinical staff. 
Intramuscular injections of vaccines will be done according to the instructions in the 
prescribing information. The vaccines will be administered separately (with 2 different 
syringes) at 2 different injection sites. 
After administration of the vaccines, subjects should stay in the office for 15 to 
20 minutes to observe for potential severe reactions to the vaccine including dyspnea, 
wheezing, dizziness, and/or rash accompanied with itching.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 58 of 133
9.2
Dosage Schedule
Table 2 summarizes study drug dosing for the 16 week treatment period. 
Table 2:
Treatment Period Dosing By Treatment Group
Treatment 
Group
Dose/route
Week(s)
Schedule
Nemolizumab 
(CD14152)
30 mg × 2 SC injections
30 mg × 1 SC injections
Baseline
4, 8, 12
Baseline
Q4W
Placebo
Placebo× 2 SC injections
Placebo× 1 SC injections
Baseline
4, 8, 12
Baseline
Q4W
Abbreviation(s): Q4W=every 4 weeks; Q8W=every 8 weeks; SC=subcutaneous.
Tdap and MCV4 will be administered separately each as a 0.5 mL intramuscular injection 
at Week 12.
Subjects requiring any rescue therapy during the screening period are ineligible for 
participation in the study. Subjects requiring systemic rescue therapy during the treatment 
period prior to Week 16 must discontinue study treatment.
9.3
Measures to Minimize Bias: Study Treatment Assignment and Blinding
Method of Study Treatment Assignment
At the baseline visit, a unique randomization number will be assigned to an eligible
subject via interactive response technology (IRT). Subjects will be randomized in a 1:1 
ratio to receive either nemolizumab or placebo. The randomization scheme will be 
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 59 of 133
stratified by baseline disease severity 
to ensure 
appropriate distribution of assignment to the 2 treatment groups.
Blinding
All attempts will be made to keep the study center staff and subjects blinded throughout 
the study. Members of the study center staff, including those responsible for DCS 
preparation, will not have access to the randomized treatment assignment. 
To ensure double-blind administration of study drug, the study center pharmacist(s) or 
other qualified personnel will prepare all nemolizumab or placebo treatments, according 
to the current version of the pharmacy manual, the instructions for use, and assigned DCS 
provided by the IRT system.
As there may be detectable differences between active and placebo during the 
reconstitution process, the DCS is delivered for injection after the reconstitution is 
complete. The pharmacist (or other qualified personnel) preparing study medication 
should not be involved with any study assessments and should not discuss any aspects of 
study drug reconstitution with the subject/caregiver or study staff involved in subject 
interviews or study assessments.
To maintain the integrity of the study blinding, the bioanalytical laboratory staff who 
process/analyze the PK/
samples will not provide any information to sponsor, 
clinical research organization (CRO), or investigational study center personnel directly 
involved with the ongoing conduct of the study that may lead to unblinding during the 
ongoing study. 
Unblinding of a subject’s individual treatment code should occur only in case of a
medical emergency or in the event of a serious medical condition that necessitates
identification of the study drug for the welfare of that subject, as judged by the
investigator. The emergency unblinding process utilizes IRT to allow the investigator to
have unrestricted, immediate, and direct access to the subject’s individual study
treatment. When possible (ie, when the health of the subject is not immediately at risk),
the investigator or sub-investigator is encouraged to consult with the medical monitor and
the sponsor before breaking the blind.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 60 of 133
If emergency unblinding is required:

Only the investigator will make the decision to unblind the treatment assignment.

Only the affected subject will be unblinded.

The IRT system will provide the treatment assignment to the investigator.
Refer to the Randomization and Trial Supply Management (RTSM) User Guide for
information on the steps for breaking the blind in the IRT system.
When the blinding code is broken, the reason must be fully documented. If the code is 
broken by the investigator, the subject must be withdrawn from the study and must also 
be appropriately followed for a minimum of 12 weeks after the last dose of study drug.
The reporting requirements for unblinding are the same for reporting an SAE (see 
Section 13.1.3).
The randomization code will remain blinded to all study sites and study team members 
until completion of the study and after the study database has been locked. Although 
initial treatment period results will be analyzed after all subjects have either completed 
the Week 16 visit, or have withdrawn or been discontinued from the study before 
Week 16, personnel from sponsor, CRO, and investigational sites directly involved with 
the ongoing conduct of the study will not have access to any information that may lead to 
unblinding for the ongoing maintenance evaluation.
The IDMC will review data at periodic intervals throughout the study as defined in the 
IDMC charter. The IDMC charter will specify the procedures for unblinding to ensure 
that treatment assignment remains undisclosed to all individuals involved in the direct 
execution and management of the study until the final database is locked. 
9.4
Dosage Modification
Dose modification of the study drug and vaccines will not be permitted during the clinical 
study. 
Any inadvertent dose modification(s) should be reported to the sponsor/CRO. 
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 61 of 133
In the event of a missed dose (ie, temporary discontinuation of the study drug), it will be 
documented in the eCRF that the drug has not been administered at the study visit, 
together with the reason (eg, for safety). Subjects will be asked to return to the study 
centers for all remaining visits and complete all study assessments and procedures as 
described in Section 10.
Dosing frequency of study drug (nemolizumab and placebo) is scheduled for Q4W, based 
on the baseline/Day 1 visit date. If a study visit occurs outside the visit window, study 
drug can be administered provided there is a minimum of 3 weeks since the last injection. 
Future visits should be scheduled within the required windows based on the 
baseline/Day 1 visit date, while maintaining the minimum 3-week interval between 
2 injections. Vaccines will be administered as single separate doses at Week 12. 
9.5
Accountability and Compliance
Study drug (nemolizumab and placebo) and vaccines will be provided to the 
investigational site. Site personnel will acknowledge receipt of the study drug using IRT 
to confirm the shipment condition and content. If a damaged shipment is received and/or 
a temperature excursion has been experienced, he/she will notify the sponsor/CRO and 
follow the guidelines according to the current version of the pharmacy manual.
The designated personnel will maintain accurate records of the study drug and vaccines 
throughout the clinical study, including the inventory delivered to the study center, the 
use by each subject, the reconciliation of all delivered and received DCS units, and the 
return/destruction of unused study drug as specified in the current version of the 
pharmacy manual. No unauthorized use is permitted. Used DCS and vaccine units will be 
properly documented in drug accountability records. Unless a product technical 
complaint (PTC) is detected or an event occurs before, during, or just after the injection, 
the used DCS and vaccine units can be disposed of in an appropriate sharps container and 
according to waste regulation(s) in the country. A DCS involved in a malfunction or an 
investigator or subject complaint must be retained on site and designated personnel must 
proceed as defined in the current version of the pharmacy manual. Refer to Section 9.6.3
for PTCs.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 62 of 133
The study monitor may check the study supplies at each study center at any time during 
the study. It is the responsibility of the study monitor to ensure that the investigator (or 
designee) has correctly documented the amount of the study drug and vaccines received, 
dispensed, and returned/destroyed on the dispensing log that will be provided. A full drug 
accountability log will be maintained at the study center at all times. The study monitor 
will arrange collection of any unused study drug not destroyed by the site. The study 
monitor will also perform an inventory of study drug and vaccines at the close-out visit to 
the study center. All discrepancies must be accounted for and documented.
9.6
Prior and Concomitant Therapies
Prior therapies and medications are defined as therapies/medications that have been 
stopped within the 3 months before the screening visit, unless relevant to the 
inclusion/exclusion criteria. Whenever possible, all prior therapies/medications for AD 
and all prior vaccinations should be documented. 
Concomitant therapies/medications are defined as follows:

Any existing therapies ongoing at the time of the screening visit,

Any changes to existing therapies (such as changes in dose, formulation or 
application frequency) during the course of the study, or

Any new therapies received by the subject since the screening visit  
The following 2 categories are to be considered for prior and concomitant therapies: 

Drugs/therapies include but are not limited to prescription, over-the-counter, birth 
control pills/patches/hormonal devices, vitamins, moisturizers, sunscreens, herbal 
medicines/supplements, homeopathic preparations, and other alternative 
medications

Medical and surgical procedures (eg, phototherapy, exodontia). Procedures whose 
sole purpose is diagnosis (non-therapeutic) are not included
Prior and concomitant therapies or medical/surgical procedures are to be recorded in the 
appropriate eCRF. 
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 63 of 133
Concomitant therapies are to be recorded, reviewed, and updated at each visit. 
At each visit, investigators should also confirm concomitant therapies for contraception. 
Contraceptive counseling should occur at screening or at appropriate visits when pre-
pubertal subjects begin menses. 
Any new concomitant therapy or modification of an existing therapy may be linked to an 
AE. In such cases, a corresponding AE form should be completed to account for the new 
therapy or change in therapy.
Restricted prior therapies are provided in Section 8.2.
Permitted Concomitant Therapy
Unless specified as prohibited therapies (see Section 9.6.2), all therapies are authorized, 
including basic skin care (cleansing and bathing), moisturizers, bleach baths, topical 
anesthetics, and antihistamines without a sedative effect.
The formation of cytochrome P450 (CYP450) metabolic enzymes can be altered by 
increased levels of certain cytokines (eg, IL-1, IL-6, and IL-10) during chronic 
inflammation. Although there is no known evidence suggesting that IL-31 affects the 
level or activity of CYP450 enzymes, the impact of nemolizumab on such enzymes has 
not been studied. Therefore, investigators should be attentive to clinical or laboratory 
signs that might indicate a potential effect of nemolizumab in subjects using other 
therapies that are CYP450 substrates and have a narrow therapeutic index.
Only the following non-live vaccinations are permitted during the study and follow-up 
period, besides the vaccines specifically administered in this study (ie, Tdap, MCV4):

seasonal vaccinations (eg, inactivated influenza)

COVID-19 vaccinations.
Wherever possible, it is recommended to avoid administration of seasonal and COVID-
19 vaccinations within 1 week before or after study drug dosing, and a different 
anatomical location should be used for study drug administration and vaccine 
administration. For guidance on administration of COVID-19 vaccines and study 
vaccinations, see Appendix 4.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 64 of 133
9.6.1.1
Topical Background Therapy
At the screening visit (≥14 days prior to baseline), subjects who are using a stable 
regimen of medium- or low-potency TCS therapy, with or without TCI therapy, should 
continue their therapy regimen. 
Background therapy use should be adjusted to the disease activity and tolerability of the 
subject, including tapering when signs and symptoms improve, discontinuation when 
lesions clear, and restarting if signs and symptoms recur, at the discretion of the 
investigator.
Subjects who are not using a stable regimen of topical therapy at the screening visit 
should not use topical background therapy during the study, unless required as rescue 
therapy (see Section 9.6.1.3).
Subjects with a history of intolerance to TCS or for whom TCS are not advisable (eg, 
hypersensitivity, significant skin atrophy) must not use TCS background therapy.
9.6.1.2
Moisturizer
Subjects will apply a moisturizer at least once daily, and liberally as needed, to dry skin 
and AD lesions beginning at screening, and throughout the study. The subject’s current 
moisturizer or a moisturizer recommended by the investigator may be used. Use should 
not occur within 8 hours before each clinic/office visit. Whenever possible, subjects 
should use the same moisturizer throughout the study. Moisturizer used and any 
adjustments should be documented in the eCRF.
9.6.1.3
Rescue Therapy
If deemed to be medically necessary by the investigator (eg, to control intolerable AD 
signs/symptoms), topical and/or phototherapy rescue treatments can be prescribed to the 
subjects at any time during the study except during the screening period. Subjects 
receiving any rescue therapy during the screening period are ineligible for participation in 
the study. Subjects receiving systemic rescue during the treatment period must 
discontinue study treatment. 
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 65 of 133
As a general guideline and per individual investigator judgment, rescue therapy should
not be prescribed within the first 2 weeks after baseline (ie, Week 2) to allow a minimum 
time for study drug exposure.
Permitted rescue therapies during the treatment period include: 

TCS (higher potency than used at baseline for subjects using TCS background 
therapy; any potency for subjects not using TCS background therapy)

TCI (only for subjects not using TCI background therapy at baseline)

Phototherapy
Rescue treatments are only approved and/or standard of care treatments that directly treat 
AD. Antihistamines, sleep aids, topical and systemic antibiotics, and anti-itch creams are 
not considered to be rescue therapy because they do not directly treat AD.
Whenever possible, investigators should first use topical medications as rescue therapy 
before escalating to systemic therapies. If subjects receive topical treatments or 
phototherapy as rescue therapy, study drug and vaccine administration should be 
continued unless there is a safety concern according to the investigator’s judgment. If 
subjects receive systemic rescue therapy, they should permanently discontinue study
treatment. 
Prohibited Medication/Therapy
Treatment with the following concomitant medications/therapies is prohibited during the 
study unless otherwise specified in Table 3. “As needed” (PRN) use of TCS or TCI is not 
permitted.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 66 of 133
Table 3:
Prohibited Medication/Therapy and Timeframe Prior to Baseline
Treatment(s)
Timeframe
Before 
Baseline/Day 1
Day 1 –
Week 24
Coal tar products
2 weeks
Prohibited
Topical PDE-4 inhibitor
2 weeks
Prohibited
TCI, only for subjects not using stable TCI therapy ≥14 days prior 
to baseline
2 weeks
Prohibited*
High- or very high-potency TCS (Class I-II according to the US 
classification)2 (applies to all subjects); any TCS only for subjects 
not using stable TCS therapy ≥ 14 days prior to baseline
2 weeks
Prohibited*
Topical medications, including TCS/TCI, with occlusive dressings 
(eg, wet wraps)
2 weeks
Prohibited
Systemic corticosteroids (corticosteroid inhalers are permitted)
4 weeks 
Prohibited
Phototherapy
4 weeks
Prohibited*
Tanning bed use
4 weeks
Prohibited 
Immunosuppressive or immunomodulatory drugs (eg, cyclosporine 
A, oral tacrolimus, cyclophosphamide, azathioprine, methotrexate, 
mycophenolate mofetil)
4 weeks or 5 half-
lives (whichever 
is longer)
Prohibited
Biologics and their biosimilars (eg, dupilumab, etanercept, 
adalimumab, infliximab, omalizumab, etc)
8 weeks or 5 half-
lives (whichever 
is longer)
Prohibited
Investigational topical and systemic medication (eg, topical or oral 
JAK inhibitors)
8 weeks or 5 half-
lives (whichever 
is longer)
Prohibited
Drugs with a sedative effect such as benzodiazepines, 
imidazopyridines, barbiturates, or sedative anti-depressants (eg, 
amitriptyline), except if these treatments were taken at a stable 
dose for at least 3 months before screening
(Stable treatment with antihistamines with sedative effect, SSRIs, 
or SNRIs is allowed.)
1 week
Prohibited
Gabapentinoids (eg, gabapentin, pregabalin)
4 weeks
Prohibited
Cannabinoids
2 weeks
Prohibited
Alternative medicine for AD (eg, traditional Chinese medicine)
2 weeks
Prohibited
Live (attenuated) vaccines
12 weeks
Prohibited
Non-live vaccines, except vaccines specifically administered in the 
study (exceptions apply; see Section 9.6.1)
12 weeks
Prohibited 
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 67 of 133
Abbreviation(s): AD=atopic dermatitis; JAK=Janus kinase; PDE-4=phosphodiesterase-4; SNRI=serotonin-
norepinephrine reuptake inhibitor; SSRI=selective serotonin reuptake inhibitor; TCI=topical calcineurin 
inhibitor; TCS=topical corticosteroid.
* Unless used as rescue therapy
Note: These treatments should not be discontinued for reasons related to this clinical study.
If a prohibited therapy becomes necessary for the safety of the subject, the investigator 
should notify the medical monitor and discuss possible alternatives. If a subject receives a 
prohibited therapy during the clinical study (eg, inadvertent short-term use), the 
investigator should also notify the medical monitor and discuss whether or not it is 
acceptable for the subject to continue receiving the study drug.
Vaccinations during the study and follow-up period are not permitted, except for use of 
vaccines specifically administered in this study (ie, Tdap, MCV4) and non-live vaccines 
specified in Section 9.6.1.
Product Technical Complaints
All DCS and vaccine units must be inspected prior to preparation/injection by the persons 
performing the preparation/injection to ensure absence of visual defects that could lead to 
a DCS or vaccine PTC. This also includes the DCS plunger rod. In case of doubt, the 
DCS or vaccine should not be used, and the deficiency must be reported as defined in the 
pharmacy manual.
All PTCs should be reported to the sponsor/designee by filing the relevant forms 
available in the Investigator Site File and the pharmacy manual and as required by local 
regulations. 
Refer to the current version of the pharmacy manual for further details.
9.7
Duration of Subject Participation
The expected duration for each subject’s participation in the study is up to 28 weeks,
including a 2- to 4-week screening period, a 16-week treatment period, and an 8-week 
follow-up period (12 weeks after the last study medication injection).
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 68 of 133
The 12-week follow-up visit is not required for subjects who will continue in the LTE
study (Protocol 118163).
Early Termination Visit
Subjects may discontinue from the study or discontinue the study treatment only and 
continue to participate in the study.
Subjects who prematurely discontinue from the study should undergo final study 
assessments according to the following guidelines:

Subjects discontinued from the study during the treatment period on/before the 
Week 16 visit should attend an early termination visit. 

A follow-up/final visit is required 12 weeks after the last study drug 
administration.
Subjects who prematurely discontinue the study drug will be asked to continue 
participation in the study; however, subjects who discontinue the study drug prior to 
Week 12 should not be vaccinated. Subjects will be asked to return for all remaining 
visits and assessments (including daily assessment of pruritus, sleep disturbance, etc). 
Participation will continue until the subject completes the final study visit or otherwise 
discontinues study participation.
Unscheduled Visit
The subject should be reminded to adhere to the study schedule. Unscheduled visits are 
defined as visits to repeat testing for abnormal laboratory results, for follow-up of AEs, or 
to conduct efficacy assessments for subjects requiring rescue medication between 
regularly scheduled study visits. Visits occurring outside of the visit window are not 
considered unscheduled visits.
Assessments to be conducted at the unscheduled visit will depend on the reason for the 
visit: Any of the procedures/assessments listed in Table 4 may be conducted, but not all 
are required. However, blood sample collection for 
 are required 
during unscheduled visits that are conducted for safety reasons.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 69 of 133
10
STUDY PROCEDURES
A written, signed ICF, assent form, and Health Insurance Portability and Accountability 
Act (HIPAA) authorization is required before any study-related procedures are 
performed. 
Upon provision of the signed ICF/assent form, each subject will be assigned a unique 
SIN. For the duration of the entire clinical study, the subject will be identified using the 
SIN in all documentations and discussion.
The planned study assessments are in Table 4. At each visit, assessments/procedures 
should be performed in the following order: 
1. Patient-reported safety measurements
2. Investigator assessments (including efficacy and safety)

Electrocardiogram (ECG) should be done before vital signs measurements and 
blood draws (see Section 13.7).
3. Sample collections for laboratory assessments
4. Sample collections for correlative assessments (PK, 
vaccine response)
5. Administration of study drug injections and vaccines
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 70 of 133
 
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL20
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 71 of 133
 
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL20
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 72 of 133
 
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL20
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 73 of 133
 
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL20
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 74 of 133
11
IMMUNOGENICITY ASSESSMENTS
11.1
Vaccine Response
Humoral immune responses to tetanus and meningococcal vaccination will be determined 
using serum samples collected from all subjects according to Table 4.
Tetanus Toxoid IgG Antibody Concentration
Serum concentrations of anti-tetanus IgG will be assessed. The detection and 
characterization of antibodies to tetanus toxoid will be performed using a validated 
immunoassay.
Meningococcal Serogroup C SBA Reciprocal Titer
Immune response to meningococcal vaccination will be determined by measuring 
functional antibody responses using an SBA assay. 
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 75 of 133
12
EFFICACY ASSESSMENTS
Efficacy measurements should be conducted by the investigators (or trained designees) 
and subjects (for patient-reported efficacy measurements) according to Table 4. 
Whenever possible, the same evaluator should make the assessment throughout the study.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 76 of 133
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 77 of 133
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 78 of 133
13
SAFETY ASSESSMENTS
Safety assessments will be conducted for all subjects at the screening visit (upon signing 
of the ICF) and at every subsequent visit.
13.1
Adverse Events
Adverse Event Definition
An AE is defined as any untoward medical occurrence in a clinical study subject 
administered a medicinal product which does not necessarily have a causal relationship 
with this treatment. An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease temporally associated 
with the use of a medicinal (investigational) product, whether or not it is related to the 
medicinal (investigational) product. This includes an exacerbation of preexisting 
conditions or events, intercurrent illnesses, drug interaction, or the significant worsening 
of the indication under investigation that is not recorded elsewhere in the eCRF under 
specific efficacy assessments. 
Note(s): 

Any new sign or symptom reported by the subject that appears after accidental or 
intentional overdose or misuse should be reported as an AE.

Whenever possible, a diagnosis should be reported on the AE form, instead of 
signs, symptoms, or abnormal laboratory values. 

Pregnancy is not to be considered an AE; however, it must be monitored and 
reported as described in Section 13.1.5.

Each worsening of a chronic disease from the screening visit should be reported 
as a new AE.
The investigator or designee will report all AEs that occur from the time the ICF is signed 
until the end of the study. The sponsor/CRO should be informed if the investigator 
becomes aware of any safety information that appears to be drug-related, even after the 
subject has completed the clinical study.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 79 of 133
At each post enrollment visit, the investigator (or sub-investigator) will question the 
subject about AEs using an open non persuasive question to elicit reporting of AEs (for 
example, “Have you noticed any change in your health since the last visit?”). Directed 
questioning and examination will then be performed as appropriate. 
Any AE occurring during the AE reporting period, whether it is related to the study 
drug(s) or not, will be recorded immediately in the source document and described on the 
Adverse Event Form (“AE Form”) along with the date of onset, severity, relationship to 
the study drug(s), and outcome, without omitting any requested and known information. 
Additional information will be requested under certain circumstances. 
Adverse events assessed as related to the treatment or study procedure will be monitored 
until they have resolved or reached a stable condition. Other AEs will be monitored until 
the last visit if they have not resolved or reached a stable condition. 
The investigator will obtain and maintain in the subject’s files all pertinent medical 
records, information and medical judgment from colleagues who assisted in the treatment 
and follow-up of the subject. If necessary, the investigator will contact the subject’s 
personal physician or hospital staff to obtain further details.
Assessment of Severity
Each AE will be assigned a category by the investigator as follows:
Mild:
An AE that is easily tolerated by the subject, causes minimal discomfort, and 
does not interfere with everyday activities.
Moderate: An AE that is sufficiently discomforting to interfere with normal everyday 
activities; intervention may be needed.
Severe:
An AE that prevents normal everyday activities; treatment or other 
intervention usually needed.
If there is a change in severity of an AE, it must be recorded as a separate event.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 80 of 133
Assessment of Causality
The investigator is to determine whether there is a reasonable causal relationship between 
the occurrence of the AE, and exposure to the study drug (ie, nemolizumab or placebo) 
and/or study procedure (eg, injection, topical background therapy, blood sample 
collection). Medical judgment should be used to determine the relationship, considering 
all relevant factors including the pattern of the reaction, temporal relationships, relevant 
medical history, and confounding factors such as co-medication or concurrent diseases.
The expression “reasonable causal relationship” is meant to convey in general that there 
are facts or arguments to suggest a causal relationship (International Council for 
Harmonisation [ICH] E2A, Section IIIA 1).
The relationship assessment for an AE is to be completed using the following definitions 
as a guideline for all AEs occurring during this clinical study:
Reasonable possibility:
According to the reporting investigator, there is a reasonable possibility (ie, suggestive 
evidence or arguments) that there is a causal relationship irrespective of the dose 
administered:

Between the study drug (nemolizumab) and the AE, and/or

Between the clinical study protocol procedure (eg, injection, topical background 
therapy, blood sample collection) and the AE
No Reasonable Possibility:
No suggestive evidence or arguments can be identified regarding a causal relationship 
between the study drug or the clinical study protocol procedure and the AE.
Action Taken
The investigator will describe the action taken in the appropriate section of the eCRF, as 
follows:

None
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 81 of 133

Study drug stopped

Study drug temporarily interrupted

Concomitant medication (any additions or discontinuations)

Other, specify
Follow-up of Adverse Events
All investigators should follow-up with subjects with AEs until the event is resolved or 
until, in the opinion of the investigator, the event is stabilized or determined to be 
chronic. Details of AE resolution must be documented in the eCRF.
Subjects should be followed up for 12 weeks (± 5 days) after receiving the last dose of 
study drug, and any AEs that occur during this time should be reported according to the 
procedures outlined above.
Documentation and Reporting of Adverse Events
Adverse events should be reported and documented in accordance with the procedures 
outlined below. All AEs occurring during the study must be documented on the relevant 
eCRF pages. The following data should be documented for each AE:

Description of the symptom event

Classification of “serious” or “not serious”

Severity

Date of first occurrence and date of resolution (if applicable)

Action taken

Causal relationship

Outcome of event (unknown, recovered, not yet recovered, recovered with 
sequelae, death [with date and cause reported])
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 82 of 133
Adverse Events of Special Interest
An AESI is a noteworthy treatment-emergent event for the study drug that should be 
monitored closely and reported promptly. See Section 13.1.4 for reporting procedure. An 
AESI can be either serious or non-serious.
Based on the potential risks of nemolizumab and the risks associated with biologics (and 
their biosimilar equivalents) in general (ie, class effects), the following AEs will be 
considered AESIs: 

Injection-related reactions
o
Anaphylactic reactions
o
Acute allergic reactions requiring treatment
o
Severe injection site reaction (ie, lasting > 24 hours)

Newly diagnosed asthma or worsening of asthma
o
More specifically, subjects with a medical history of asthma will be referred 
to the physician who manages their asthma when:
-
ACT score ≤ 19: An ACT score ≤ 19 conveys asthma that may not be 
adequately controlled. An AESI is reported based on the investigator’s 
clinical judgment, including consideration of the managing physician’s 
report.
-
PEF < 80% of the predicted value: An AESI should be reported.
-
Unexpected worsening of asthma is observed or reported. An AESI is 
reported based on the investigator’s clinical judgment. 
o
Subjects without a medical history of asthma will be referred to an appropriate 
respiratory physician/specialist when:
-
Signs and/or symptoms suggestive of asthma have been observed or 
reported. An AESI is reported based on the investigator’s clinical 
judgment of the specialist’s report.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 83 of 133
-
Respiratory assessments (eg, examination, PEF) suggest a decline in the 
subject’s respiratory health. An AESI is reported based on the 
investigator’s clinical judgment of the specialist’s report.

Infections
o
Any severe infection or any infection requiring treatment with parenteral 
antibiotics or oral antibiotics/antivirals/antifungals for > 2 weeks
o
Any confirmed or suspected COVID-19 infection

Peripheral edema: limbs, bilateral

Facial edema

Elevated ALT or AST (> 3 × ULN) in combination with elevated bilirubin (> 2 × 
ULN)
Serious Adverse Events
An SAE is any untoward medical occurrence or effect that, at any dose,

Results in death.

Is life-threatening (an AE is life-threatening if the subject was at immediate risk 
of death from the event as it occurred, ie, it does not include a reaction that might 
have caused death if it had occurred in a more serious form).

Requires or prolongs inpatient hospitalization. (Complications occurring during 
hospitalization are AEs and SAEs if they cause prolongation of the current 
hospitalization. Inpatient hospitalization is considered to have occurred if the 
subject has had to stay for a night at the hospital. The criterion for prolongation of 
hospitalization is also defined as an extra night at the hospital. Hospitalization 
may not constitute sufficient grounds to be considered as an SAE if it is solely for 
the purpose of diagnostic tests [even if related to an AE], elective hospitalization 
for an intervention that was already planned before subject enrollment in the 
clinical study, admission to a day care facility, social admission [eg, if the subject 
has no place to sleep], or administrative admission [eg, for a yearly examination]. 
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 84 of 133
The details of such hospitalizations must be recorded on the medical history or 
physical examination eCRF.)

Results in persistent or significant disability/incapacity. (An AE is incapacitating 
or disabling if it results in a substantial and/or permanent disruption of the 
subject’s ability to carry out normal life functions.)

Results in a congenital anomaly/birth defect.

An important medical event that may not result in death, be life-threatening, or 
require hospitalization, may be considered an SAE when, based upon appropriate 
medical judgment, the event may jeopardize the safety of the subject, and may 
require medical or surgical intervention to prevent 1 of the outcomes listed above 
in this definition. Examples of such events are intensive treatment in an 
emergency room or at home for allergic bronchospasm, blood dyscrasia, or 
convulsions that do not result in hospitalization.
Procedure for Reporting a Serious Adverse Event
For any SAE occurring during the clinical study, regardless of whether or not related to 
the study drug and/or procedure, the investigator must:
1. Take prompt and appropriate medical action, if necessary. The safety of the 
subject is the first priority.
2. Ensure that the event is evaluated as an SAE. Immediately notify (within 24 
hours of receipt of the event) the 
 
group of an SAE report, by email or fax:
 
 
Note: Immediate SAE reporting is required by the investigator if it occurs during 
the clinical study or within 12 weeks (± 5 days) of receiving the last dose of study 
drug, whether or not the event is considered to be related to the investigational 
product.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
PPD
PPD


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 85 of 133
The demographics, medical history, drugs/therapies, and medical and surgical 
procedures forms must also be available for review in eCRF, at that time.
3. Send any relevant information or anonymized medical records (eg, laboratory test 
results) to the 
(see contact 
details above), within 24 hours of receipt of this relevant information.
4. Monitor and record the progress of the event until it resolves or reaches a stable 
condition, with or without sequelae. For all additional follow-up evaluations, 
complete an updated SAE report within 24 hours of receipt of the updated 
information.
5. Obtain and maintain in the subject files all pertinent medical records, information, 
and medical judgments from colleagues who participate in the treatment and 
follow-up of the subject. If necessary, contact the subject’s personal physician or 
hospital staff to obtain further details.
6. When the outcome of the event is known, complete an updated SAE report, if 
appropriate.
7. Prompt notification of SAEs by the investigator is essential so that legal 
obligations and ethical responsibilities toward the safety of subjects are met. The 
sponsor has a legal responsibility to notify both the local regulatory authority and 
other regulatory agencies about the safety of a product under clinical 
investigation. The sponsor or its delegate (ie, the CRO) will comply with country-
specific regulatory requirements relating to safety reporting to regulatory 
authorities, IRB/IEC and investigators. Investigator safety reports are prepared for 
SUSARs according to local regulatory requirements, and are forwarded to 
investigators as necessary.
An investigator who receives an investigator safety report describing an SAE(s) 
or other specific safety information (eg, summary or listing of SAEs) from the 
sponsor or its delegate (ie, the CRO) will file it accordingly (ie, within the Trial 
Master File [TMF]), and will notify the IRB/IEC, if appropriate according to local 
requirements.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
PPD


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 86 of 133
8. Comply with the applicable regulatory requirement(s) related to the reporting of 
SAEs to the IRB/IEC.
Procedure for Reporting an Adverse Event of Special Interest
For any AESI occurring during the clinical study, regardless of whether or not related to 
the treatment, the investigator must:
1. Take prompt and appropriate medical action, if necessary. The safety of subjects 
is the first priority.
2. Ensure that the event is evaluated as an AESI. Notify (within 3 days of receipt of 
the event) the 
 of an AESI 
report, by email or fax. Refer to Section 13.1.1. 
Note: AESI reporting is required by the investigator if it occurs during the clinical 
study following the first dose of study drug or within 12 weeks (± 5 days) of 
receiving the last dose of study drug, whether or not the event is considered to be 
related to the investigational product.
The demographics, medical history, drugs/therapies, and medical and surgical 
procedures forms must also be available for review in the eCRF, at that time.
3. Send any relevant information or medical records (eg, laboratory test results) to the 
 within 3 days of receipt of this 
relevant information.
4. Monitor and record the progress of the event until it resolves or reaches a stable 
condition, with or without sequelae. For all additional follow-up evaluations, update 
the AESI form within 3 days of receipt of the updated information.
5. Obtain and maintain in the files all pertinent medical records, information, and 
medical judgments from colleagues who participate in the treatment and follow-up of 
the subject. If necessary, contact the subject’s personal physician or hospital staff to 
obtain further details.
6. When the outcome of the event is known, update the AESI form, if appropriate.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
PPD
PPD


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 87 of 133
Procedure for Reporting Pregnancies
Any pregnancy occurring during clinical studies where the fetus could have been exposed 
to the study drug must be monitored until its outcome in order to ensure the complete 
collection of safety data. If a subject becomes pregnant, the investigator must:
1. Withdraw the subject from the clinical study. The subject must not receive any 
further injection of the study drug.
2. Complete as fully as possible the Pregnancy Surveillance Form – Part I: History 
and Start of Pregnancy. Send by email or fax along with the exit form within 24 
hours of receipt of the information, to the 
 
 Refer to Section 13.1.5. 
Note: Immediate pregnancy reporting is required by the investigator if it occurs 
during the clinical study or within 12 weeks (± 5 days) of receiving the last dose 
of study drug, whether or not the event is considered to be related to the 
investigational product.
3. Monitor and record the progress of the pregnancy until its outcome. Contact the 
subject’s regular physician (general practitioner or gynecologist) or hospital staff 
to obtain further details and ask for regular follow-up information.
4. Provide tri-monthly updates until the final outcome of the pregnancy, by 
completing the Pregnancy Surveillance Form – Part II: Course and Outcome of 
Pregnancy. For all additional follow-up evaluations, send the form by email or fax 
to the 
within 24 hours of 
receipt of the information. If the subject can no longer be reached (ie, lost to 
follow-up), documentation of the non-response/contact with 2 phone calls and a 
letter (certified with return receipt) is required.
5. At the outcome of the pregnancy, complete as fully as possible the Pregnancy 
Surveillance Form – Part II: Course and Outcome of Pregnancy. Print and send 
the form by email or fax to the 
 
 within 24 hours of receipt of the information.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
PPD
PPD
PPD


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 88 of 133
6. If the pregnancy leads to an abortion (ie, voluntary abortion, spontaneous 
abortion, or therapeutic abortion), in utero death or congenital anomaly, follow 
the procedure for declaration of/reporting an SAE (see Section 13.1.3).
Unexpected Adverse Reactions
Unexpected Adverse Reaction Definition
An unexpected adverse reaction is any untoward and unintended response that is related 
to the administration of the study drug at any dose, the nature or severity of which is not 
consistent with the applicable product information (eg, reference safety information in the 
IB for nemolizumab, study protocol, etc).
The sponsor or its delegate (ie, 
 will comply with country-specific 
regulatory requirements relating to safety reporting to regulatory authorities, IRB/IEC 
and investigators. Investigator safety reports are prepared for SUSARs according to local 
regulatory requirements and sponsor policy, and are forwarded to investigators as 
necessary.
An investigator who receives an investigator safety report describing an SAE(s) or other 
specific safety information (eg, summary or listing of SAEs) from the sponsor or its 
delegate (ie, 
 will file it accordingly (ie, with the TMF), and will notify the 
IRB/IEC, if appropriate according to local requirements.
13.2
Clinical Laboratory Assessments
The hematology laboratory analyses, clinical chemistry laboratory analyses, and 
urinalyses will be performed at a central laboratory. Reference ranges will be supplied by 
the central laboratory and used by the investigator to assess the laboratory data for
clinical significance and pathological changes. 
The investigator or medically qualified sub-investigator must review and evaluate 
laboratory values for each subject in a timely manner. Study centers should refer to the 
current version of the laboratory manual for laboratory values outside of normal limits. 
For each out-of-range laboratory result, the investigator or designee will evaluate whether 
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
PPD
PPD


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 89 of 133
he/she considers it to be clinically significant, defined as meeting at least 1 of the 
following conditions: 

The abnormality suggests a disease and/or organ toxicity, or

The abnormality is of a degree that requires additional active management, eg, 
discontinuation of the drug, close observation, more frequent follow-up 
assessments, or further diagnostic investigation. 
If the investigator observes a clinically significant laboratory result, the test will be 
repeated as soon as possible and the subject will be monitored until the value returns to 
normal and/or an adequate explanation for the abnormality is found. 
Investigators will also be allowed to repeat specific laboratory test(s) or procedure(s) 
where the investigator suspects an inaccuracy or false result and that which may impact 
the safety of the subject or the interpretation of the trial results; only after discussion with 
medical monitor.
All clinically significant out-of-range laboratory values at the screening visit will be 
recorded in the medical history form (report a diagnosis rather than the laboratory value 
whenever possible). All clinically significant out-of-range laboratory values after the 
screening visit are to be reported as an AE if this abnormality was not present at the 
screening visit or is assessed as having worsened since the screening visit (ie, changed 
significantly from the screening visit). Whenever possible, the investigator should 
provide a diagnosis of an AE when reporting the abnormal laboratory value.
Subjects should be reminded to be well hydrated before all visits for phlebotomy 
purposes. Subjects should fast for at least 8 hours before the visits when blood chemistry 
testing is planned, except for the screening visit. The screening visit laboratory values 
must be available before the baseline visit. Laboratory testing conducted in a nonfasting 
state will not be a protocol deviation.
Total blood volumes to be drawn at each visit are provided in the clinical laboratory 
manual. Additional samples may be required if medically indicated (eg, at unscheduled 
visits for safety reasons, when an abnormal laboratory value is observed and requires a 
re-test). 
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 90 of 133
See Sections 13.2.4, 13.2.5, and 13.2.6 for details regarding pregnancy testing, virology, 
and TB testing samples, respectively. 
The following laboratory safety tests will be performed as specified in.
Hematology
Hemoglobin, hematocrit, white blood cell count (with differential including eosinophils), 
red blood cell count, platelet count, and mean cell volume. 
Clinical Chemistry
Subjects should fast for at least 8 hours before the visits when blood chemistry is 
planned, except the screening visit.
Creatinine, ALT, AST, gamma glutamyltransferase, alkaline phosphatase, lactate 
dehydrogenase, total bilirubin, direct bilirubin, albumin, total protein, uric acid, sodium, 
potassium, calcium, chloride, glucose, urea, total cholesterol, triglycerides, low-density 
lipoprotein, high-density lipoprotein, creatine phosphokinase (CPK), and CPK 
isoenzyme. 
Urinalysis
Glucose, pH, ketones, blood, protein, leukocytes, nitrites, bilirubin, urobilinogen, and 
specific gravity.
Pregnancy Testing
All women of childbearing potential will have a serum pregnancy test at the screening 
visit and urine pregnancy tests (UPTs) at subsequent visits according to Table 4. 
Pregnancy test results must be available prior to the administration of the study drug.
Subjects with a positive serum pregnancy test result at screening must not be enrolled. 
Urine pregnancy tests with a sensitivity < 25 IU/L will be provided to the study centers 
for use in the trial. 
UPTs will be performed at the study centers, and all other samples will be sent to central 
laboratory for analysis. 
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 91 of 133
If the result of a UPT is positive, it must be confirmed with a serum pregnancy test, and 
no study drug or vaccine should be administered pending the serum pregnancy test result. 
Subjects with a positive serum pregnancy test result during the trial must discontinue 
treatment and be withdrawn from the trial.
Virology
Virology including HBsAg, HBcAb, hepatitis C, HIV-1, and HIV-2 antibody will be 
assessed at the screening visit. Subjects with a positive HBcAb and a negative HBsAg 
will also be assessed for hepatitis B surface antibody. 
Tuberculosis Testing
Immunosuppressant biologic treatments have been shown to increase the risk of TB 
infection or to cause conversion from latent to active TB in some circumstances. Because 
of this, subjects will be screened for active or latent TB before entry into this study.
13.2.6.1 Active/Latent Tuberculosis Definitions
Active TB is a disease caused by Mycobacterium tuberculosis in any part of the body and 
that is in an active state as determined by either a smear or culture taken from any source 
in the person’s body which tests positive for TB or by radiographic evidence. Individuals 
with active TB are symptomatic, depending upon the location of the disease (most 
commonly in the lungs but also possibly in the brain, kidneys, spine, or elsewhere), and 
can spread the infection to others. 
Latent TB is said to exist when an individual is infected with M tuberculosis, as 
evidenced by a positive Interferon Gamma Release Assay, such as QuantiFERON-TB 
Gold, but is asymptomatic and has no evidence of active infection on screening pathology 
or radiographic tests. Such individuals do not pass the disease to others and should 
commence a course of prophylactic antimycobacterial treatment to eliminate the infection 
and commit to completing the course of treatment.
13.2.6.2 Tuberculosis Screening
Ideally, as part of the medical history, the subject should be asked if they have presented 
with active or latent TB in the past and whether they have received a bacillus Calmette-
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 92 of 133
Guérin (or BCG) vaccination. They should also be asked if they have been in contact 
with any individuals known to have active TB or been placed in any circumstances that 
may have exposed them to an increased risk of TB infection, such as travel to TB 
endemic regions, close contact with persons with active TB, or workplace risk (eg, 
prison, hospitals). 
A subject who tests positive for latent TB (with a positive QuantiFERON-TB gold test) 
should be referred to the subject’s treating physician for appropriate follow-up. If the 
result is indeterminate, the test may be repeated once. If confirmed indeterminate, the 
subject should then be managed as though he/she has a positive test result.
13.3
Vital Signs
Vital signs will be evaluated at the screening visit and at each subsequent visit according 
to Table 4. Vital signs will include pulse rate, systolic and diastolic blood pressure (after 
the subject has been sitting for at least 5 minutes), and body temperature. All abnormal 
values at the screening visit identified as clinically significant by the investigator will be 
recorded in the medical history form. Any clinically significant changes from the 
screening visit will be recorded as an AE.
13.4
Height and Weight
Height and weight will be measured, according to Table 4. 
Subjects must be at least 30 kg at both screening and baseline visits in order to be 
enrolled into this clinical study.
After the screening visit, additional height assessments will only be conducted for 
adolescent subjects (aged 12 to 17).
13.5
Physical Examination
Complete physical examination should be performed at the screening, and certain 
subsequent scheduled visits, according to Table 4. A complete physical examination will 
include assessments of the head, ears, eyes, nose, throat, neck (including thyroid), 
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 93 of 133
skin/integumentary system, cardiovascular system, respiratory system (for additional 
respiratory assessments), gastrointestinal system, musculoskeletal system, lymph nodes, 
extremities, and nervous system. 
Investigator should assess all abnormal findings for clinical significance. All clinically 
significant abnormal findings at the screening visit will be recorded in the medical history 
form. Any clinically significant changes from the screening visit will be recorded as an 
AE.
13.6
Respiratory Assessments
At screening, the investigator should specifically question all subjects about any medical 
history of asthma and their respiratory health (eg, wheezing, coughing, allergies, and 
infections). Subjects with a history of asthma will be questioned about the seasonality of 
their asthma and known triggers, such as allergens. Newly diagnosed asthma or 
worsening of asthma during the study will be reported as an AESI.
Asthma Control Test
Subjects with a medical history of asthma will take the ACT at visits according to Table 4
before questioning and physical examination by the investigator. Subjects with a new (de 
novo) diagnosis of asthma will take the ACT beginning at the visit the diagnosis was first 
confirmed and at all subsequent study visits thereafter. Subjects with an ACT score ≤ 19 
will be referred to the physician managing their asthma. 
The ACT is an assessment to determine if a subject’s asthma symptoms are well-
controlled. The ACT is designed for adults and adolescents 12 years or older, and is 
composed of 5 questions. For each question, the subject will choose the best answer out 
of 5 possible answers. The test provides a numerical score ranging from 5 to 25 to assess 
asthma control; a higher score indicates better asthma control while a score of 19 or less 
indicates the subject’s asthma may not be under control (Appendix 9).
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 94 of 133
Respiratory Examination
A respiratory examination will be required to be performed for all subjects at all 
scheduled visits, according to Table 4. The ACT will aid the investigator’s questioning of 
subjects with a medical history of asthma and should be completed before the clinical 
questioning. After the screening visit, all subjects will be asked non-leading questions 
about any respiratory changes. The investigator or designee will then perform a 
respiratory examination of all subjects at all visits. 
Subjects with a medical history of asthma will be referred to the physician managing their 
asthma if unexpected worsening of asthma is observed or reported. Subjects without a 
medical history of asthma who experience respiratory changes (examination findings or 
newly reported signs and/or symptoms suggestive of asthma) should be referred to a 
respiratory specialist. 
Peak Expiratory Flow
All subjects will undergo PEF testing at screening, baseline, and specified visits 
according to Table 4. For subjects reporting a medical history of asthma, PEF will be 
conducted at all visits. 
Subjects with a new (de novo) diagnosis of asthma will be evaluated by PEF at all visits 
after the diagnosis is first made according to Table 4. 
PEF testing during the clinical study will be performed under the supervision of qualified 
study personnel. Peak expiratory flow measurements should consist of 3 good efforts, 
with the best result documented. It is preferable that the PEF measurement be performed 
before noon or at the same time during each study visit whenever possible. Obtained PEF 
values will be compared to predicted values based on the subject’s age, sex and 
height.27,28
Subjects should be asked to withhold asthma medication on study visit days until after 
PEF testing is complete, to the extent it does not pose an undue risk to the subject, to 
avoid interference with PEF measurements. 
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 95 of 133
Subjects with a medical history of asthma will be referred to the physician managing their 
asthma if PEF < 80% of the predicted value.
Respiratory Referrals
Subjects with a medical history of asthma will be referred to the physician who manages 
their asthma when:

PEF < 80% of the predicted value. 

ACT score ≤ 19 (an ACT score ≤ 19 conveys asthma that may not be adequately 
controlled).  

Unexpected worsening of asthma is observed or reported at any time during the 
study.
At any study visit, subjects without a medical history of asthma will be referred to an 
appropriate specialist physician whenever: 

Signs and/or symptoms suggestive of asthma are newly observed or reported.

Respiratory assessment suggests a decline in the subject’s respiratory health.
13.7
Electrocardiogram
A 12-lead Electrocardiogram (ECG) will be performed and read centrally according to 
visits specified in Table 4 using the ECG machine provided. 
ECGs will be performed in the supine position at the time points described in the 
schedule of assessments and before any scheduled vital sign measurements and blood 
draws. Subjects should be monitored for potentially clinically significant ECG results 
(refer to the current version of the central laboratory manual). Tests with abnormal results 
that are deemed clinically significant should be repeated to ensure reproducibility of the 
abnormality. ECG abnormalities present at screening should be recorded in the medical 
history form. Any abnormalities considered by the investigator to be clinically significant 
after the screening visit are to be recorded as AEs and discussed with the medical 
monitor, as needed.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 96 of 133
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 97 of 133
15
OTHER ASSESSMENTS
15.1
Independent Data Monitoring Committee 
An IDMC will review and monitor subject safety throughout the study. The IDMC will 
provide recommendations on the safety of subjects. Details on the IDMC, including the 
plan of analysis for IDMC outputs, the composition of the IDMC, the procedures, roles, 
responsibilities, and their communications are provided in the IDMC charter.
15.2
Independent Adjudication Committee
An IAC will review all asthma-related AEs throughout the study. Details on the IAC, 
including the plan of analysis for IAC outputs, the composition of the IAC, the 
procedures, roles, responsibilities, and their communications are provided in the IAC
charter.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 98 of 133
16
STATISTICAL ANALYSIS
A statistical analysis plan (SAP) will be created and finalized before database lock. This 
document will provide details regarding the definition of analysis variables and analysis 
methodology to address all study objectives. The SAP will contain further detailed and 
technical descriptions of specific data conventions, calculations and of statistical 
procedures for executing the analyses that are specified in this protocol. Any changes 
made to the analysis after finalization of the SAP (ie, post-database lock) will be
discussed and documented in the clinical study report.
The statistical evaluation will be performed using SAS® software version 9.4 or higher 
(SAS Institute, Cary, NC). All data will be listed, and summary tables will be provided. 
Summary statistics will be presented by treatment group. For continuous variables, data 
will be summarized with the number of subjects (N), mean, standard deviation, median, 
minimum, and maximum by treatment group. For categorical variables, data will be 
tabulated with the number and proportion of subjects for each category by treatment 
group.
Unless otherwise stated, the baseline value for any variable will be the last non-missing 
value taken prior to the receipt of study treatment at the Baseline visit (Day 1). 
Unless otherwise stated, all statistical tests other than the primary vaccine response 
endpoint will be 2-sided and conducted at the 5% level. All presented confidence 
intervals will be 2-sided 95% confidence intervals.
A full discussion of inclusion/exclusion of subjects into the analysis populations
described here will be provided close to database lock, including any decisions on data 
handling and other topics, and will be documented in the Blind Data Review Meeting
(BDRM) Plan and subsequently in the BDRM Report. No Per-Protocol population is 
included in this study.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 99 of 133
16.1
Analysis Populations
Screened Population
The Screened population comprises all subjects who signed the ICF. This population
includes screen failures, and randomized subjects. For clarity, screen failed subjects are 
defined as are those subjects who fail to meet inclusion criteria or meet exclusion criteria 
and discontinued the study prior to randomization. Subjects that are re-screened will only 
be counted once, under the subject ID assigned for the repeat screening.
Intent-to-Treat Population (ITT)
The ITT population will consist of all randomized subjects. The ITT population will be 
the primary population for efficacy analyses. All analyses under the ITT population will 
be analyzed under the treatment group as randomized.
Modified Intent-to-Treat Population (mITT)
The mITT population will consist of all randomized subjects who received at least one 
administration of study drug and vaccine injection, have an evaluable vaccine response
and did not receive any systemic rescue therapy prior to the post-vaccination vaccine 
response assessment. The mITT will be the primary population for vaccine response. All 
analyses under the mITT will be analyzed under the treatment group actually received.
Safety Population (SAF)
The SAF will consist of all randomized subjects who received at least one administration 
of study drug. The treatment group assignment in this population will be defined by the 
treatment actually received. This population will be used for the analyses of safety.
Pharmacokinetic Analysis Population (PKAP)
The PK analysis population (PKAP) will consist of all subjects included in the SAF, with 
at least one measurable post-baseline PK assessment. Similar to SAF, the treatment group 
assignment in this population will be defined by the treatment actually received. This 
population will be used for the analyses of PK.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 100 of 133
16.2
Subject Disposition
The number of subjects included in each analysis population and the reasons for 
discontinuation will be summarized. In addition, subjects’ status with regard to study 
treatment and follow-up will also be summarized.
16.3
Demographics and Other Baseline Characteristics
Demographic and other baseline characteristics (e.g., age, sex, race, height, body weight, 
body mass index, and applicable baseline data for primary and key secondary efficacy 
assessments) will be summarized for the ITT, mITT, and SAF populations. Medical 
history, plus prior and concomitant therapies (including prohibited therapies) will be 
summarized for the ITT, mITT, and SAF populations.
16.4
Vaccine Response Analysis
Unless otherwise stated, vaccine response analyses will be performed on the mITT 
population, and where appropriate on the ITT.
Definition of Primary Vaccine Response Endpoint
The primary endpoint for this study is the proportion of subjects with a positive serum 
IgG response to tetanus toxoid at Week 16 (4 weeks post-vaccination), defined as:
1. ≥ 4-fold increase in anti-tetanus IgG concentration from baseline in subjects with 
pre-vaccination anti-tetanus IgG concentrations ≥ 0.1 IU/mL, OR
2. ≥ 0.2 IU/mL anti-tetanus IgG concentrations in subjects with pre-vaccination anti-
tetanus IgG concentrations < 0.1 IU/mL.
Subjects in receipt of systemic rescue medication will not be vaccinated, and so will thus 
not be included in the mITT. Thus, for the primary analysis of the primary vaccine 
response endpoint, no imputation is required as all subjects included in the mITT are 
required to have an evaluable vaccine (IgG) response.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 101 of 133
Analysis of Primary Vaccine Response Endpoint
The estimate of the corresponding proportion for the endpoint will be adjusted for the 
randomization strata baseline 
 using the Cochran-
Mantel-Haenszel (CMH) estimate of the risk difference and corresponding 2-sided 90% 
CI. This primary analysis will be conducted on the mITT population.
Sensitivity Analyses of the Primary Vaccine Response Endpoint
Sensitivity analyses for the primary analysis of the primary endpoint will also be 
conducted in order to test for the robustness of the primary analysis. The primary analysis 
above will be repeated on the ITT population as sensitivity, whereby any subjects without 
an evaluable vaccine response will be regarded as a Non-Responder. Further to this, an 
observed case analysis on the ITT population will also be performed, with no imputation 
for missing data at Week 16.
Secondary Vaccine Response Endpoints
The following secondary vaccine response endpoints are to be analyzed, in any order:

Proportion of subjects with a positive serum IgG response to tetanus toxoid at 
Week 16 (≥2-fold increase in anti-tetanus IgG concentration from baseline in 
subjects with pre-vaccination anti-tetanus IgG concentration ≥ 0.1 IU/mL OR
≥0.2 IU/mL anti-tetanus IgG concentrations in subjects with pre-vaccination anti-
tetanus IgG concentrations < 0.1 IU/mL) 

Proportion of subjects with serum anti-tetanus IgG concentrations of ≥ 0.1 IU/mL 
at Week 16

Proportion of subjects with serum anti-tetanus IgG concentrations of ≥ 1.0 IU/mL 
at Week 16

Proportion of subjects with a positive serum bactericidal antibody response to 
meningococcal serogroup C polysaccharide at Week 16 (4 weeks post-
vaccination) defined as ≥ 4-fold increase in SBA reciprocal titer from baseline
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 102 of 133

Proportion of subjects with a positive serum bactericidal antibody response to 
meningococcal serogroup C polysaccharide at Week 16 defined as SBA 
reciprocal titer ≥ 8 
All secondary vaccine response endpoints will be analyzed on the mITT population.
For all secondary vaccine response endpoints, the same analysis methods as for the 
primary vaccine response endpoint will be utilized.
Subgroup analyses may be conducted based on selected demographic variables of 
interest, and by vaccine response for the endpoints described in Section 16.4, if needed.
Further details on all vaccine response endpoints and analyses will be included in the 
SAP.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 103 of 133
Discrete binary secondary efficacy endpoints will be analyzed in the same manner as the 
primary vaccine response endpoint, using a CMH method to estimate the risk difference 
and two-sided 95% CI, stratified by baseline 
Given that the population for 
efficacy is the ITT population, the analysis will be conducted with any missing data at the 
time point imputed as Non-Responder.
Continuous secondary endpoints will be analyzed primarily as observed (ie, non-
imputed) using a mixed-effect model for repeated measures approach, including baseline 
as factor and baseline result for the endpoint as 
covariate. The estimated treatment difference for each endpoint at each visit will be 
displayed in the summary of statistical analysis together with the two-sided 95% 
confidence interval and associated p-value. An unstructured covariance matrix will be
used to model the correlation among repeated measurements, and the Kenward-Roger 
adjustment will be used with restricted maximum likelihood for statistical inference. 
Additionally, an analysis of covariance approach, including baseline 
as 
factor and baseline result as covariate will be conducted for the specific secondary
endpoint, based on data as observed.
Further to the above efficacy analyses, for all secondary efficacy endpoints, any missing 
data at any post-baseline visit (including Week 16) will be imputed utilizing multiple 
imputation (MI) using missing not at random (MNAR) with a controlled-based pattern 
mixture approach.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI
CCI
CCI
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 104 of 133
The MI will be carried out as follows: 
1) Fifty (50) imputed datasets with a monotone missing pattern will be multiply 
created using SAS MI procedure based on the observed data (Markov-Chain-
Monte-Carlo method). The seed to be used is 118380 (the protocol number).
2) Each of the imputed datasets will be used to generate 50 complete datasets, using 
a regression method and the profiles from placebo subjects to impute the missing 
data of subsequent visits, including factors for treatment and randomization strata, 
and any applicable baseline as covariate. 
3) The complete datasets will be modelled for the endpoint as specified above for 
discrete binary or continuous endpoints
4) The results from the analysis of the multiple imputed datasets will be combined 
by the MIANALYZE procedure of the SAS system.
Further details will be provided in the SAP.
For subjects in receipt of rescue medication at any point during the study, their data 
collected post-rescue intake will be set to missing, and analyzed in the manner above as 
observed and/or imputed. An additional analysis including all collected data as observed 
will also be conducted, with no adjustment for data collected post-rescue medication 
intake.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved




Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 106 of 133
event stopped prior to study treatment start) will be included as treatment-emergent. The 
incidence of TEAEs by severity, counting multiple AEs under SOC and PT for a subject 
at the maximum severity will be presented. All AEs will be listed by subject, along with 
information regarding onset, duration, relationship and severity to study drug, action 
taken with study drug, treatment of event, and outcome.
Clinical laboratory data and vital signs will be summarized using descriptive statistics, 
including observed values and change from baseline values, as well as numbers of 
subjects with values outside limits of the normal range, including shifts from baseline at 
each time point.
Summary tables will be provided for 12-Lead ECG, Physical Examination (Full and 
Symptom-oriented), ACT, PEF, and Respiratory Exam, by treatment group and visit 
where appropriate. Listings will also be provided.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 107 of 133
16.9
Determination of Sample Size
Approximately 245 subjects will be randomized (~123 per arm) to show that the 90% 
confidence interval of the proportion difference between treatment groups will exclude a 
difference of more than 10%.
16.10
Protocol Deviations
Protocol deviations may be categorized into the following main categories (not 
exhaustive):

Inclusion or Exclusion Criteria

Investigational Product (Incorrect kit, Dosing, Storage issues etc.)

Randomization

Study Procedure compliance
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 108 of 133

Concomitant Medication / Administration of prohibited medication

Visit Window (adherence)
All protocol deviations will be identified, evaluated, and closed before the respective 
database lock (final analysis) and will be discussed in the clinical study report. Protocol 
deviations occurring during the study will be listed. Protocol deviations incurred as a 
direct result of the COVID-19 pandemic should be specifically recorded as a COVID-19 
deviation. Further details of Protocol Deviations will be provided in the Protocol 
Deviation and Non Compliance Management Plan.
16.11
Interim Analysis 
No interim analysis will be performed.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 109 of 133
17
STUDY MANAGEMENT
17.1
Approval and Consent
Regulatory Guidelines
This study will be conducted in accordance with the accepted version of the Declaration 
of Helsinki and/or all relevant regulations, as set forth in Parts 50, 56, 312, Subpart D, of 
Title 21 of the US Code of Federal Regulations (CFR), in compliance with ICH and GCP 
guidelines, and according to the appropriate regulatory requirements in the countries 
where the study was conducted.
Institutional Review Board/Independent Ethics Committee
Conduct of the study must be approved by an appropriately constituted IEC/IRB.
Approval is required for the study protocol, protocol amendments (if applicable), IB, 
ICFs, recruitment material and subject information sheets and other subject-facing 
material.
Informed Consent
For each study subject, written informed consent will be obtained before any protocol-
related activities. As part of this procedure, the principal investigator or designee must 
explain orally and in writing the nature of the study, its purpose, procedures, expected 
duration, alternative therapy available, and the benefits and risks involved in study 
participation. The subject should be informed that he/she may withdraw from the study at 
any time, and the subject will receive all information that is required by local regulations 
and guidelines for ICH. The PI will provide the sponsor or its representative with a copy 
of the IEC-/IRB-approved ICF before the start of the study.
17.2
Data Management
The designated CRO will be responsible for activities associated with the data 
management of this study. This will include, but is not limited to, setting up a relevant 
database and data transfer mechanisms, along with appropriate validation of data and 
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 110 of 133
resolution of queries. All data management activities will be detailed in the data 
management plan.
Study centers will enter data directly into an electronic data capture (EDC) system by 
completing the eCRF via a secure internet connection. Data entered into the eCRF must 
be verifiable against source documents at the study center. Data to be recorded directly on 
the eCRF will be identified and the eCRF will be considered the source document. Any 
changes to the data entered into the EDC system will be recorded in the audit trail.
17.3
Source Documents
Source documents are considered to be all information in original records and certified 
copies of original records of clinical findings, observations, data, or other activities in a 
clinical study necessary for the reconstruction and evaluation of the study. The 
investigator will provide direct access to source documents and/or source data in the 
facilitation of trial-related monitoring, audits, review by IECs/IRBs, and regulatory 
inspections.
The investigator/institution should maintain adequate and accurate source documents and 
trial records that include all pertinent observations on each of the site’s trial subjects. 
Source data should be attributable, legible, contemporaneous, original, accurate, and 
complete. Changes to source data should be traceable, not obscure the original entry, and 
be explained if necessary.
Sponsor monitors, auditors and regulatory inspectors should have direct access to source 
data.
17.4
Record Retention
Study records and source documents must be preserved for at least 15 years after the 
completion or discontinuation of/withdrawal from the study, at least 2 years after the drug
being studied has received its last approval for sale, or at least 2 years after the drug 
development has stopped, and in accordance with the applicable local privacy laws, 
whichever is the longer period.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 111 of 133
The investigator agrees to comply with all applicable federal, state, and local laws and 
regulations relating to the privacy of subject health information, including, but not limited 
to, the Standards for Individually Identifiable Health Information, 45 CFR, Parts 160 and 
164 (HIPAA Privacy Regulation). The investigator shall ensure that study subjects
authorize the use and disclosure of protected health information in accordance with 
HIPAA Privacy Regulation and in a form satisfactory to the sponsor.
17.5
Monitoring
The study will be monitored according to the monitoring plan to ensure that it is 
conducted and documented properly according to the protocol, GCP, and all applicable 
regulatory requirements.
Monitoring visits and contacts will be made at appropriate times during the study. The 
principal investigator will assure he/she and adequate site personnel are available 
throughout the study to collaborate with clinical monitors. Clinical monitors must have 
direct access to source documentation in order to check the completeness, clarity, and 
consistency of the data recorded in the eCRFs for each subject.
The investigator will make available to the clinical monitor all source documents and 
medical records necessary to review protocol adherence and eCRFs. In addition, the 
investigator will work closely with the clinical monitor and, as needed, provide them 
appropriate evidence that the study is being conducted in accordance with the protocol, 
applicable regulations, and GCP guidelines.
17.6
Quality Control and Quality Assurance
The sponsor or its designee will perform the quality assurance and quality control 
activities of this study; however, responsibility for the accuracy, completeness, security, 
and reliability of the study data presented to the sponsor lies with the investigator 
generating the data.
The sponsor will arrange audits as part of the implementation of quality assurance to 
ensure that the study is being conducted in compliance with the protocol, standard 
operating procedures, GCP, and all applicable regulatory requirements. Audits will be 
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 112 of 133
independent of and separate from the routine monitoring and quality control functions. 
Quality assurance procedures will be performed at study sites and during data 
management to assure that safety and efficacy data are adequate and well documented.
17.7
Protocol Amendment and Protocol Deviation
Protocol Amendment
Amendments to the protocol that entail corrections of typographical errors, clarifications 
of confusing wording, changes in study personnel, and minor modifications that have no 
effect on the safety of subjects or the conduct of the study will be classed as 
administrative amendments and will be submitted to the IEC/IRB for information only.
The sponsor will ensure that acknowledgement is received and filed. Amendments that 
are classed as substantial amendments must be submitted to the appropriate regulatory 
authorities and the IECs/IRBs for approval and will not be implemented at sites until such 
approvals are received other than in the case of an urgent safety measure.
Protocol Deviations
Should a protocol deviation occur, the sponsor must be informed as soon as possible.
Protocol deviations and/or violations and the reasons they occurred will be included in 
the clinical study report. Protocol deviations will be reported to the IRB/IEC and in 
accordance with applicable regulatory authority mandates.
17.8
Ethical Considerations
This study will be conducted in accordance with this protocol, the accepted version of the 
Declaration of Helsinki and/or all relevant federal regulations, as set forth in Parts 50, 56, 
312, Subpart D, of Title 21 of the CFR; EU 536/2014, Annex 1, D, 17 (a); and in 
compliance with GCP guidelines.
IECs/IRBs will review and approve this protocol and the ICF. All subjects are required to 
give written informed consent before participation in the study.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 113 of 133
17.9
Financing and Insurance
Before the study commences, the sponsor (or its designee) and the investigator (or the 
institution, as applicable) will agree on costs necessary to perform the study. This 
agreement will be documented in a financial agreement that will be signed by the 
investigator (or the institution signatory) and the sponsor (or its designee).
The investigator is required to have adequate current insurance to cover claims for 
negligence and/or malpractice. The sponsor will provide no-exclusion insurance coverage 
for the clinical study as required by national regulations.
17.10
Publication Policy/Disclosure of Data
Both the use of data and the publication policy are detailed within the clinical study 
agreement. Intellectual property rights (and related matters) generated by the investigator 
and others performing the clinical study will be subject to the terms of a clinical study 
agreement that will be agreed between the institution and the sponsor or their designee.
With respect to such rights, the sponsor or its designee will solely own all rights and 
interests in any materials, data, and intellectual property rights developed by investigators 
and others performing the clinical study described in this protocol, subject to the terms of 
any such agreement. In order to facilitate such ownership, investigators will be required 
to assign all such inventions either to their institution or directly to the sponsor or its 
designee, as will be set forth in the clinical study agreement.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 114 of 133
18
REFERENCES
1. Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109-22.
2. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of 
atopic dermatitis: section 2. Management and treatment of atopic dermatitis with 
topical therapies. J Am Acad Dermatol. 2014;71(1):116-32.
3. Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema prevalence in the United 
States: data from the 2003 National Survey of Children's Health. J Invest Dermatol. 
2011;131(1):67-73.
4. Silverberg JI, Simpson EL. Associations of childhood eczema severity: a US 
population-based study. Dermatitis. 2014;25(3):107-14.
5. Rutkowski K, Sowa P, Rutkowska-Talipska J, Sulkowski S, Rutkowski R. Allergic 
diseases: the price of civilisational progress. Postepy Dermatol Alergol. 
2014;31(2):77-83.
6. Bagci, IS, Ruzicka, T. IL-31: A new player in dermatology and beyond. J Allergy 
Clin Immunol. 2017;141(3):858-66.
7. Stott B, Lavendar P, Lehmann S, Pennino D, Durham S, Schmidt-Weber CB. Human 
IL-31 is induced by IL-4 and promotes Th2-driven inflammation. J Allergy Clin 
Immunol. 2013;132(2):446-54.e5.
8. Singh B, Jegga AG, Shanmukhappa KS, et al. IL-31-driven skin remodeling involves 
epidermal cell proliferation and thickening that lead to impaired skin-barrier function. 
PLoS One. 2016;11(8):e0161877.
9. Gittler JK, Shemer A, Suárez-Fariñas M, et al. Progressive activation of 
T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and 
chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130(6):1344-54.
10. Szegedi K, Kremer AE, Kezic S, et al. Increased frequencies of IL-31-producing T 
cells are found in chronic atopic dermatitis skin. Exp Dermatol. 2012;21(6):431-6.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 115 of 133
11. Neis MM, Peters B, Dreuw A, et al. Enhanced expression levels of IL-31 correlate 
with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol. 
2006;118(4):930-7.
12. Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T cells and 
pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117(2):411-7.
13. Kato A, Fujii E, Watanabe T, et al. Distribution of IL-31 and its receptor expressing 
cells in skin of atopic dermatitis. J Dermatol Sci. 2014;74(3):229-35.
14. Saito S, Aoki A, Arai I, et al. Regulation of Th2 responses by different cell types 
expressing the interleukin-31 receptor. Allergy Asthma Clin Immunol. 2017;13:23.
15. Hänel KH, Pfaff CM, Cornelissen C, et al. Control of the physical and antimicrobial 
skin barrier by an IL-31-IL-1 signaling network. J Immunol. 2016;196(8):3233-44.
16. Wahlgren CF. Itch and atopic dermatitis: an overview. J Dermatol. 
1999;26(11):770-9.
17. Sidbury R, Davis DM, Cohen DE, et al; American Academy of Dermatology.
Guidelines of care for the management of atopic dermatitis: section 3. Management 
and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 
2014;71(2):327-49.
18. TOX12-0076 Clinical Study Report: A 26-week intermittent subcutaneous dose (once 
every 2 weeks, 14 times total) toxicity study of CH5427227 in mature cynomolgus 
monkeys followed by a 17-week recovery period. 2014.
19. Adacel Prescribing Information. Swiftwater PA: 
20. Menectra Prescribing Information. Swiftwater PA: 
21. Meningococcal vaccines: WHO position paper: 2011;47(86):521-540. 
https://www.who.int/wer/2011/wer8647.pdf?ua=1. Accessed October 11, 2019.
22. Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, 
Baker CJ, Messonnier NE; Centers for Disease Control and Prevention (CDC). 
Prevention and control of meningococcal disease: recommendations of the Advisory 
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
PPD
PPD


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 116 of 133
Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR-
2):1-28. https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm. Accessed 
October 11, 2019.
23. WHO Expert Committee on Biological Standardization, 63rd Report. WHO Technical 
Report Series, No. 980. Annex 5: Recommendations to assure the quality, safety and 
efficacy of tetanus vaccines (adsorbed). 2014:271-333. 
https://www.who.int/biologicals/WHO_TRS_980_WEB.pdf?ua=1. Accessed October 
11, 2019.
24. Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, 
a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment 
of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 
2016;75(3):494-503.e6.
25. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The Eczema 
Area and Severity Index (EASI): assessment of reliability in atopic dermatitis. EASI 
Evaluator Group. Exp Dermatol. 2001;10(1):11-8.
26. Simpson EL, Bieber T, Guttman-Yassky E, et al; SOLO 1 and SOLO 2 Investigators. 
Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 
2016;375(24):2335-48.
27. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung 
volumes and forced ventilatory flows. Eur Respir J. 1993;6 Suppl 16:5-40.
28. Polgar G, Weng TR. The functional development of the respiratory system from the 
period of gestation to adulthood. Am Rev Respir Dis. 1979;120(3):625-95.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 117 of 133
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 118 of 133
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 119 of 133
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 120 of 133
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 121 of 133
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 122 of 133
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 123 of 133
Appendix 4
Specific Guidance for Study Conduct and Subject Safety During 
the Covid-19 Pandemic
This guidance applies during the COVID-19 pandemic, as defined by regional and/or 
local authorities. The updates summarized below are relevant to the referenced sections 
of the protocol.
Section 5.3
Clinical Risks/Benefits
During the COVID-19 pandemic, additional risks to participants may exist, including 
generic environmental risks (e.g., being outside the home, possible contact with 
unsanitized surfaces) and study-related activities (e.g., interaction with study staff). 
Potential new subjects with known or suspected COVID-19 infection are ineligible for 
study enrollment until the infection has resolved. Furthermore, potential new subjects in a 
high-risk population for COVID-19 (e.g., 60 years and older or with comorbidities), 
should be temporarily deferred until the COVID-19 risk has subsided at the location of 
the enrolling site, according to investigator judgement. Risk mitigation measures to be 
implemented for enrolled subjects and for new subjects during the COVID-19 pandemic 
are detailed in Additional Measures for Subjects Amidst COVID-19 Pandemic below. 
Subjects with a known or suspected COVID-19 infection will immediately discontinue 
study drug; instructions for resuming treatment are described in Section 8.4.2. Known or 
suspected COVID-19 infection will also be followed as an AESI.
New Subsection to Section 7.1, Overall Study Design and Plan:
Additional Measures for Subjects Amidst COVID-19 Pandemic
All investigational sites should act according to applicable site regulations, to 
guidelines and restrictions implemented by local authorities, and to best practices 
for conducting clinical research during the COVID-19 pandemic. 
- Guidance for New Subjects:
Best practices currently in place must be followed when evaluating eligibility of 
subjects to participate in the study during the COVID-19 pandemic.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 124 of 133
For potential subjects in a high-risk population for COVID-19 as defined by the 
American Academy of Dermatology (AAD)1 (e.g., 60 years and older or with 
comorbidities) or local guidelines, deferring participation in the study should be 
considered. Deferment of enrollment is based on the potential risk posed by 
generic environmental risks (e.g., being outside home, possible contact with 
unsanitized surfaces) and study-related activities (e.g., interaction with study 
staff).
For potential subjects in the low-risk population for COVID-19 (e.g., less than 60 
years of age and without comorbidities), the risks and benefits of participation in 
the study should be assessed on a case by case basis. 
If at the time of screening, in the opinion of the Investigator, the subject will not 
be willing and able to reach the investigational site and comply with all of the 
time commitments and requirements of the clinical study protocol, the subject 
should not be considered for enrollment. The subject may be rescreened at a later 
time.
Pre-screening phone calls should be conducted to exclude potential 
candidates/subjects who display possible symptoms of COVID-19 or are at high 
risk of having been exposed to COVID-19.
- Guidance for Enrolled Subjects:
If the local situation allows for subjects to reach the clinical investigational site 
and complete all study procedures, the following measures should be taken:
-
Implement and document in the subject records regular 
communication with the subject between visits to attempt to ensure 
early detection of potential signs/symptoms of COVID-19 infection, 
and provide adequate advice, as per local medical practice and public 
health guidelines for suspected COVID-19 infection. Please refer to 
the Centers for Disease Control (CDC; https://www.cdc.gov/ 
coronavirus/2019-ncov/symptoms-testing/symptoms.html) and 
applicable local guidelines for assessment of subjects’ COVID-19 
status.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 125 of 133
-
Following the same guidelines, implement and document in the 
subject records an additional communication to the subject just before 
the scheduled visit. 
-
Discontinue study drug administration in case of confirmed or 
suspected COVID-19 infection until the infection is resolved. See 
Section 8.4.2. 
-
Report any COVID-19 infection (confirmed or suspected) as an AE:

if any seriousness criterion is met, also report as an SAE
(see Section 13.1.3). 

if it occurs during the clinical study following the first 
dose of study drug administration, also report as AESI (see 
Section 13.1.4). 
-
Implement preventive infection control measures against COVID-19 
infection following local guidelines (i.e. good hygiene practice, clean 
techniques, and use of personal protective equipment such as gloves, 
goggles, and masks). 
-
Implement preventive measures in handling all subject-facing study-
mandated assessment devices and parts: 

PEF meter device body is to be cleaned after each use, with 
recommended wipes, as per user manual 

PEF meter flow sensor is to be disposed of after each set of 
measurements is taken

Approved bacterial/virus filters may be used; if used, they 
must be disposed of after each set of measurements is taken
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 126 of 133

Offer protective gloves to subjects for use while filling out 
assessments on a tablet and provide training on hygienic 
removal and disposal of gloves
If the local situation allows for subjects to reach the investigational site and 
complete only some study procedures where visit duration needs to be limited, 
the above measures also apply. All assessments should be conducted if possible. 
Specific efforts should be made to administer vaccines and collect all 
immunogenicity assessments at the scheduled visits. Subject-reported 
assessments that would usually be collected on the site tablet (e.g., ACT) may be 
collected remotely (e.g., completed over the phone), as available.
Taking into account the local situation and risk of exposure to COVID-19, 
subjects can be dosed with study drug and vaccines only if the site considers that:
-
The study drug subcutaneous injection can be performed at the 
investigational site according to the instructions in the protocol, 
pharmacy manual and instruction for use, including preparation of 
study drug by an independent pharmacist or other qualified personnel.
-
Vaccine injections can be performed and vaccine response samples 
collected at the investigational site according to the instructions in the 
protocol, pharmacy manual and instruction for use  

In the event a subject cannot receive the vaccinations or 
provide vaccine response samples according to the Schedule 
of Assessments (protocol Section 10, Table 4), contact the 
Sponsor
-
ACT (for subjects with a medical history of asthma) and PEF (for all 
subjects) can be performed according to the protocol. 
-
All other safety assessments are to be performed as per protocol: 
physical exam, vital signs, ECG, laboratory assessments, pregnancy 
test, monitoring of AEs and concomitant medications. 
-
All missing assessments should be appropriately documented with 
COVID-19 recorded as the reason, where applicable.
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 127 of 133
If the local situation does not allow for subjects to reach the investigational site:
-
See New Subsection to Section 9.4, Dosage Modification: 
Management of Subjects with Missed Doses of Study Drug due to 
COVID-19 Pandemic (below) for guidance on further dosing of 
subjects.
-
Remote collection of data by Investigator or delegate is still to be
done for the following assessments at the regularly scheduled visit 
time, by phone or video call:

AE collection

ACT (for subjects with a history of asthma)

Concomitant therapies used, 

Moisturizer use/background topical therapy 

UPT results (for WOCBP),
-
All laboratory samples should be collected at the site and analyzed at 
the central lab. Only in exceptional situations when subject safety 
cannot be assured otherwise and subject cannot reach the site, a local 
laboratory test (i.e., hematology, blood chemistry, urinalysis) can be 
performed and reported, based on investigator judgment. 
-
Subject-reported assessments that would usually be collected on the 
site tablet (e.g., ACT), may be completed over the phone, as available.
All missing assessments should be appropriately documented with COVID-19 recorded 
as the reason, where applicable.
New Subsection to Section 9.4, Dosage Modification:
Management of Subjects with Missed Doses of Study Drug due to COVID-19 
Pandemic
If a subject misses a dose of study drug due to the COVID-19 pandemic, study drug 
administration may be continued. Study drug can be administered provided that there is a 
minimum 3-week interval between injections. If a subject cannot come to a planned visit 
due to COVID-19, the visit should be conducted remotely according to Additional 
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 128 of 133
Measures for Subjects Amidst COVID-19 Pandemic. If a subject misses a dose of 
study drug or cannot receive the vaccinations or provide vaccine response samples 
according to the Schedule of Assessments (protocol Section 10, Table 4), the investigator 
must contact the Sponsor for further guidance. 
Subjects with missed doses of study drug may still be eligible to enter the LTE study 
SPR.118163 after the Week 16 visit has been completed, even if done remotely. 
Enrolment of subjects into the LTE study must be done in accordance with the LTE study 
protocol. Subjects who decline or are not eligible to enter into the LTE study will 
complete a follow-up visit 12 weeks after the last study drug injection.
9.6.1 Permitted Concomitant Therapy
COVID-19 vaccination and study vaccinations should be administered according to
current CDC guidelines for co-administration of COVID-19 vaccines with other vaccines
(https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html).
17.5 Monitoring
On-site interim monitoring visits may not be feasible during COVID-19 restrictions; 
therefore, remote monitoring will be completed until on-site monitoring can be conducted 
again. Site monitoring activity will comply with the processes documented within the 
COVID-19 Site Management Risk Assessment Form.
1https://assets.ctfassets.net/1ny4yoiyrqia/PicgNuD0IpYd9MSOwab47/2461e6c12cd8895
3632a13cd68952b71/Guidance on medications
10-12-20.pdf
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 129 of 133
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 130 of 133
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 131 of 133
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI


Galderma S.A./Galderma R&D, LLC
RD.06.SPR.118380
Nemolizumab (CD14152)
Version 4.0 
This document is confidential.
Page 132 of 133
 
              
11-Jul-2022 00:00:00
RD.06.SPR.118380 Protocol V04 06JUL2022 eUS
1.0
Approved
CCI



SAP_001.pdf: 
 
 
This document is confidential. 
SAP Version: Version 5.0 15Feb2024 
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018 
Filing requirements: TMF 
Page 1 of 68 
Statistical Analysis Plan 
 
Sponsor Name: Galderma S.A./Galderma R&D, LLC 
 
Protocol Number: RD.06.SPR.118380 
Protocol Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess Immunization 
Responses in Adult and Adolescent Subjects with Moderate-to-Severe Atopic Dermatitis 
Treated with Nemolizumab 
 
Protocol Version and Date: 4.0 (06-Jul-2022) 
 
 
 
Authors: 
 
       
 
 
 
 
 
 
 
Notice of Confidential and Proprietary Information: 
The information contained in this document is confidential belonging to Galderma S.A./Galderma R&D, 
LLC. Acceptance of this document constitutes agreement by the recipient that no information contained 
herein will be published or disclosed without prior written authorization from an official of Galderma S.A. 
/Galderma R&D, LLC.  However, this document may be disclosed to appropriate Institutional Review 
Board and Ethics Committees or duly authorized representatives of a national regulatory authority under 
the condition that they are requested to keep it confidential. In the event of an actual or suspected breach 
of this obligation, 
 
PPD
PPD
PPD
PPD




Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 3 of 68
I confirm that I have reviewed this document and agree with the content.
PPD


Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 4 of 68
Table of Contents
Revision History ............................................................................................................................................ 2
Approvals ...................................................................................................................................................... 3
Glossary of Abbreviations ................................................................................................................... 7
Purpose ............................................................................................................................................. 10
Study Objectives ............................................................................................................................... 11
Endpoints........................................................................................................................................... 18
Analysis Population ........................................................................................................................... 21
General Aspects for Statistical Analysis............................................................................................ 22


Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 5 of 68
Demographic, Other Baseline Characteristics and Medication......................................................... 26
Vaccine Response Analysis.............................................................................................................. 30
Efficacy Analysis ............................................................................................................................... 33
Safety Analysis.................................................................................................................................. 38


Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 6 of 68
Pharmacokinetics Analysis................................................................................................................ 43
Anti-Drug Antibodies Analysis........................................................................................................... 45
Interim Analyses................................................................................................................................ 46
Changes from Analysis Planned in Protocol..................................................................................... 47
Programming Considerations............................................................................................................ 48
Quality Control................................................................................................................................... 52
Index of Tables.................................................................................................................................. 53
Index of Figures................................................................................................................................. 60
Index of Listings ................................................................................................................................ 62
CCI








Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 10 of 68
Purpose
The purpose of this statistical analysis plan (SAP) is to ensure that the data listings, summary tables and 
figures which will be produced, and the statistical methodologies that will be used, are complete and 
appropriate to allow valid conclusions regarding the study objectives.
Responsibilities
will perform the statistical analyses and are responsible for the production and quality control 
of all tables, figures and listings. Descriptive summary will be provided for pharmacokinetics parameters. 
The derivation of Pharmacokinetics parameters and the statistical modelling will be specified in a separate 
Modeling Analysis Plan and PK Analysis Plan, respectively.
PPD


Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 11 of 68
Study Objectives
Primary Objective
The primary objective is to assess the effect of nemolizumab (CD14152) on humoral immune responses to 
tetanus and meningococcal vaccination in adult and adolescent subjects with moderate-to-severe atopic 
dermatitis (AD).
The main estimand for primary objective is listed as below:  
Primary 
Endpoint
The proportion of subjects with a positive serum IgG response to tetanus toxoid at 
Week 16 (4 weeks post-vaccination) defined as:
≥ 4-fold increase in anti-tetanus IgG concentrations from baseline in subjects with 
pre-vaccination anti-tetanus IgG concentrations ≥ 0.1 IU/mL
OR
≥ 0.2 IU/mL anti-tetanus IgG concentrations in subjects with pre-vaccination anti-
tetanus IgG concentrations < 0.1 IU/mL
Population
Of all defined by the study inclusion / exclusion criteria, the analysis population will 
include all randomized subjects who received at least one dose of study drug and 
vaccine injection, have an evaluable vaccine response and did not receive any 
systemic rescue therapy prior to the post-vaccination vaccine response assessment 
(mITT population).
Population-
level Summary
Primary endpoint will be analyzed by the Cochran-Mantel-Haenszel (CMH) estimate 
of the risk difference and corresponding 2-sided 90% CI, adjusted for the 
randomization stratum baseline 
 using weighted 
average of stratum-specific proportion.
Intercurrent 
Event
None
Secondary Objective(s)
The secondary objectives are to assess the safety and efficacy of nemolizumab (CD14152) after a 16-
week treatment period in adult and adolescent subjects with moderate-to-severe AD.
Brief Description
This is a randomized, double-blind, placebo-controlled, multi-center, parallel-group study in adult and 
adolescent subjects (≥ 12 to 54 years) with moderate-to-severe AD. Eligible subjects must have a 
documented history of inadequate response to topical AD medication(s).
Approximately 245 subjects will be randomized 1:1 to receive either 30 mg nemolizumab (with a 60 mg 
loading dose) or placebo, stratified by baseline disease severity 
The study consists of a 2- to 4-week screening period, a 16-week treatment period, and an 8-week follow-
up period (12 weeks after the last study drug injection).
The screening period will evaluate subject eligibility. Subjects will apply a moisturizer at least once daily, 
beginning at screening. Subjects using a stable regimen of low- or medium-potency topical corticosteroid 
(TCS) with or without topical calcineurin inhibitor (TCI) at the screening visit (ie, ≥ 14 days prior to the 
baseline visit) should continue their therapy regimen. Subjects not using a stable regimen of TCS with or 
CCI
CCI


Statistical Analysis Plan 
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022 
 
 
This document is confidential. 
SAP Version: 5.0, 15Feb2024 
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018 
Filing requirements: TMF 
Page 12 of 68 
without TCI at the screening visit should not use these topical therapies during the study unless required 
as rescue therapy. 
At the baseline visit, subjects will receive a loading dose of nemolizumab (60 mg) or placebo via 2 
subcutaneous injections. Nemolizumab (30 mg) or placebo will then be administered via a single 
subcutaneous injection every 4 weeks (Q4W) at Week 4, 8, and 12. At the Week 12 visit, subjects will 
also receive single doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (
 
 and quadrivalent meningococcal conjugate 
 
vaccines. Clinical assessments will occur according to the schedule of assessments. Refer 
to Figure 1 for an overview of the study design. 
Subjects will continue to apply a moisturizer at least once daily throughout the study. Subjects using 
background topical therapy (TCS with or without TCI) from the screening visit will continue use in the 
treatment period, which should be adjusted according to the disease activity and tolerability, based on 
investigator clinical judgment. (Subjects not using background topical therapy from the screening visit 
should not apply background topical therapy in the study.) If deemed to be medically necessary by the 
investigator (eg, to control intolerable AD signs/symptoms), topical and/or phototherapy rescue therapies 
can be prescribed to any subject at any time during the study, except during the screening period. 
Subjects who complete the Week 16 treatment period may be eligible to enroll into a long-term extension 
(LTE) study (Protocol 118163). The follow-up visit is not required for subjects who participate in the LTE 
study. 
Subjects who decline or are not eligible to enter into the LTE study will complete a follow-up visit at Week 
24 (12 weeks after their last study drug injection). 
Subjects who discontinue the study prematurely should complete an early termination visit and a follow-
up visit 12 weeks after their last study drug injection. 
An independent data monitoring committee (IDMC) will review and monitor subject safety throughout the 
study, and an independent adjudication committee (IAC) will review all asthma-related adverse events 
(AEs). 
An overview of the study design is present in the Figure 1. 
Figure 1. 
Study Design 
PPD
PPD


Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 13 of 68
Subject Selection
Subjects will be selected based on the inclusion and exclusion criteria in Protocol Sections 8.1 and 8.2.
Determination of Sample Size
Approximately 245 subjects will be randomized (123 per arm) to show that the 90% confidence interval of 
the proportion difference between treatment groups will exclude a difference of more than 10%.
Treatment Assignment & Blinding
At the baseline visit, a unique randomization number will be assigned to an eligible subject via interactive 
response technology (IRT). Subjects will be randomized in a 1:1 ratio to receive either nemolizumab or 
placebo. The randomization scheme will be stratified by baseline disease severity 
 
 to ensure appropriate distribution of assignment to the 2 treatment groups.
All attempts will be made to keep the study center staff and subjects blinded throughout the study. 
Members of the study center staff, including those responsible for dual-chamber, single-use syringe
[DCS] preparation, will not have access to the randomized treatment assignment. 
To ensure double-blind administration of study drug, the study center pharmacist(s) or other qualified 
personnel will prepare all nemolizumab or placebo treatments, according to the current version of the 
pharmacy manual, the instructions for use, and assigned DCS provided by the IRT system.
As there may be detectable differences between nemolizumab and placebo during the reconstitution 
CCI
CCI


Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 14 of 68
process, the DCS is delivered for injection after the reconstitution is complete. The pharmacist (or other 
qualified personnel) preparing study medication should not be involved with any study assessments and 
should not discuss any aspects of study drug reconstitution with the subject/caregiver or study staff 
involved in subject interviews or study assessments.
To maintain the integrity of the study blinding, the bioanalytical laboratory staff who process/analyze the 
 and the central laboratory staff  who will analyze sample for 
vaccines response ( immunogenicity)  will not provide any information to sponsor, clinical research 
organization (CRO), or investigational study center personnel directly involved with the ongoing conduct 
of the study that may lead to unblinding during the ongoing study. 
Unblinding of a subject’s individual treatment code should occur only in case of a medical emergency or 
in the event of a serious medical condition that necessitates identification of the study drug for the welfare 
of that subject, as judged by the investigator. The emergency unblinding process utilizes IRT to allow the 
investigator to have unrestricted, immediate, and direct access to the subject’s individual study treatment. 
When possible (ie, when the health of the subject is not immediately at risk), the investigator or sub-
investigator is encouraged to consult with the medical monitor and the sponsor before breaking the blind.
When the blinding code is broken, the reason must be fully documented. If the code is broken by the 
investigator, the subject must be withdrawn from the study and must also be appropriately followed for a 
minimum of 12 weeks after the last dose of study drug.
The reporting requirements for unblinding are the same for reporting a serious adverse event (SAE).
The randomization code will remain blinded to all study sites and study team members until completion of 
the study and after the study database has been locked. Although initial treatment period results will be 
analyzed after all subjects have either completed the Week 16 visit, or have withdrawn or been 
discontinued from the study before Week 16, personnel from sponsor, CRO, and investigational sites 
directly involved with the ongoing conduct of the study will not have access to any information that may 
lead to unblinding for the ongoing maintenance evaluation.
The IDMC will review data at periodic intervals throughout the study as defined in the IDMC charter. The 
IDMC charter will specify the procedures for unblinding to ensure that treatment assignment remains 
undisclosed to all individuals involved in the direct execution and management of the study until the final 
database is locked. 
Administration of Study Medication
At the baseline visit, subjects will receive a loading dose of nemolizumab (60 mg) or placebo via 
2 subcutaneous injections. Nemolizumab (30 mg) or placebo will then be administered via a single 
subcutaneous injection every 4 weeks (Q4W) at Week 4, 8, and 12. At the Week 12 visit, Tdap and 
MCV4 vaccines will be administered separately each as a 0.5 mL intramuscular injection.
Study Procedures and Flowchart
Provision of a written, signed informed consent form (ICF) is required before any study-related 
procedures are performed.
The planned study assessments are in Table 1. At each visit, assessments/procedures should be 
performed in the following order: 
CCI






Statistical Analysis Plan 
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022 
 
This document is confidential. 
SAP Version: 5.0, 15Feb2024 
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018 
Filing requirements: TMF 
Page 17 of 68 
CCI


Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 18 of 68
Endpoints
Primary Vaccine Response Endpoint
The primary endpoint of this study is the proportion of subjects with a positive serum immunoglobulin G
(IgG) response to tetanus toxoid at Week 16 (4 weeks post-vaccination) defined as:
x
≥ 4-fold increase in anti-tetanus IgG concentrations from baseline in subjects with pre-vaccination 
anti-tetanus IgG concentrations ≥ 0.1 IU/mL, OR
x
≥ 0.2 IU/mL anti-tetanus IgG concentrations in subjects with pre-vaccination anti-tetanus IgG 
concentrations < 0.1 IU/mL
Secondary Endpoints
Secondary Vaccine Response Endpoints
The secondary vaccine response endpoints are as follows:
x
Proportion of subjects with a positive serum IgG response to tetanus toxoid at Week 16 defined 
as:
o
≥ 2-fold increase in anti-tetanus IgG concentrations from baseline in subjects with pre-
vaccination anti-tetanus IgG concentrations ≥ 0.1 IU/mL, OR
o
≥ 0.2 IU/mL anti-tetanus IgG concentrations in subjects with pre-vaccination anti-tetanus IgG 
concentrations < 0.1 IU/mL
x
Proportion of subjects with serum anti-tetanus IgG concentrations of ≥ 0.1 IU/mL at Week 16
x
Proportion of subjects with serum anti-tetanus IgG concentrations of ≥ 1.0 IU/mL at Week 16
x
Proportion of subjects with a positive serum bactericidal antibody response to meningococcal 
serogroup C polysaccharide at Week 16 (4 weeks post-vaccination) defined as ≥ 4-fold increase 
in serum bactericidal assay (SBA) reciprocal titer from baseline
x
Proportion of subjects with a positive serum bactericidal antibody response to meningococcal 
serogroup C polysaccharide at Week 16 defined as SBA reciprocal titer ≥ 8
CCI


Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 19 of 68
Safety Endpoints
The safety endpoint of this study is as follows:
x
Incidence and severity of AEs, including AEs of special interest (AESI) [defined in protocol 
Section 13.1.1], treatment-emergent AE (TEAE), and SAE.
x
Clinical laboratory tests
x
Physical examination and vital signs
x
Respiratory examination and assessments (ie, asthma control test [ACT], peak expiratory flow 
[PEF])
x
12-lead electrocardiogram (ECG)
CCI
CCI


Statistical Analysis Plan 
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022 
 
 
This document is confidential. 
SAP Version: 5.0, 15Feb2024 
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018 
Filing requirements: TMF 
Page 20 of 68 
CCI


Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 21 of 68
Analysis Population
Screened Population
The Screened population comprises all subjects who signed the informed consent. This population
includes screen failures, and randomized subjects. For clarity, screen failed subjects are defined as those 
subjects who fail to meet inclusion criteria or meet exclusion criteria and discontinued the study prior to 
randomization. Subjects that are re-screened will only be counted once, under the subject ID assigned for 
the repeat screening.
Safety Population (SAF)
The SAF will consist of all randomized subjects who received at least one administration of study drug. 
The treatment group assignment in this population will be defined by the treatment actually received. This 
population will be used for all the analyses of safety endpoints.
Intent-to-Treat Population (ITT)
The ITT population will consist of all randomized subjects. The ITT population will be the primary 
population for efficacy analyses. All analyses under the ITT population will be analyzed under the 
treatment group as randomized.
Modified Intent-to-Treat Population (mITT)
The mITT population will consist of all randomized subjects who received at least one dose of study drug 
and vaccine injection, have an evaluable vaccine response and did not receive any systemic rescue 
therapy prior to the post-vaccination vaccine response assessment. 
An evaluable vaccine response is defined as measured responses to the tetanus toxoid vaccine, i.e. an 
evaluable serum IgG response to tetanus toxoid as per the protocol section 16.4.1. The mITT will be the 
primary population for vaccine response. All analyses under the mITT will be analyzed under the 
treatment group actually received.
Pharmacokinetic Analysis Population (PKAP)
The PK analysis population (PKAP) will consist of all subjects included in the SAF, with at least one 
measurable post-baseline PK concentration assessment. Similar to SAF, the treatment group assignment 
in this population will be defined by the treatment actually received. This population will be used for the 
analyses of PK.


Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 22 of 68
General Aspects for Statistical Analysis
General Methods
The statistical evaluation will be performed using SAS® software version 9.4 or higher (SAS Institute, 
Cary, NC). All data will be listed, and summary tables will be provided. Summary statistics will be 
presented by treatment group. Summaries will be presented for each treatment and overall for 
Demographic, Other Baseline Characteristics and Medication. For all other analyses, summaries will be 
presented for each treatment.
Continuous variables will be summarized using the number of observations (n), mean, standard deviation 
(SD), median, minimum, and maximum by treatment group. Categorical variables will be summarized 
using number of observations (n), frequency and percentages of subjects for each category by treatment 
group.
All statistical tests on the vaccine response endpoints will be conducted at the 2-sided 10% level and the 
90% CI will be estimated. For all other endpoints, the statistical tests will be conducted at the 2-sided 5% 
level and the 95% CI will be estimated.
Key Definitions
Baseline
Unless otherwise stated, the baseline value for any variable will be the last non-missing value taken prior 
to the receipt of study treatment at the Baseline visit (Day 1). The receipt of study treatment is defined as 
the 1st injection of study drug if it exists. Otherwise, baseline is defined as the last value taken prior to the
randomization.
For diary data (
), the baseline values will be derived from data 
collected during the 7 days prior to the first administration of study drug, if it exists. Otherwise, the data 
collected during 7 days prior to randomization will be used. Baseline score will be the weekly prorated 
average of non-missing subject diary scores reported during the 7 days. A minimum of 4 daily scores out 
of the 7 days is required to calculate the weekly prorated average score.
Study Day
Study Day is the number of days since the first dose date. If the assessment date is after the 
randomization, the study day is calculated as (date of assessment - first dose date + 1). If the assessment 
date is prior to the first dose date, the study day is calculated as (date of assessment - first dose date).
Study period
First treatment date is defined as the date of 1st study drug (Nemolizumab or Placebo) injection.
Last treatment date is defined as the date of last study drug (Nemolizumab or Placebo) injection.
Treatment period is defined as follow:
x
Subject completed the treatment: first dose date up to Week 16
x
Subject who discontinued the treatment: first dose date up to earliest among:
CCI


Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 23 of 68
o
4 weeks after the last study drug administration
o
the early study termination date if available
Screening period is defined the period before the treatment period.
Follow-up period is defined the period after the treatment period.
Missing Data
Adverse events and concomitant medications with missing assessment times will have imputed times for 
the purposes of assessing treatment emergence for AEs or classifying medications into prior/concomitant. 
However, the assessment times (start date, stop date) without imputation will be presented in the listings.
For the start of a concomitant medication or AE:
x
Only the year is reported: If the subject received the first study drug dose in the year reported, 
then the date of the first dose of study drug will be used as the start date; otherwise, January 1 of 
the year reported will be used as the start date.
x
The month and year are reported: If the subject received the first study drug in the month and 
year reported, then the date of the first dose of study drug will be used as the start date; 
otherwise, the first day of the month and year will be used as the start date.
x
The time is missing: If the start date is the same as the date the subject started receiving study 
drug, then the time of the first dose of study drug will be used as the start time; otherwise, 00:00 
will be used as the start time.
For the end of a concomitant medication or AE:
x
Only the year is reported: The earlier between December 31 of the year reported and the date of 
the last study contact with the subject will be used as the stop date.
x
The month and year are reported: The earlier between the last date of the month and year 
reported and the date of the final contact with the subject will be used as the stop date.
If an AE has the start date completely missing and the stop date on/after the first dose date of study drug, 
this AE will be considered as treatment emergent.
If a medication has the stop date completely missing and ongoing tick box in CRF is checked, this 
medication will be considered as concomitant.
Imputations or calculations for specific efficacy endpoints will be included in the section that describes the 
analysis of that endpoint.
Visit Windows
Efficacy by-visit summaries will use the analysis visit. Unscheduled and early termination visits will be 
windowed based on the following analysis visit window which is based on study day. If multiple 
measurements are taken within the same window, the one taken closest to the target study day will be 




Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 25 of 68
These analysis visits will be used in the calculations for all week-based parameters collected on subject’s 
diary data. Other non-diary data, such as, 
 vital signs, body weight, clinical laboratory assessments, 
respiratory assessment/PEF, will be analyzed according to actual scheduled visits. 
Unscheduled labs will be included in listings and considered in the derivation of last, worst post-baseline 
values, but not summaries of the data by visit.
Pooling of Centers
No center pooling is planned.
Subgroups
Subgroup analysis will be performed in an exploratory manner to investigate the treatment effect across 
various subgroup. The following subgroup analyses will be performed for the primary and secondary 
vaccine response endpoints:
x
By age (<18 years; >=18 years)
x
By sex (Male, Female)
x
By race (White, Black or African American, Asian, Other)
x
x
Baseline Weight (≤Q1, <Q1 - median, <median - Q3, > Q3)
x
Baseline Weight (≤90 kg, > 90 kg)
x
Coronavirus disease-19 (COVID-19) Infection (Subjects infected by COVID-19, Subjects not 
infected)
x
Background therapy (subjects with background therapy, subject without background therapy)
In addition, analyses will be performed on the last subgroup (background therapy) for selected secondary 
efficacy endpoints.
CCI
CCI


Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 26 of 68
Demographic, Other Baseline Characteristics and Medication
Subject Disposition and Withdrawals
The screened subjects, screen failures and reasons for screen failures will be summarized in the 
disposition table.
In addition, the following frequencies (subject number and percent) will be summarized based on ITT
Population by treatment group and overall for:
x
Randomized subjects
x
Subjects treated with at least one dose of study drug
x
Subjects who completed treatment (until Week 16)
x
Subject who discontinued the treatment and Primary reason for early treatment discontinuation
o
Subject who discontinued from treatment with COVID-19 related reason [This will be 
identified using Other specify field in CRF]
x
Subjects who completed study
x
Subject who discontinued the study and Reason for study discontinuation
o
Subject who discontinued from study with COVID-19 related reason [This will be 
identified using Other specify field in CRF]
x
ITT Population (subject number only)
x
mITT Population
x
SAF Population
x
PKAP
The number and frequency will be summarized by site and by treatment group and overall for:
x
Subjects screened, 
x
Screen failure, percentage calculated based on number of screened
x
Subjects randomized, percentage calculated based on number of screened
x
Subjects treated, percentage calculated based on ITT
Summary of subjects at each visit will be provided by treatment group and overall on ITT population.


Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 27 of 68
The individual time (days) to Permanent Discontinuation of Study Drug by Reason will be presented 
graphically by treatment group using ITT population. Time to permanent discontinuation is defined as 
(date of last study drug administration – date of 1st study drug administration + 1). 
By-subject listings of eligibility details, randomization details, and withdrawal/study completion details 
(including reason for discontinuation and duration of treatment prior to discontinuation) will be provided. 
A listing of subjects in different analysis population (ITT, mITT, SAF, PKAP) will also be produced.
Protocol Deviations
All protocol deviations will be identified, evaluated, and finalized before the respective database lock (final 
analysis) and will be discussed in the clinical study report. Protocol deviations will be categorized by type, 
and whether major or minor based on clinical review and will be determined before database lock. 
Individual deviations (major and minor) will be presented in a data listing. A summary table for number 
and percentage of subjects with major protocol deviation and with COVID-19 related deviation will be 
summarized by type of deviation and treatment group.
Demographic and Other Baseline Characteristics
The following demographic and baseline characteristics will be summarized by treatment group and 
overall using descriptive statistics for ITT, mITT and safety population: 
x
Demographics data: Age (years) at screening as continuous and as categorical (12-17 years, >= 
18 years), sex, ethnicity, race, height (cm) at screening, body weight (kg) at baseline (overall and 
by age group), body mass index (overall and by age group). 
x
Baseline disease characteristics: smoking status, 
 
 
 
 and disease 
severity based on 
The stratification factor will also be summarized on ITT and mITT population to show if any discrepancies 
between what was reported through Interactive Voice Response System (IVRS)/Interactive Web 
Response System (IWRS) versus baseline value derived using eCRF data.
By-subject listings of demographic data and other baseline characteristics (as summarized above) will be 
provided. 
Medical History
Medical history will be coded using Medical Dictionary for Regulatory Activities (MedDRA Version 25.0).
Medical history will be summarized by treatment group using the number and percent of subjects 
reporting each system organ class (SOC) and preferred term (PT) and sorted by descending overall total 
of SOC and PT. Summary tables will be presented for ITT, mITT, and SAF populations.
Medical history data listings will also be provided.
CCI
CCI
CCI
CCI


Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 28 of 68
Medical and Surgical Procedures
Medical and surgical procedures will be coded using MedDRA Version 25.0.
Prior procedures are defined as procedures which stop before 1st injection of study drug. Concomitant 
procedures are defined as procedures which start or stop on or after the 1st injection of study drug.
Prior and concomitant medical and surgical procedures will be summarized separately by treatment group 
using the number and percent of subjects reporting each SOC and PT and sorted by descending overall 
total of SOC and PT. Summary tables will be presented for ITT population.
Medical and surgical procedures will also be listed.
Medications/Therapies
Prior medications/therapies are defined as medications/therapies which stop before 1st injection of study 
drug. Concomitant medications/therapies are defined as medications/therapies which start or stop on or
after the 1st injection of study drug.
If start and/or stop dates of medications and therapies are missing or partial, the dates will be compared 
as far as possible with the date of first dose of study drug.  Medications and therapies will be assumed to 
be Concomitant, unless there is clear evidence (through comparison of partial dates) to suggest that they 
started and stopped prior to the first dose of study treatment.  If there is clear evidence to suggest that the 
medication or medical and surgical procedure started and stopped prior to the first dose of study drug, 
they will be assumed to be Prior. 
For prior and concomitant medications, incomplete (i.e., partial missing) start dates and/or stop dates will 
be imputed using the algorithm described in Section 6.3.
Medications will be coded using the World Health Organization’s Drug Dictionary (WHO DD) Version 
Global B3 SEP 2019 using the Preferred Anatomical Therapeutic Chemical (ATC) terms. TCI and TCS 
will be automatically identified using the following rule:
x
TCS will be identified by ATC code “D07A”.
x
TCI will be identified by ATC code “D11AH” and with standardized medication name 
“TACROLIMUS” and “PIMECROLIMUS”.
Prior and Concomitant medications will be summarized separately by Anatomical Therapeutic Chemical 
(ATC) level 2, level 4, and preferred name in frequency tables using ITT, mITT and safety population.  
Subjects with more than one medication in a given ATC level and preferred name will be counted only 
once in that category. It will be sorted in descending frequency of ATC level and of PT within ATC level 
term.
The following summaries will be produced:
x
Prior medication
x
Concomitant medication
x
Rescue medication during treatment period (ITT Population only)
x
Rescue medication during follow-up period (ITT Population only)


Statistical Analysis Plan 
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022 
 
 
This document is confidential. 
SAP Version: 5.0, 15Feb2024 
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018 
Filing requirements: TMF 
Page 29 of 68 
x 
Background therapy (ITT Population only) consisting of TCS and TCI with start date prior to study 
drug administration and that are not classified as rescue therapy 
All medications will be listed. The background TCS dispensation/receipt will also be listed. 


Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 30 of 68
Vaccine Response Analysis
Primary Vaccine Response Endpoint and Analysis
Primary Analysis of Primary Endpoint
The primary endpoint of this study is the proportion of subjects with a positive serum IgG response to 
tetanus toxoid at Week 16 (4 weeks post-vaccination), defined as:
x
≥ 4-fold increase in anti-tetanus IgG concentrations from baseline in subjects with pre-vaccination 
anti-tetanus IgG concentrations ≥ 0.1 IU/mL, OR
x
≥ 0.2 IU/mL anti-tetanus IgG concentrations in subjects with pre-vaccination anti-tetanus IgG 
concentrations < 0.1 IU/mL
Anti-tetanus IgG concentrations and the ratio from baseline will be summarized by treatment group and 
by visit using descriptive statistics. 
The analysis for primary endpoint will be using the Cochran-Mantel-Haenszel (CMH) estimate of the risk 
difference and corresponding 2-sided 90% CI. It will be adjusted for the randomization stratum baseline 
using weighted average of stratum-specific proportion using CMH.
The example SAS code for CMH model is included in Section 20.1. The primary analysis will be 
conducted on the mITT population.
Subjects in receipt of systemic rescue medication will not be vaccinated. As the primary analysis will be 
conducted on the mITT, no imputation is required. 
Sensitivity Analysis of Primary Endpoint
Three sensitivity analyses will be performed on ITT population and the same statistical testing as the 
primary analysis will be performed:
CCI
CCI


Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 31 of 68
x
Non-responder Imputation: any subjects without an evaluable vaccine response will be 
regarded as a Non-Responder. Non-evaluable vaccine response: defined as a response that 
cannot be classified as positive or negative due to missing assessment for the endpoint. 
x
Observed Case: No data will be imputed. All data as observed will be included in the analysis 
and the percentage will be calculated based on the number of observation available. 
x
COVID-19 Affected Case: Removal of subjects with COVID-19 (i.e. exclusion of subjects who 
had COVID-19).
Subgroup Analysis of Primary Endpoint
The subgroup analyses as specified in section 6.6 will be performed for the primary endpoints on mITT 
population: 
The results from the analysis will be presented as forest plot summarizing frequencies in each treatment 
group, risk difference and the corresponding 2-sided 90% CI on each subgroup.
Secondary Vaccine Response Endpoints and Analyses
The following secondary vaccine response endpoints are to be analysed:
x
Proportion of subjects with a positive serum IgG response to tetanus toxoid at Week 16 (≥2-fold 
increase in anti-tetanus IgG concentration from baseline in subjects with pre-vaccination anti-
tetanus IgG concentration ≥ 0.1 IU/mL OR ≥0.2 IU/mL anti-tetanus IgG concentrations in 
subjects with pre-vaccination anti-tetanus IgG concentrations < 0.1 IU/mL) 
x
Proportion of subjects with serum anti-tetanus IgG concentrations of ≥ 0.1 IU/mL at Week 16
x
Proportion of subjects with serum anti-tetanus IgG concentrations of ≥ 1.0 IU/mL at Week 16
x
Proportion of subjects with a positive serum bactericidal antibody response to meningococcal 
serogroup C polysaccharide at Week 16 (4 weeks post-vaccination) defined as ≥ 4-fold increase 
in SBA reciprocal titer from baseline
x
Proportion of subjects with a positive serum bactericidal antibody response to meningococcal 
serogroup C polysaccharide at Week 16 defined as SBA reciprocal titer ≥ 8 
CCI


Statistical Analysis Plan 
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022 
 
 
This document is confidential. 
SAP Version: 5.0, 15Feb2024 
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018 
Filing requirements: TMF 
Page 32 of 68 
CCI


Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 33 of 68
CCI


Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 34 of 68
CCI


Statistical Analysis Plan 
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022 
 
 
This document is confidential. 
SAP Version: 5.0, 15Feb2024 
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018 
Filing requirements: TMF 
Page 35 of 68 
CCI


Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 36 of 68
CCI


Statistical Analysis Plan 
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022 
 
 
This document is confidential. 
SAP Version: 5.0, 15Feb2024 
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018 
Filing requirements: TMF 
Page 37 of 68 
CCI


Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 38 of 68
Safety Analysis
The population used for safety analyses will be the SAF.
Extent of Exposure
The extent of exposure will be summarized by treatment group as follows:
x
Treatment duration (in days): calculated as [(date of last treatment - date of first treatment) + 1],
x
the number of subjects exposed to study drug at visit Baseline, Week 4, Week 8 and Week 12,
x
Cumulative dose received (mg): calculated as sum of all dose of study drug administered
x
The number of subjects who received vaccines (Tdap and MCV4 and overall) at Week 12. 
x
The number of subjects missed at least one dose and the number of doses missed due to COVID-
19, i.e. the reason for dose not administered reported in eCRF is related to COVID-19
x
The subject with Vaccine injection missed due to COVID-19, i.e. the reason for dose not 
administered reported in eCRF is related to COVID-19
Extent of exposure information, study drug administration and vaccine administration will be listed, 
separately.
Treatment Compliance 
Dose modification of the study drug (nemolizumab 30 mg or Placebo) will not be permitted during the 
clinical study. 
Treatment compliance of study drug will be calculated as the ratio (expressed as percentage) between 
the total number of actual injections and the total number of expected injections. 
The total number of actual injections will be counted based on collected study drug administration data. 
The total number of expected injections will be counted based on the following dosage schedule.
Table 2: Treatment Period Dosing By Treatment Group
Treatment Group
Dose/route
Week(s)
Schedule
Nemolizumab (CD14152)
30 mg × 2 SC injections
30 mg × 1 SC injections
Baseline
4, 8, 12
Baseline
Q4W
Placebo
Placebo× 2 SC injections
Placebo× 1 SC injections
Baseline
4, 8, 12
Baseline
Q4W
Abbreviation(s): Q4W=every 4 weeks; SC=subcutaneous.
The compliance data will be listed and summarized by treatment group.
Adverse Events / Adverse Drug Reactions
Adverse events (AEs) will be coded using MedDRA Version 25.0. 
Treatment-emergent AEs (TEAEs) is defined as AEs with an onset date on or after the first dose date of 
study treatment. Partially missing date will be handled using the algorithm described in Section 6.3. AE


Statistical Analysis Plan 
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022 
 
 
This document is confidential. 
SAP Version: 5.0, 15Feb2024 
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018 
Filing requirements: TMF 
Page 39 of 68 
related to study drug is defined as AE with a relationship to study drug reported as 'Reasonable 
Possibility' or missing. 
Summary table for adverse events will include the number and percent of subjects and the numbers of 
events by treatment group and by System Organ Class (SOC) and Preferred Term (PT). SOC and PT 
within each SOC will be sorted by descending overall frequency. Subjects who have multiple events in 
the same SOC and the same PT within each SOC will be counted only once in the subject counts, but all 
events will be considered and presented (if applicable). For summary by maximum severity, subjects who 
experience multiple occurrences of an AE, the most severe category for each SOC and for each PT 
within each SOC will be considered in the summary. 
The summary tables for following TEAEs will be presented: 
x 
Overall Summary: summary of the number and percentage of subjects reporting TEAEs, TEAEs by 
maximum severity, serious TEAEs, study drug-related TEAEs, drug-related serious TEAE, study 
drug-related TEAEs by maximum severity, treatment-emergent AESI, Confirmed or suspected 
COVID-19 infection, TEAEs leading to study drug withdrawal, TEAEs leading to study drug 
interruption, TEAEs leading to study discontinuation, and TEAEs leading to death 
x 
The total number and incidence of TEAEs by SOC and PT 
x 
The total number and incidence of Serious TEAEs by SOC and PT 
x 
The total number and incidence of TEAEs related to study drug by SOC and PT 
x 
The total number and incidence of serious TEAEs related to study drug by SOC and PT 
x 
The total number and incidence of TEAEs by SOC, PT, and maximum severity 
x 
The total number and incidence of drug-related TEAEs by SOC, PT, and maximum severity  
x 
The total number and incidence of TEAEs leading to temporary interruption of study drug by SOC and 
PT 
x 
The total number and incidence of TEAEs leading to permanent discontinuation of study drug by SOC 
and PT 
x 
The total number and incidence of TEAEs leading to study discontinuation by SOC and PT 
x 
The total number and incidence of TEAEs of special interest by SOC and PT 
x 
Most common TEAEs (frequency > 5%) by PT. All TEAEs with a frequency >5% in any treatment 
group will be presented.   
Subject listings will be presented for all AEs, all SAEs, AEs leading to study drug withdrawal, AEs of 
special interest (AESIs). All AEs will be listed by subject, along with information regarding onset, duration, 
relationship and severity to study drug, action taken with study drug, treatment of event, and outcome. 


Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 40 of 68
Laboratory Evaluations
Clinical laboratory tests are performed at Screening, Baseline, Week 8, Week 16, Follow-up Visit, and 
Early Termination Visit. All laboratory values will be reported in SI units.
For statistical and graphical summaries of the laboratory tests, values below or above the limit of 
detection (e.g. ‘< 3’ or ‘>500’) are substituted with the lower limit of detection minus 1% for values below 
the lower limit and are substituted with the upper limit of detection plus 1% for values above the upper 
limit (e.g. ‘< 3’ is substituted by ‘2.97’, ‘> 500’ is substituted by ‘505’). In data listings, the values are 
shown including the < or > sign.
Results from the central laboratory (hematology, blood chemistry and urinalysis) will be summarized by 
treatment group and visit using descriptive statistics, including observed values and change from baseline 
values (for numeric laboratory parameters), distribution of categories (for categorical laboratory 
parameters). By visit summaries will be performed at all visits (scheduled and ET visits) and for the last 
post-baseline results during treatment period. Last-post baseline results will include unscheduled visits in 
the derivation.
In addition, the number and percentage of subjects who met criteria of Potentially Clinically Significant 
Values (PCSV) will be summarized by treatment group and by visit. Criteria for PCSV are included in 
Section 20.2.
Shift tables from baseline will be generated by treatment group using the reference ranges at each visit, 
last post-baseline during treatment period, the worst post-baseline. Hematology, chemistry and applicable 
urinalysis results will be classified as low (L), normal (N), and high (H) by the laboratory parameter’s 
normal range. Worst post-baseline value is defined the value farthest from the reference range (lower and 
higher limit). If all post-baseline values are "Normal”, the subject is classified as Normal. If any post-
baseline value is "Abnormal" ("High" or "Low"), select the farthest one from Lower or Higher limit of 
reference range.
Distribution of Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase 
(ALP), Total bilirubin and Creatinine Phosphokinase (CPK) will be displayed graphically as boxplot by 
treatment group for each scheduled visit and the maximum post-baseline values. 
Listings for laboratory test satisfying PCSV criteria and all laboratory tests (hematology, blood chemistry, 
urinalysis, pregnancy test, virology, tuberculosis test) will be provided.
Vital Signs, Weight and Height
Weight, Height and Vital signs including systolic blood pressure, diastolic blood pressure, pulse rate and 
temperature will be summarized using descriptive statistics by treatment group and visit, including 
observed values and change from baseline values. By visit summaries will be performed at all visits 
(scheduled and ET visits) and for the last post-baseline results during treatment period. Last-post 
baseline results will include unscheduled visits in the derivation.
In addition, the number and percentage of subjects who met criteria of Potentially Clinically Significant 
Values (PCSV) will be summarized by treatment group and by visit. Criteria for PCSV are included in 
Section 20.2.


Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 41 of 68
Shift tables from baseline will be generated by treatment group using the reference ranges at each visit, 
last post-baseline during treatment period, the worst post-baseline. Weight, Height and Vital signs results 
will be classified as normal, abnormal CS (clinically significant), and abnormal NCS (not clinically 
significant). Worst post-baseline value is defined the value farthest from the reference range (lower and 
higher limit). If all post-baseline values are "Normal”, the subject is classified as Normal. If any post-
baseline value is "Abnormal" ("High" or "Low"), select the farthest one from Lower or Higher limit of 
reference range.
Vital signs data and data satisfying PCSV criteria will also be listed.
ECG
A standard 12-lead ECG will be performed at Screening, Week 16, and Early Termination Visit. ECGs will 
be performed in the supine position. Subjects will be monitored for potentially clinically significant ECG 
results. Tests with abnormal results that are deemed clinically significant will be repeated to ensure 
reproducibility of the abnormality.
The overall ECG interpretations will be collected as “Normal”, “Abnormal, not clinically significant” and 
“Abnormal, clinically significant”.  Summary of overall interpretation will be tabulated by treatment group 
and visit.
Listings for all ECG data will be provided.
Physical Examination
Complete physical examination (PE) will be performed at the Screening, Week 8, Week 16, and Early 
Termination Visit. A complete physical examination will include assessments of the head, ears, eyes, nose, 
throat, neck (including thyroid), skin/integumentary system, cardiovascular system, respiratory system (for 
additional respiratory assessments), gastrointestinal system, musculoskeletal system, lymph nodes, and 
nervous system.
The PE results will be categorized as “Normal”, “Abnormal, not clinically significant” and “Abnormal, 
clinically significant”. Summary table of PE results will be provided by treatment group, visit and body 
system. Listing will also be provided.
Respiratory Assessments
All data will be listed. A separate listing will be provided for subject with a drop by >= 15% from Baseline 
for either PEF or ACT.
Asthma Control Test (ACT)
Subjects with a medical history of asthma will take the ACT at all visits according to Table 1. Subjects with 
a new (de novo) diagnosis of asthma will take the ACT beginning at the visit the diagnosis was first
confirmed and at all subsequent study visits thereafter. Subjects with an ACT score ≤ 19 will be referred 
to the physician managing their asthma.
The ACT is an assessment to determine if a subject’s asthma symptoms are well controlled. The ACT is 
designed for adults and adolescents 12 years or older and is composed of 5 questions. For each 
question, the subject will choose the best answer out of 5 possible answers. The test provides a 


Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 42 of 68
numerical score ranging from 5 to 25 to assess asthma control; a higher score indicates better asthma 
control while a score of 19 or less indicates the subject’s asthma may not be under control.
Results from ACT test will be summarized by treatment group and visit using descriptive statistics, 
including observed values and change from baseline values.
Number and frequency of subjects with ACT score ≤ 19 will be summarized by visit and by treatment 
group. 
Respiratory Examination
A respiratory examination will be required to be performed for all subjects at all scheduled visits, 
according to Table 1. At screening, the investigator should specifically question all subjects about any 
medical history of asthma and their respiratory health (eg, wheezing, allergies, and infections). After the 
screening visit, all subjects will be asked non-leading questions about any respiratory changes. 
Results will be summarized by treatment group and visit for each question in respiratory examination form 
per CRF.
Peak Expiratory Flow (PEF)
PEF measurements will be performed for all subjects at Screening, Baseline, Week 8, Week 16, Follow-
up Visit, and Early Termination Visit. For subjects reporting a medical history of asthma, PEF 
measurements will be performed at all visits during the clinical study (ie, PEF testing at Visit 3 and 5 will 
occur in asthmatic subjects only). For subjects diagnosed with de novo asthma, PEF measurements will 
be performed at all visits starting with the visit in which the diagnosis was confirmed.
Results from PEF testing [actual PEF rate (L/min) and/or actual PEF rate of the predicated value (%)] will 
be summarized by treatment group and visit using descriptive statistics, including observed values and 
change from baseline values.
Number and frequency of subjects with abnormal PEF (actual PEF < 80% of the predictive value) will be 
summarized by visit, treatment group.


Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 43 of 68
CCI


Statistical Analysis Plan 
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022 
 
 
This document is confidential. 
SAP Version: 5.0, 15Feb2024 
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018 
Filing requirements: TMF 
Page 44 of 68 
All PK parameters will be listed by subject. 


Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 45 of 68
CCI


Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 46 of 68
Interim Analyses
No interim analysis will be performed.


Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 47 of 68
Changes from Analysis Planned in Protocol
Concomitant Medications and Therapies
In protocol Section 9.6 (Prior and Concomitant Therapies), concomitant medications/therapies are defined 
as any therapies taken during the study (ie, from the screening visit to the end of study). 
However, for the analysis purpose, the medications are classified as taken prior or concomitantly with the 
study drug administration. Concomitant medications/therapies are defined as medications/ therapies 
which start or stop on or after the 1st injection of study drug. The purpose of this analysis is to provide 
information separately on:
x
the medication taken in addition to the study drug;
x
the medication taken prior to the study drug administration. 
This analysis could be used to identify any medication that could potentially interact with the study drug.
Analysis of Secondary Endpoints
In protocol Section 16.5.1 (Secondary Efficacy Endpoints), for binary efficacy endpoints, one sensitivity 
analysis is to have CMH analysis conducted based on observed data, with data post rescue medication 
set to treatment failure. This sensitivity analysis is removed in current SAP, since the rest analyses 
provide sufficient assessment.
For continuous secondary efficacy endpoints, analysis using ANCOVA on OC will not be performed as 
the current analyses provide sufficient assessment on these endpoints.
MI analyses will be performed using MAR assumption instead of MNAR assumption. This is to align with 
the overall Arcadia program of the study drug; also, the MNAR models require to have sufficient amount 
of non-missing data in reference group in each of the stratums, and the issue of MNAR models failing to 
impute the missing data with MNAR assumption due to lack of sufficient non-missing data in the 
reference group was observed during the dry-run. Thus, it is determined that MI with MAR assumption will 
be employed in the final run. 
Estimands Section
Description of estimands for main primary endpoints were listed in section 3.1
Analysis of Vaccine Secondary Endpoints
Additional vaccine secondary endpoints will be provided, computing the Geometric Mean 
Concentration/Titers ratios from Week 16 to Baseline


Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 48 of 68
Programming Considerations
General Considerations
x
One SAS program can create several outputs.
x
One output file can contain several outputs.
x
Output files will be delivered in Word format (.rtf) and portable document format (.pdf).
x
Numbering of TFLs will follow International Conference on Harmonization (ICH) E3 guidance.
Table, Listing, and Figure Format
General
x
All TFLs will be produced in landscape format, unless otherwise specified.
x
All TFLs will be produced using the Courier New font, size 8.
x
The data displays for all TFLs will have a minimum blank 1-inch margin on all 4 sides.
x
Headers and footers for figures will be in Courier New font, size 8.
x
Legends will be used for all figures with more than 1 variable, group, or item displayed.
x
TFLs will be in black and white (no color), unless otherwise specified
x
Specialized text styles, such as bolding, italics, borders, shading, and superscripted and 
subscripted text, will not be used in the TFLs, unless otherwise specified. 
x
Only standard keyboard characters will be used in the TFLs. Special characters, such as non-
printable control characters, printer-specific, or font-specific characters, will not be used. 
Hexadecimal-derived characters will be used, where possible, if they are appropriate to help 
display math symbols (e.g., μ). Certain subscripts and superscripts (e.g., cm2, Cmax) will be 
employed on a case-by-case basis.
x
Mixed case will be used for all titles, footnotes, column headers, and programmer-supplied formats, 
as appropriate.
Headers
x
All output should have the following header at the top left of each page:
Galderma Protocol RD.06.SPR.118380
Draft/Final Run
x
All output should have Page n of N at the top or bottom right corner of each page. TFLs are
internally paginated in relation to the total length (i.e., the page number should appear sequentially 
as page n of N, where N is the total number of pages in the table).


Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 49 of 68
x
The date output was generated should appear along with the program name as a footer on each 
page.
Display Titles
x
Each output are identified by the designation and a numeral. (i.e., Table 14.1.1). The title is 
centered. The analysis set is identified on the line immediately following the title. The title and table 
designation are single-spaced. A solid line spanning the margins will separate the display titles 
from the column headers. There will be 1 blank line between the last title and the solid line.
Table x.y.z
First Line of Title
Second Line of Title if Needed
(XX Analysis Set)
Column Headers
x
Column headings are displayed immediately below the solid line described above in initial upper-
case characters.
x
Analysis set sizes will be presented for each treatment group in the column heading as (N=xx) (or 
in the row headings, if applicable). This is distinct from the ‘n’ used for the descriptive statistics 
representing the number of subjects in the analysis set.
x
The order of treatments in the tables and listings will be Placebo first in the case of placebo 
controlled studies and Active comparators first in the case of active comparator trials, followed by a 
total column (if applicable).
Body of the Data Display
15.2.5.1.
General Conventions
Data in columns of a table or listing are formatted as follows:
x
Alphanumeric values are left-justified;
x
Whole numbers (e.g., counts) are right-justified; 
x
Numbers containing fractional portions are decimal aligned.
15.2.5.2.
Table Conventions
x
Units will be included where available.
x
If the categories of a parameter are ordered, then all categories between the maximum and 
minimum category are presented in the table, even if n=0 for all treatment groups in a given 
category that is between the minimum and maximum level for that parameter. 
x
If the categories are not ordered (e.g., Medical History, Reasons for Discontinuation from the 
Study, etc.), then only those categories for which there is at least 1 subject represented in 1 or 
more groups are included.


Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 50 of 68
x
Unless otherwise specified, the estimated mean, median, Q1 and Q3 for a set of values are printed 
out to 1 more significant digit than the original values, and standard deviations are printed out to 2 
more significant digits than the original values. The minimum and maximum should report the same 
significant digits as the original values. 
x
P-values are output in the format: “0.xxx”, where xxx is the value rounded to 3 decimal places. 
Every p-value less than 0.001 will be presented as <0.001. If the p-value is returned as >0.999,
then present as >0.999.
x
Percentage values are printed to one decimal place, in parentheses with no spaces, one space 
after the count (e.g., 7 (12.8%), 13 (5.4%)). Unless otherwise noted, for all percentages, the 
number of subjects in the analysis set for the treatment group will be the denominator. Percentages 
after zero counts should not be displayed and percentages equating to 100% are presented as 
100%, without decimal places. 
x
Where a category with a subheading (such as system organ class) has to be split over more than 
one page, output the subheading followed by “(cont)” at the top of each subsequent page.  The 
overall summary statistics for the subheading should only be output on the first relevant page.
15.2.5.3.
Listing Conventions
x
Listings will be sorted for presentation in order of treatment groups as above, subject number, 
visit/collection day, and visit/collection time.
x
Missing data are represented on subject listings as either a hyphen (“-”) with a corresponding 
footnote (“- = unknown or not evaluated”), or as “N/A”, with the footnote “N/A = not applicable”, 
whichever is appropriate.
x
Dates are printed in SAS DATE9.format (“DDMMMYYYY”: 01JUL2000). Missing portions of dates 
are represented on subject listings as dashes (--JUL2000). Dates that are missing because they 
are not applicable for the subject are output as “N/A”, unless otherwise specified.
x
All observed time values are to be presented using a 24-hour clock HH:MM or HH:MM:SS format 
(e.g., 11:26:45, or 11:26). Time will only be reported if it was measured as part of the study.
x
Units will be included where available.
Footnotes
x
A solid line spanning the margins will separate the body of the data display from the footnotes. 
x
All footnotes will be left justified with single-line spacing immediately below the solid line 
underneath the data display.
x
Footnotes should always begin with “Note:” if an informational footnote, or 1, 2, 3, etc. if a 
reference footnote. Each new footnote should start on a new line, where possible.
x
Subject specific footnotes are avoided, where possible.


Statistical Analysis Plan 
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022 
 
 
This document is confidential. 
SAP Version: 5.0, 15Feb2024 
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018 
Filing requirements: TMF 
Page 51 of 68 
x Footnotes will be used sparingly and add value to the table, figure, or listing. If more than six lines 
of footnotes are planned, then a cover page is strongly recommended to be used to display 
footnotes, and only those essential to comprehension of the data will be repeated on each page.  
x The last line of the footnote section will be a standard source line that indicates the name of the 
program used to produce the data display, date the program was run (eg., ‘Program : 
myprogram.sas    Table Generation: DDMMMYYY HH:MM’). 


Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 52 of 68
Quality Control
SAS programs are developed to produce output such as analysis data sets, summary tables, data listings, 
figures or statistical analyses. 
 End-to-End Process of the Production of Analysis Datasets (ADs) and Tables, Figures and 
Listings (TFLs) SOP (3922) and the SAS Programming and Validation Plan describe the quality control 
procedures that are performed for all SAS programs and output. Quality control is defined here as the 
operational techniques and activities undertaken to verify that the SAS programs produce the output by 
checking for their logic, efficiency and commenting and by review of the produced output.  
PPD




Statistical Analysis Plan 
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022 
 
 
This document is confidential. 
SAP Version: 5.0, 15Feb2024 
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018 
Filing requirements: TMF 
Page 54 of 68 
14.2.2.2.1 
Analysis of Proportion of Subjects with Serum Anti-tetanus IgG 
Concentrations of ≥ 0.1 IU/mL at Week 16  
mITT  
14.2.2.2.2 
Sensitivity Analysis of Proportion of Subjects with Serum Anti-tetanus IgG 
Concentrations of ≥ 0.1 IU/mL at Week 16 – Missing as Non-Responder 
ITT  
14.2.2.2.3 
Sensitivity Analysis of Proportion of Subjects with Serum Anti-tetanus IgG 
Concentrations of ≥ 0.1 IU/mL at Week 16 – Observed Case 
ITT  
14.2.2.2.4 
 
Sensitivity Analysis of Proportion of Subjects with Serum Anti-tetanus IgG 
Concentrations of ≥ 0.1 IU/mL at Week 16 – COVID-19 Affected Case 
ITT 
14.2.2.3.1 
Analysis of Proportion of Subjects with Serum Anti-tetanus IgG 
Concentrations of ≥ 1.0 IU/mL at Week 16  
mITT  
14.2.2.3.2 
Sensitivity Analysis of Proportion of Subjects with Serum Anti-tetanus IgG 
Concentrations of ≥ 1.0 IU/mL at Week 16 – Missing as Non-Responder 
ITT  
14.2.2.3.3 
Sensitivity Analysis of Proportion of Subjects with Serum Anti-tetanus IgG 
Concentrations of ≥ 1.0 IU/mL at Week 16 – Observed Case 
ITT  
14.2.2.3.4 
Sensitivity Analysis of Proportion of Subjects with Serum Anti-tetanus IgG 
Concentrations of ≥ 1.0 IU/mL at Week 16 – COVID-19 Affected Case 
ITT 
14.2.2.4.1 
Analysis of Proportion of Subjects with Positive Serum Bactericidal Antibody 
Response to Meningococcal Serogroup C Polysaccharide at Week 16 – 
Imputed Values 
mITT  
14.2.2.4.2 
Sensitivity Analysis of Proportion of Subjects with Positive Serum 
Bactericidal Antibody Response to Meningococcal Serogroup C 
Polysaccharide at Week 16 – Missing as Non-Responder – Imputed Values 
ITT  
14.2.2.4.3 
Sensitivity Analysis of Proportion of Subjects with Positive Serum 
Bactericidal Antibody Response to Meningococcal Serogroup C 
Polysaccharide at Week 16 – Observed Case – Imputed Values 
ITT  
14.2.2.4.4 
Sensitivity Analysis of Proportion of Subjects with Positive Serum 
Bactericidal Antibody Response to Meningococcal Serogroup C 
Polysaccharide at Week 16 – COVID-19 Affected Case – Imputed Values 
ITT  
14.2.2.4.7 
Analysis of Proportion of Subjects with Positive Serum Bactericidal Antibody 
Response to Meningococcal Serogroup C Polysaccharide at Week 16 – 
Non-Imputed Values 
mITT  
14.2.2.4.8 
Sensitivity Analysis of Proportion of Subjects with Positive Serum 
Bactericidal Antibody Response to Meningococcal Serogroup C 
Polysaccharide at Week 16 – Missing as Non-Responder – Non-Imputed 
Values 
ITT  
14.2.2.4.9 
Sensitivity Analysis of Proportion of Subjects with Positive Serum 
Bactericidal Antibody Response to Meningococcal Serogroup C 
Polysaccharide at Week 16 – Observed Case – Non-Imputed Values 
ITT  
14.2.2.4.10 
Sensitivity Analysis of Proportion of Subjects with Positive Serum 
Bactericidal Antibody Response to Meningococcal Serogroup C 
Polysaccharide at Week 16 – COVID-19 Affected Case – Non-Imputed 
Values 
ITT  
14.2.2.5.1 
Analysis of Proportion of Subjects with Positive Serum Bactericidal Antibody 
Response to Meningococcal Serogroup C Polysaccharide using Different 
Criteria at Week 16 – Non-Imputed Values 
mITT  
14.2.2.5.2 
Sensitivity Analysis of Proportion of Subjects with Positive Serum 
Bactericidal Antibody Response to Meningococcal Serogroup C 
Polysaccharide using Different Criteria at Week 16 – Missing as Non-
Responder – Non-Imputed Values 
ITT  
14.2.2.5.3 
Sensitivity Analysis of Proportion of Subjects with Positive Serum 
Bactericidal Antibody Response to Meningococcal Serogroup C 
ITT  


Statistical Analysis Plan 
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022 
 
 
This document is confidential. 
SAP Version: 5.0, 15Feb2024 
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018 
Filing requirements: TMF 
Page 55 of 68 
Polysaccharide using Different Criteria at Week 16 – Observed Case – Non-
Imputed Values 
14.2.2.5.4 
Sensitivity Analysis of Proportion of Subjects with Positive Serum 
Bactericidal Antibody Response to Meningococcal Serogroup C 
Polysaccharide using Different Criteria at Week 16 – COVID-19 Affected 
Case – Non-Imputed Values 
ITT  
14.2.2.6.1 
Analysis of Proportion of Subjects with Positive Serum Bactericidal Antibody 
Response to Meningococcal Serogroup C Polysaccharide using Different 
Criteria at Week 16 – Imputed Values 
mITT  
14.2.2.6.2 
Sensitivity Analysis of Proportion of Subjects with Positive Serum 
Bactericidal Antibody Response to Meningococcal Serogroup C 
Polysaccharide using Different Criteria at Week 16 – Missing as Non-
Responder – Imputed Values 
ITT  
14.2.2.6.3 
Sensitivity Analysis of Proportion of Subjects with Positive Serum 
Bactericidal Antibody Response to Meningococcal Serogroup C 
Polysaccharide using Different Criteria at Week 16 – Observed Case – 
Imputed Values 
ITT  
14.2.2.6.4 
Sensitivity Analysis of Proportion of Subjects with Positive Serum 
Bactericidal Antibody Response to Meningococcal Serogroup C 
Polysaccharide using Different Criteria at Week 16 – COVID-19 Affected 
Case – Imputed Values 
ITT  
14.2.2.7.1 
Analysis of Geometric Mean Concentration of Anti-tetanus IgG at Baseline 
and Week 16 
mITT 
14.2.2.7.2 
Sensitivity Analysis of Geometric Mean Concentration of Anti-tetanus IgG at 
Baseline and Week 16 – Observed Case 
ITT 
14.2.2.7.3 
Sensitivity Analysis of Geometric Mean Concentration of Anti-tetanus IgG at 
Baseline and Week 16 – COVID-19 Affected Case 
ITT 
14.2.2.8.1 
Analysis of Geometric Mean Titers of MenC SBA at Baseline and Week 16 – 
Imputed Values 
mITT 
14.2.2.8.2 
Sensitivity Analysis of Geometric Mean Titers of MenC SBA at Baseline and 
Week 16 – Observed Case – Imputed Values 
ITT 
14.2.2.8.3 
Sensitivity Analysis of Geometric Mean Titers of MenC SBA at Baseline and 
Week 16 – COVID-19 Affected Case – Imputed Values 
ITT 
CCI


Statistical Analysis Plan 
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022 
 
 
This document is confidential. 
SAP Version: 5.0, 15Feb2024 
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018 
Filing requirements: TMF 
Page 56 of 68 
CCI


Statistical Analysis Plan 
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022 
 
 
This document is confidential. 
SAP Version: 5.0, 15Feb2024 
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018 
Filing requirements: TMF 
Page 57 of 68 
14.3.1.1 
Overall Summary of Treatment-Emergent Adverse Events   
SAF  
14.3.1.2 
Treatment-Emergent Adverse Events by System Organ Class and Preferred 
Term 
SAF  
CCI


Statistical Analysis Plan 
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022 
 
 
This document is confidential. 
SAP Version: 5.0, 15Feb2024 
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018 
Filing requirements: TMF 
Page 58 of 68 
14.3.1.3 
Treatment-Emergent Adverse Events Related to Study Drug by System 
Organ Class and Preferred Term 
SAF  
14.3.1.4 
Serious Treatment-Emergent Adverse Events by System Organ Class and 
Preferred Term 
SAF  
14.3.1.5 
Serious Treatment-Emergent Adverse Events Related to Study Drug by 
System Organ Class and Preferred Term 
SAF  
14.3.1.6 
Treatment-Emergent Adverse Events by System Organ Class, Preferred 
Term and Maximum Severity 
SAF 
14.3.1.7 
Treatment-Emergent Adverse Events Related to Study Drug by System 
Organ Class, Preferred Term and Maximum Severity  
SAF  
14.3.1.8 
Treatment-Emergent Adverse Events Leading to Study Drug Withdrawal by 
System Organ Class and Preferred Term 
SAF  
14.3.1.9 
Treatment-Emergent Adverse Events of Special Interest by System Organ 
Class and Preferred Term  
SAF  
14.3.1.10 
Treatment-Emergent Adverse Events Leading to Temporary Interruption of 
Study Drug by System Organ Class and Preferred Term  
SAF  
14.3.1.11 
Treatment-Emergent Adverse Events Leading to Study Discontinuation by 
System Organ Class and Preferred Term  
SAF  
14.3.1.12 
Most Common Treatment-Emergent Adverse Events (Frequency > 5%) by 
Preferred Term  
SAF  
14.3.1.13 
Adjudicated Treatment Emergent Adverse Events (TEAEs) by SOC and PT  
SAF 
14.3.1.14 
Treatment Emergent Adverse Events (TEAEs) of Asthma and Asthma 
related events reported by Investigator with Adjudication Outcome by IAC  
SAF 
14.3.1.15 
Confirmed Adjudicated Treatment Emergent Adverse Events (TEAEs) by 
SOC, PT and Maximum Severity  
SAF 
14.3.2.1 
Listing of Serious Adverse Events 
SAF  
14.3.2.2 
Listing of Adverse Events Leading to Study Drug Withdrawal 
SAF  
14.3.2.3 
Listing of Adverse Events of Special Interest 
SAF  
14.3.2.4 
Listing of Adjudicated Asthma Treatment-Emergent Adverse Events 
(TEAEs) 
SAF 
14.3.2.5 
Listing of Adjudicated Asthma Treatment-Emergent Adverse Events 
(TEAEs) Comments 
SAF 
14.3.4.1.1.1 
Summary of Observed Values and Changes from Baseline for Hematology 
Value by Visit  
SAF  
14.3.4.1.1.2 
Shift from Baseline of Hematology Values by Visit and by Reference Range  
SAF 
14.3.4.1.1.3 
Proportions of Subjects with Potentially Clinically Significant Hematology 
Value 
SAF 
14.3.4.1.1.4 
Listing of Subjects with Potentially Clinically Significant Hematology Value 
SAF 
14.3.4.1.2.1 
Summary of Observed Values and Changes from Baseline for Chemistry 
Value by Visit  
SAF  
14.3.4.1.2.2 
Shift from Baseline of Chemistry Values by Visit and by Reference Range  
SAF 
14.3.4.1.2.3 
Proportions of Subjects with Potentially Clinically Significant Chemistry 
Value 
SAF 
14.3.4.1.2.4 
Listing of Subjects with Potentially Clinically Significant Chemistry Value 
SAF 
14.3.4.1.3.1 
Summary of Observed Values and Changes from Baseline for Urinalysis 
Value by Visit 
SAF  
14.3.4.1.3.2 
Shift from Baseline of Urinalysis Values by Visit and by Reference Range 
SAF  
14.3.4.1.3.3 
Proportions of Subjects with Potentially Clinically Significant Urinalysis Value 
SAF 
14.3.4.1.3.4 
Listing of Subjects with Potentially Clinically Significant Urinalysis Value 
SAF 


Statistical Analysis Plan 
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022 
 
 
This document is confidential. 
SAP Version: 5.0, 15Feb2024 
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018 
Filing requirements: TMF 
Page 59 of 68 
14.3.4.2.1 
Summary of Observed Values and Changes from Baseline for Vital Signs, 
Height and Weight by Visit 
SAF  
14.3.4.2.2 
Shift from Baseline of Vital Signs, Height and Weight by Visit and by 
Reference Range  
SAF 
14.3.4.2.3 
Proportions of Subjects with Potentially Clinically Significant Vital Signs, 
Height and Weight  
SAF 
14.3.4.2.4 
Listing of Subjects with Potentially Clinically Significant Vital Signs, Height 
and Weight 
SAF 
14.3.4.3 
Summary of 12-Lead Electrocardiogram (ECG) Overall Interpretation 
SAF  
14.3.4.4 
Summary of Physical Examination  
SAF 
14.3.4.5.1 
Summary of Asthma Control Test (ACT) 
SAF  
14.3.4.5.2 
Summary of Asthma Control Test (ACT) Score <= 19 
SAF  
14.3.4.6 
Summary of Respiratory Examination 
SAF  
14.3.4.7.1 
Summary of Peak Expiratory Flow (PEF) 
SAF  
14.3.4.7.2 
Summary of Peak Expiratory Flow (PEF) < 80% of Predicted Value 
SAF  




Statistical Analysis Plan 
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022 
 
 
This document is confidential. 
SAP Version: 5.0, 15Feb2024 
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018 
Filing requirements: TMF 
Page 61 of 68 
 




Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 63 of 68
CCI


Statistical Analysis Plan 
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022 
 
 
This document is confidential. 
SAP Version: 5.0, 15Feb2024 
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018 
Filing requirements: TMF 
Page 64 of 68 
CCI


Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 65 of 68
CCI


Statistical Analysis Plan 
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022 
 
 
This document is confidential. 
SAP Version: 5.0, 15Feb2024 
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018 
Filing requirements: TMF 
Page 66 of 68 
CCI


Statistical Analysis Plan
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022
This document is confidential.
SAP Version: 5.0, 15Feb2024
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018
Filing requirements: TMF
Page 67 of 68
CCI


Statistical Analysis Plan 
Sponsor: Galderma S.A./Galderma R&D, LLC; Protocol No.: RD.06.SPR.118380  V4.0, 06Jul2022 
 
This document is confidential. 
SAP Version: 5.0, 15Feb2024 
Controlled Document ID: 3903A.01, Effective Date 29-Oct-2018 
Filing requirements: TMF 
Page 68 of 68 
 
CCI


PPD


PPD